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Abstract
A major goal in clinical organ transplantation is to devise new strategies for the 
induction of specific immunological tolerance to the allograft. This would 
obviate the need for long-term immunosuppressive drugs and leave the immune 
system of the recipient otherwise intact to protect the recipient from the 
development of infection and malignancy. CD4 T cells play a central role in
!
i allograft rejection and the CD4 molecule has therefore attracted considerable
interest as a molecular target for manipulating the allograft response. In this 
thesis, mouse monoclonal antibodies (mAbs) directed against the rat CD4 
molecule were used in an attempt to prolong allograft survival and possibly to 
promote tolerance to a heterotopic cardiac allograft in the rat.
| In preliminary studies, administration of the mouse IgG2a anti-CD4 mAb MRC
0X38 (directed against an epitope on the distal domains of the rat CD4 
molecule) for a brief period immediately prior to transplantation [10 mg/kg on 
i day -3 and 2 mg/kg on day -2, -1 and day 0 (day of transplantation)] prolonged
heart allograft survival indefinitely (>200 days) in the Lewis to DA rat strain 
combination. Long-standing allograft recipients displayed donor-specific 
tolerance by rejecting a second “third party” (PVG) heart graft but permanently 
accepting a second donor-specific (Lewis) heart graft.
I
The ability of 0X38 mAb to induce transplant tolerance was highly dependent 
on the rat strain combination studied. Although 0X38 mAb treatment 
consistently increased cardiac allograft survival in other fully allogeneic rat
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strains tested (e.g. DA to PVG and DA to Lewis), long-term survival was not 
observed.
Further studies were performed with additional anti-CD4 mAbs directed against 
epitopes on the proximal (0X70, 0X71 and 0X73) or distal domains (W3/25) 
of the CD4 molecule. All of the mAb’s tested, with the exception of W3/25, led 
to a marked increase in the survival of Lewis heart allografts in DA recipients 
and many recipients accepted their grafts permanently. The mAb W3/25 mAb 
depleted CD4 T cells to a lesser extent than the other anti-CD4 mAb tested, 
which may explain, at least in part, its inability to prolong graft survival 
indefinitely.
Further studies were performed to investigate some of the possible mechanisms 
involved in the induction and maintenance of anti-CD4 induced transplant 
tolerance. The ability of anti-CD4 mAbs to prolong cardiac allograft survival 
was significantly dependent on the presence of the thymus gland, since 
thymectomised DA recipients treated with 0X38 or 0X70 mAb did not become 
tolerant to Lewis strain heart grafts. Administration of exogenous recombinant 
interleukin-2 (rEL-2) during the induction of tolerance by anti-CD4 mAbs 
(0X38 and 0X73) failed to abrogate induction of tolerance, suggesting that a 
lack of endogenous IL-2 alone does not account for allograft survival after 
anti-CD4 therapy. On the other hand, treatment with a neutralising anti-EL-4 
mAb (MRC 0X81) during the induction of tolerance with 0X38 mAb reduced 
the efficacy of tolerance induction. Although not conclusive, this finding 
suggests a possible role for IL-4 during the induction phase of tolerance
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following anti-CD4 mAbs therapy. The role of CD8 cells in the induction and 
maintenance of transplant tolerance was also examined. Administration of the 
depleting anti-CD8 mAb (0X8) during the induction of tolerance abrogated the 
ability of anti-CD4 mAb to increase cardiac allograft survival but when 0X8 
mAb was given to animals bearing long-term tolerant heart grafts it did not 
prevent such animals from accepting a second donor strain heart indefinitely. 
Thus CD8 cells appear to be necessary for induction but not maintenance of the 
tolerant state following anti-CD4 therapy. In further experiments adoptive 
transfer studies using splenocytes obtained from 0X38 treated tolerant 
recipients provided evidence for the existence of immunoregulatory (or 
suppressor) lymphocytes. Thus, transfer of 2x108 spleen cells from tolerant 
animals to secondary unmodified graft recipients enabled them (in 2 of 4 
recipients) to maintain their graft indefinitely.
Finally, purified CD4 T cells were obtained from animals bearing long-standing 
Lewis heart allografts following anti-CD4 mAb treatment (0X38 or 0X70) to 
determine their in vitro proliferative response and cytokine production. CD4 T 
cells from 0X38 treated recipients showed near normal levels of proliferation to 
irradiated donor (Lewis) stimulators in the in vitro MLR. Moreover, CD4 T 
cells from 0X38 treated tolerant animals released levels of IFNy and IL-4 into 
the culture supernatants which were comparable to those produced in response 
to third party stimulators or released by CD4 T cells obtained from normal DA 
strain rats in response to Lewis stimulators cells. Interestingly, there was a 
reduction in IL-2 levels in culture supernatants of tolerant CD4 cells from
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0X38 treated when compared with CD4 cells from normal rats. Analysis of the 
in vitro response of CD4 T cells from long-term tolerant animals which received 
0X70 mAb gave unexpected results which contrasted with those from 0X38 
treated recipients. Such cells showed a reduction in both proliferation and IL-2 
production to both donor and third party allogeneic stimulator cells.
IFNy levels were comparable (0X38) or marginally reduced (0X70) in culture 
supernatants from tolerant CD4 T cells when compared with normal CD4 T 
cells. Overall, these observations suggest that the cytokine pattern of CD4 T 
cells from animals rendered tolerant by anti-CD4 T cells is complex and 
variable. The findings are not consistent with the view held by some workers 
that anti-CD4 induced tolerance correlates with a simple polarisation of the 
cytokine response from Thl (IL-2 and IFNy) in rejection to Th2 (IL-4, IL-5, 
IL-6 and IL-10) in tolerance.
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Abbreviation
ADCC antibody dependent cellular cytotoxicity.
Ag antigen.
APC antigen presenting cell.
ALG/S Anti-lymphocyte globulin/serum.
B2m p2-microglobulin.
BCGF B-cell growth factor.
BM bone marrow.
BSA bovine serum albumin.
CsA Cyclosporin A.
CDRs complementarity determining regions.
CTL cytotoxic T-lymphocyte.
DST donor specific blood transfusion.
DTH delayed type hypersensitivity.
ELISA enzyme-linked immunosorbent assay.
ER endoplasmic reticulum.
FACS fluorescence-activated cell sorter.
FCS foetal calf serum.
G-CSF granulocyte colony stimulating factor.
GVHD graft versus host disease.
HLA human leukocyte antigen.
IFN-y interferon-y.
ICAM intercellular adhesion molecule
21
Ig immunoglobulin.
IVC inferior vena cava.
IL-2R interleukin-2 receptor
Kd kilodalton.
LFA leukocyte functional antigen.
LNC lymph node cells.
mAb monoclonal antibody.
mH minor histocompatibility antigen.
MHC major histocompatibility complex.
MLR/C mixed lymphocyte reaction or culture.
MMF Mycophenolate Mofetil.
MST mean survival time.
NK natural killer.
PBL peripheral blood lymphocytes.
PBS phosphate buffered saline.
TAP transporters in antigen processing.
TCR T-cell receptor (a|3 or y5).
TGFP transforming growth factor-p.
Th T-helper.
TNF tumour necrosis factor.
TCGF T-cell growth factor.
VC AM vascular cell adhesion molecule
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CHAPTER ONE 
Clinical perspective of organ transplantation
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1:1 The development of clinical organ transplantation
In the space of little more than 30 years, organ transplantation has progressed 
from an essentially unsuccessful experimental procedure conducted in a small 
number of pioneering medical research centres to a widespread and routine 
procedure performed throughout the world. Transplantation of the kidney, heart 
and liver are now widely practised at specialist centres across the western world 
and transplantation of the pancreas and small bowel are becoming more 
commonplace.
Despite early attempts, no real progress in organ transplantation was made until 
the middle of the 20th century. The first human kidney transplant was carried 
out in 1933 by a Russian surgeon, Vorony, who used a cadaveric kidney to treat 
a patient with acute renal failure caused by mercuric chloride poisoning. It is 
unlikely that the transplanted kidney ever functioned as it had been harvested 
some 6 hours after the donor’s death and the graft recipient died within 48 
hours of surgery (Voronoy, 1936; Hume DM, 1979).
Two important events paved the way for the development of successful kidney 
transplantation, namely the invention of the artificial kidney machine by Wilhelm 
KolfF in 1944 (KolfF et al, 1944) and the synthesis of steroid hormones and 
antimitotic drugs, such as nitrogen mustard (reviewed by Hamilton, 1988). In 
the early 1950s a small number of human cadaveric kidney transplants were 
performed at centres in both Paris and Boston (Servelle et al, 1951, Hume et al, 
1955). However, effective immunosuppressive drugs with which to prevent 
rejection were not then available and despite a promising outcome in one
25
patient, the overall results in both centres were very disappointing . These early 
attempts at kidney transplantation confirmed the view that before clinical 
success could be expected a major immunlogical barrier would need to be 
overcome.
From experimental work with skin grafts it was known that exchange of tissue 
was possible between identical twins without encountering the problems of graft 
rejection and in 1954 the Boston group, headed by Joseph Murray, began a 
series of kidney transplants between identical twins (Murray et al, 1955). 
Richard Herrick, a 24 year old man with end stage renal failure received a renal 
transplant from his identical twin brother Ronald on December 23rd 1954. The 
transplanted kidney subsequently functioned well for eight years before 
eventually succumbing to recurrence of the primary renal disease. This 
important success heralded the first of many subsequent transplants between 
identical twins. It demonstrated the technical feasibility of kidney transplantation 
but the problem of immunological rejection between non-identical individuals 
remained.
The development of a new antimitotic drug, 6-mercaptopurine, and the 
discovery that it had potent immunosuppressive effects led Roy Caine in 1960 
to use this agent in dogs receiving kidney allografts (Caine RY, 1960). Caine 
subsequently pioneered the use of azathioprine, a similar but less myelotoxic 
and therefore superior immunosuppressive agent, initially to prevent renal 
allograft rejection in dogs (Caine, Alxander and Murray, 1962) and later in 
clinical practice (Murray et al, 1963).
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Further improvements in the results of kidney transplantation occurred over the 
next two decades. These were attributable to the routine use of 
lymphocytotoxic crossmatching prior to transplantation, the introduction of 
prospective matching of histocompatibility antigens, the use of antilymphocytic 
preparations and the adoption of deliberate blood transfusion policies (Opelz et 
al, 1973, Opelz et al, 1992). As a result by the 1980’s renal transplantation had 
become the preferred treatment for most patients with end-stage renal disease, 
although considerable scope for further improvement in the outcome of 
transplantation remained.
The introduction of cardiac transplantation into clinical practice was less rapid. 
Following the first cardiac transplant in dogs, reported by Carrel and Guthrie in 
1905 (Carrel and Guthrrie, 1905), little further interest was shown in this 
procedure until reliable methods of cardiopulmonary bypass were developed in 
the 1950s. Then it became possible to devise surgical techniques which allowed 
intrathoracic, orthotopic cardiac transplantation and the pioneering work in 
dogs reported in the 1960s by Lower and Shumway opened the way towards 
clinical cardiac transplantation (Lower and shumway, 1960). Advances in the 
treatment and control of kidney graft rejection in the late 1960s encouraged 
cardiac surgeons to use similar strategies for achieving success after cardiac 
transplantation. The first successful human orthotopic cardiac allograft was 
performed by Christiaan Neethling Barnard in 1967 in South Africa but 
unfortunately the patient died 18 days later (Barnard, 1967). Soon afterwards 
cardiac surgeons in North America, notably Shumway who had first developed
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the surgical technique used by Barnard, established clinical programmes of 
cardiac transplantation and the procedure was widely adopted for the treatment 
of various cardiac conditions such as cardiomyopathy, ischaemic heart disease 
and some congenital heart diseases (Yaccoub et al, 1987).
1:2 Cyclosporin A and the modern era of transplantation 
Until the late 1970s, azathioprine and steroids were the principle 
immunosuppressive agents used in renal transplantation (Groth CC, 1972). 
However, the widespread introduction of cyclosporin A (CsA) into clinical 
practice in the early 1980s markedly improved the early results of renal 
transplantation and made the results of heart and liver transplantation clinically 
acceptable, thereby enabling transplantation of these organs to be pursued on an 
almost routine basis in many centres (reviewed by Jain and Fung, 1996).
The potent immunosuppressive properties of CsA, a fungal metabolite, were 
first discovered by Borel while working in the microbiology department of 
Sandoz in Basle, Switzerland (Borel and White, 1982; Borel et al, 1976). The 
new agent was found to prolong survival of skin, heart and kidney allografts in 
experimental animals with results superior to those obtained earlier with 
azathioprine (Kostakis et al, 1977; Caine RY and White DJ, 1977). As with 
azathioprine, it was Caine in Cambridge, who showed that the new agent was 
also effective in clinical organ transplantation (Caine and Wood, 1985, Clane, 
1987) thus heralding a new era in immunosuppressive therapy. It is now known 
that CsA acts predominately on helper T lymphocytes (Th), suppressing the 
production of a variety of lymphokines, particularly the T cell growth factor
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interleukin-2 (IL-2). Although CsA selectively inhibits T cell activation and 
proliferation, it still leads to generalised immunosuppression and its attendant 
problems of increased susceptibility to infection. In addition, it may impair renal 
function and induce hypertension as well as causing a variety of other, usually 
less serious, side effects (Thomson, 1989; Schreiber and Crabtree, 1992).
1:3 FK506 and other new immunosuppressive drugs 
In the late 1980s two new macrolide antibiotics, FK506 and rapamycin, were 
shown to be very effective in prolonging organ allograft survival in experimental 
animals (Kino et al, 1987). FK506 (Tacrolimus) is now licensed for use in renal 
transplantation and has been shown in recent clinical trials to be as efficacious as 
CsA in the prevention and rescue of allograft rejection as cyclosporin (reviewed 
by Klintmalm G, 1994; Shapiro et al, 1991).
Rapamycin is currently undergoing phase 3 clinical trials and the results of 
preliminary testing with this drug are promising (Sehgal et al, 1995). Both 
FK506 and rapamycin inhibit T cell proliferation but, despite having close 
structural similarity and sharing the same immunophilin, they have very distinct 
modes of action within the T cell. Like CsA, FK506 inhibits the very early 
events following T cell activation via the cell surface T cell receptor 
(TCR)/CD3 complex which lead to the transcription of IL-2 and other cytokine 
genes (reviewed by Schreiber and Crabtree, 1992). Both FK506 and CsA bind 
to cytosolic immunophilins (FK-binding protein and cyclophilin respectively) 
and the respective drug-immunophilin complex inhibits the translocation from 
the cytoplasm to the cell nucleus of nuclear factor of activated T cell (NF-AT),
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a regulatory protein which controls transcription of IL-2 and other cytokines. 
Although, rapamycin binds to the same immunophilin as FK506 (FK-BP), it 
does not affect cytokine gene expression but acts instead at a later stage in the 
cell cycle blocking the response of T cells to IL-2 (Cardenas et al, 1995). 
Mycophenolate mofetil is another promising immunosupressive agent recently 
licensed for clinical use in renal transplantation. It is an ethyl ester which is 
metabolised to its active ingredient mycophenolic acid after administration. 
Mycophenolate blocks the de-novo pathway of purine synthesis by inhibiting 
inosine monophosphate dehydrogenase (IMPDH), which converts inosine 
monophosphate to guanosine triphosphate, thus preventing DNA synthesis 
(Allison et al, 1993; Nagai et al, 1992). Recent multicentre trials have shown 
that MMF reduces the incidence of acute rejection episodes following renal 
transplantation but it remains to be seen whether it reduces long-term graft loss 
from chronic rejection (Keown PA, 1996; reviewed by Fulton and Markham, 
1996).
Leflunomide, is an immunosuppressive molecule which is still at an early stage 
of development. It is an isoxazol derivative and is not chemically related to CsA, 
MMF or rapamycin. Leflunomide inhibits the proliferation of activated T and B 
cells (Chong et al, 1993), prevents allograft rejection in rats (Kuchle et al, 1991; 
Williams et al, 1993) but has not yet been fully evaluated in clinical trials 
(Reviewed by Brazelton and Morris, 1996, Waer M, 1996).
Finally, the immunosuppressive 15-Deoxyspergualin trihydrochloride (DSG), a 
synthetic form of the natural antibiotic spergualin, is produced by the bacterium,
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Bacillus laterosporus. It has significant immunosuppressive activity and inhibits 
the activity of both B and T cells as well as macrophage and monocyte function. 
Its mechanism of action differs from other immunosuppressants in that it binds 
to the heat shock protein (hsp70). Although licensed for clinical use in Japan 
(Amemiya et al, 1990 & 1993), only pilot studies of DSG in organ 
transplantation have been conducted in Western Europe and North America 
(reviewed by Kaufman et al, 1996).
1:4 Biological immunosuppression (antibodies)
In addition to the “small molecule” immunosuppressive agents already 
described, biological immunosuppressive agents (principally antibodies) are an 
important addition to the immunosuppressive armamentarium.
1:4:1 Polyclonal antibodies
Polyclonal antibodies preparations directed against lymphocytes have been used 
in clinical transplantation for the prevention of graft rejection since the early 
1960s (Starzl TE, 1968). Antilymphocyte serum (ALS) and antilymphocyte 
globulin (ALG) are usually raised in horses, rabbits or goats by immunisation 
with human lymphoid cells (lymphblasts or thymocytes). These polyclonal 
antibody preparations target both T and B lymphocytes and comprise a range of 
antibodies with specificity for different lymphocytes surface antigens which 
include CD45, CD3, TCR, LFA1, CD4 and CD8 (Rebellato et al, 1994, 
Bonnefoy-Berard et al, 1991). They deplete lymphocytes from the circulation by 
lysis and opsonization and they also impair the function of residual lymphocytes
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by blocking or modulating cell surface molecules (reviewed by Powelson and 
Cosimi, 1994).
Although ALG, together with azathioprine and prednisolone, was used in renal 
transplant recipients as prophylactic therapy in the early 1970s, the 
improvement seen in graft survival failed to reach statistical significance when 
compared with azathioprine and prednisolone therapy alone (Cosimi AB, 1976). 
However, several studies have suggested that ALG may be superior to high 
dose steroids in reversing acute rejection episodes and also as a “rescue” 
therapy in steroid resistant rejection (Cosimi AB, 1988). Some transplant 
centres still use ALG as induction therapy in the early post-transplant period, 
particularly to avoid cyclosporin-induced nephrotoxicity in kidney transplant 
recipients (Frey et al, 1992). However, these preparations are powerful agents 
and there is a significant risk of lymphoproliferative disorders when ALG is 
combined with cyclosporin (Merion et al, 1984). Polyclonal antibody 
preparations such as ALS and ALG have several other limitations. These 
include their broad specificity, their potential for undesirable cross-reactions and 
the inevitable batch to batch variability which results during their manufacture. 
Fortunately, anaphylactic reactions or serum sickness are relatively uncommon 
problems (Bach and Strom, 1985).
1:4:2 Monoclonal antibodies
The advent of hybridoma technology, opened the way to development of 
monoclonal antibodies (mAbs) which, unlike polyclonal preparations, have 
predictable and consistent reactivity (Kohler et al, 1975 and Galfre et al, 1979).
*
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However, the introduction of mAbs into clinical transplantation has been 
disappointingly slow. Table 1:1 summarises various mAbs which have been tried 
in human transplant recipients. OKT3 is the only mAb currently in wide spread 
use in clinical transplantation. It is an IgG2a murine monoclonal antibody 
directed against the CD3 molecule on the surface of T lymphocytes and was 
first shown by Cosimi to be an effective agent in reversing renal allograft 
rejection (Cosimi et al, 1981). Administration of OKT3 produces rapid and 
substantial T cell depletion and, in addition, residual T cells are coated with 
mouse antibody and display modulation of the CD3/TCR complex (reviewed by 
Masroor et al, 1994). OKT3 has been used successfully as a rescue therapy to 
treat steroid resistant renal allograft rejection (Ortho Multicenter Transplant 
Study Group, 1985, Delminco et al, 1988) and also has been shown in heart 
transplantation to reverse acute rejection episodes which are refractory to high 
dose steroids or ALS (Gilbert et al, 1987).
Prophylactic therapy with OKT3 is not generally used in the UK, because of the 
profound non-specific immunosuppression it induces and the attendant risks of 
infection and malignancy which may follow its use (Thistlethwaite et al, 1987, 
Monaco et al, 1987, Cosimi et al, 1987, Fung et al, 1987). However, some 
centres, particularly in the USA, use OKT3 for prophylaxis against rejection, 
especially when delayed graft function is encountered after renal transplantation 
(Kahana et al, 1990). A particular problem associated with OKT3 is that of 
cytokine release syndrome. This is a syndrome of fever, chills, rigors and
A
33
Table 1:1 Summary of the various mAbs which have been used
in clinical organ transplantation.
Mab
used
Target
molecule
Type of 
study
No of 
Patients
Authors Type of 
Graft
OKT3 Anti-CD3 RCT 123 0),(2),(3) Kidney
(BMA031) Anti-TCR
(Op)
RCT 24 (4) Kidney
(T10B9.1A
-31)
Anti-TCR
(«P)
RCT 76 (5) Kidney
anti-CD25 Anti- CD25 RCT 100 (6) Kidney
Anti-Tac RCT 40 (7) Kidney
BT563 RCT 60 (12) Heart
LO-Tac RCT 129 (13) Liver
33B3.1 RCT 40 (14) SPK
BT563 RCT 32 (15) Liver
Anti-LFAl Anti-LFAl pilot study 7 (8) BM
25-3 pilot study 15 (16) Kidney
BL4 Anti-CD4 Pilot study 12 (9) kidney
MAX.16H5 Pilot study 30 (10) Kidney
OKT4A Pilot study 30 (11) Kidney
Abbreviations
RCT=Randomised Clinical Trial 
SPK=Synchronous Pancreas Kidney transplantation. 
BM =Bone marrow.
Study Authors
1) Ortho Multicenter Transplant Study group, 1985
2) Thistlethwaiite et al, 1984
3) Delmnico et al, 1988
4) Knight et al, 1994
5) Waid et al, 1992
6) Soulillou et al, 1990
7) Kirkman et al, 1991
8) Fischer et al, 1986
16) Le MaufF and Soulillou, 1995
(9) Morel et al, 1990
(10) Reinke et al, 1995
(11) Matas et, 1995
(12) Gelder et al, 1996
(13) Reding et al, 1996
(14) Cantrovich et al, 1994
(15) Nashan et al, 1996
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generalised malaise attributable to massive release of tumour necrosis factor 
(TNFa,P), IFNy and other cytokines following the first dose of OKT3 
(Chatenoud et al, 1990, Ambramowicz et al, 1989).
Few other mAbs have been used to an appreciable extent in clinical 
transplantation (see table 1:1). The TCRap molecule on the T cell surface is an 
obvious target for mAbs and at least two different, anti-TCR mAbs have been 
tested in patients. BMA031 and T10B9.1A-31 are mouse anti-human apTCR 
mAbs of the IgG2b and IgM class respectively. The former mAb has been tested 
to a limited extent for its ability to prevent renal allograft rejection and to treat 
graft-versus host disease following allogeneic bone marrow transplantation 
(Schlitt et al, 1989). BMA-031 was found to be effective as rescue treatment in 
steroid resistant renal allograft rejection (Land et al, 1988). More recently, the 
results of phase II and randomised phase m  trials of BMA031 in the prevention 
of renal allograft rejection have been reported (Knight et al, 1994). The 
antibody appeared, in these limited studies, to be safe and comparable in 
efficacy to OKT3 (Dendorfer et al, 1990, Chatenoud et al, 1993). The mAb 
T10B9.1A-31 was tested in a randomised double-blind phase II trial involving 
76 patients and was also found to be comparable in efficacy to OKT3 in 
reversing acute renal allograft rejection (Waid et al, 1992).
The IL-2 receptor (IL-2R) is another promising molecular target for mAbs in 
clinical transplantation. 33B3.1 and anti-Tac are both IgG2a subclass mouse 
anti-human mAbs directed against the IL-2R. The former mAb blocks IL-2 
binding and was found to be comparable in efficacy to ALS as prophylactic
4
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treatment to prevent early renal allograft rejection but long term follow up 
results have not yet been reported (Soulillou et al, 1990). In another randomised 
trial the anti-Tac mAb was found to reduce early acute renal graft rejection 
episodes but did not have a significant effect on either graft or patient survival 
(Kirkman et al, 1991). Gelder and colleagues, in a randomised trial involving 60 
heart transplant patients, compared anti-IL-2 (BT563) with OKT3 for safety 
and efficacy (Gelder et al, 1996). In this study BT563 had similar efficacy to 
OKT3 but was devoid of the accompanying side effects (Gelder et al, 1996). 
BT563 was also compared to ATG as immunoprophylaxis in a randomised 
clinical trial involving 32 recipients of orthotopic liver transplants. The mAb was 
not associated with any major side effects and significantly reduced the 
incidence of acute rejection when compared with the standard 
immunosuppression regimen using ATG (Nashan et al, 1996). The anti-EL-2R 
33B3.1 (a rat anti-human IgG2a monoclonal antibody directed against the a  
chain of IL-2) was compared with ATG as induction therapy (along with 
standard triple therapy) in cadaveric combined pancreas-kidney transplantation. 
During the follow up period, which ranged from 8 to 41 months, 33B3.1 treated 
patients were noted to have a higher incidence of rejection episodes than those 
given ATG (Cantrovich et al, 1994).
MAbs directed against the adhesion molecule LFA-1 have also been tested in 
preliminary clinical studies in an attempt to prevent rejection of cadaveric renal 
allografts. Soulillou and colleagues used anti-LFA-1 (25-3) in a pilot study 
involving 15 patients to test tolerability of the mAb. The 25-3 mAb was well
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tolerated and the authors propose to perform further clinical trials to evaluate its 
role in preventing rejection (Le MaufF et al, 1995).
The CD4 molecule is an obvious and exciting target molecule for preventing 
graft rejection and, in an experimental context, is the principal subject of this 
thesis. However, anti-CD4 mAbs have, so far only been used to a limited extent 
in clinical transplantation. Three different mouse anti-human CD4 monoclonals, 
have been studied in transplant patients. Matas and colleagues used the mAb 
OKT4A, along with the standard triple therapy immunosuppression (CsA, 
Azathioprine and prednisolone), in a pilot study involving 30 recipients to assess 
the safety and tolerability of multiple intravenous infusions of the mAb. OKT4A 
was given for a total of 12 days, starting on the day of transplantation and was 
not associated with any obvious side effects (Matas et al, 1995).
Morel et al used the anti-CD4 mAb BL4 (IgG2a) (together with azathioprin 
and prednisolone) in 12 recipients of cadaveric renal allografts. Treatment with 
BL4 was started on day 1 after transplantation and discontinued after 2 weeks. 
The results using BL4 appeared comparable to those obtained with ALG 
although patients numbers were very small (Morel et al, 1990). In a small pilot 
study, Reinke and colleagues used the anti-CD4 mAb MAX.16H5 to treat acute 
rejection episodes in renal allograft recipients. MAX.16H5 was found to have a 
comparable results to OKT3 and to be better than ATG in the treatment of 
acute renal allografts rejection (Reinke et al, 1995). Clearly it would be 
premature from these limited clinical studies to draw any conclusions on the 
likely benefit of CD4 mAb in human organ transplantation
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1:5 Current status and future goals of organ transplantation
Although the early results of organ transplantation have been improved by 
better immunosuppression, particularly with the introduction in the early 1980s 
of CsA, graft rejection and the side effects of non-specific immunosuppression 
(i.e. infection and malignancy) still remain the major problem in clinical 
transplantation. Moreover, although CsA undoubtedly improves the early graft 
survival after renal transplantation, it is disturbing to note that graft loss in the 
longer term (principally because of chronic rejection) has remained largely 
unchanged over the last 15 years (Thorogood et al, 1992; Caine RY, 1987).
The one year actuarial graft survival rate following cadaveric renal 
transplantation is around 85% but survival at 5 and 10 years is 60% and 30% 
respectively (Ferguson, 1995, Hayry, 1995, Azuma and Tilney, 1994, Opelz, 
1989a).
In the precyclosporin era the actuarial one year survival rates for patients 
undergoing cardiac transplantation at Stanford University Medical Centre 
between 1968 and 1973 was 42% and between 1975 and 1981 it rose to 60%. 
CsA markedly improved the early results of heart transplantation and, in one 
large series of 389 patients operated on between 1981 and 1990, the one year 
graft survival rate was 83%. As for kidney transplantation, however, the 
actuarial 5 years survival for heart transplantation is around 55% and chronic 
rejection is a major problem (Hunt and Billingham, 1991, Wallwork, 1989). 
Since the pioneering experiments of Medawar (Medawar, 1943 & 1944) a 
major goal in transplantation has been to devise strategies for rendering organ
*
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allograft recipients specifically tolerant to their grafts. Tolerance induction 
would eliminate the problem of graft rejection and leave the recipients immune 
system otherwise intact for defence against opportunistic infection. 
Unfortunately little progress has been made in the clinic towards achieving the 
goal of transplantation tolerance. However, there is increasing optimism that 
some form of ‘operational’ or partial tolerance may soon be achievable and 
this hope has been strengthen by the results of several recent case reports.
In an interesting study, Strober reported three patients who were treated with 
total lymphoid x-radiation prior to cadaveric renal transplantation. Although 
antilymphocyte globulin and corticosteroids were given initially, all 
immunosuppressive therapy was subsequently withdrawn and the patients 
apparently displayed donor-specific tolerance and retained good function for the 
duration of follow up which ranged from 47 to 94 months (Strober et al, 1989). 
More recently, two cases of acquired immunological tolerance to renal 
allografts were described by Sayegh in patients who had previously undergone 
bone marrow transplantation from the same HLA-identical sibling (Sayegh et al, 
1991). In a similar report, tolerance to an HLA-B, DR disparate renal allograft 
after bone marrow transplantation from the same donor was reported in a child 
with Wiskott-Aldrich syndrome and chronic glomerulonephritis (Jacobsen et al, 
1994). Clearly the approaches used in these small case studies are not applicable 
to most renal or cardiac transplant recipients but never the less these interesting 
cases serve to indicate that some form of transplant tolerance is perhaps a 
realisable goal in the clinic. To achieve this goal however, requires a better
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understanding of the regulation of immune system and insight how it can be 
manipulated to optimise tolerance induction.
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CHAPTER TWO 
Immunological basis of transplantation
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2:1 The major histocompatibility complex (MHC)
The fate of tissue grafted from one individual to another is dependent principally 
upon cell-surface antigens which are encoded by that area of the genome known 
as Major Histocompatibility Complex (MHC). The MHC was first described by 
Gorer et al in 1948 (Gorer et al, 1948) as the genetic region responsible for 
determining the strength of skin allograft rejection in mice. It is the most highly 
polymorphic region of the genome and whilst this poses considerable difficulties 
from the point of view of the transplant clinician trying through matching to 
minimise the MHC disparity between organ donor and recipient, MHC 
polymorphism confers a survival advantage for the species because of the 
biological function of class I and class II MHC molecules (discussed in page 
44).
The MHC is located on the short arm of chromosome six in man, the middle 
portion of chromosome 17 in the mouse (where it is designated H-2 complex) 
and on chromosome number 20 in the rat (where it is designated RT1) 
{Gunther et al, 1979; Gill et al, 1978; J.Klein, 1979}.
In man MHC antigens were first identified on peripheral blood leukocytes and 
designated human leukocytes antigens (HLA) (Dausset, 1958). The first HLA 
antigens identified were MHC class I antigens but the observation that 
individuals matched for class I HLA antigens still showed a strong in vitro 
mixed lymphocyte response led to the discovery of a second group of surface 
HLA antigens which were designated class II antigens (or D region). These
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were first detected serologically in 1973 (Van Leeuwen et al, 1973; Thorsby 
and Piazza, 1975).
2:1:1 The class I MHC region
There are at least 17 MHC class I loci in the human, but the classical 
transplantation antigens are HLA-A, -B, and -C (Trowsdale et al, 1992 and 
Campbell and Trowsdale, 1993). In the mouse, class I molecules are encoded 
by the H-2D, H-2K and H-2L regions (Rammensee et a l , 1993) and in the rat 
class I antigens are encoded by the RT1A and RT1C regions (Gunther et al, 
1979 and Blankenhom et al, 1983).
2:1:2 The class H MHC region
The human class II region is encoded by the HLA-DP, -DR and -DQ loci. In the 
mouse, class II antigens are encoded by the H-2I region genes, including I-A 
(which is equivalent to HLA-DQ) and I-E (which is analogous to HLA-DR). In 
the rat, the RT1B and RT1D loci encode for class II molecules which are 
analogous to the mouse IA and IE regions respectively (Blankenhom et al, 1980 
and 1983; Blankenhom and Cramer, 1985).
The class II region of the MHC also contains genes which govern antigen 
processing (Cho et al, 1991) and are called Tapi and Tap2 in humans 
(transporters in antigen processing), mtpl and mtp2 in rats (MHC linked 
transporter protein) and HAM1 and HAM2 (histocompatibility antigen 
modifier) in mice. These genes encode for proteins which function as 
transmembrane pumps which deliver peptides for loading into class I MHC 
molecules (Spies et al, 1992; Solheim et al, 1997 and Monaco, 1993).
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2:1:3 The class D1 region
The class III region of the MHC is telomeric to class II genes and encodes for 
components of the complement system including C2, C4 (C4A and C4B) and 
factor B. This region also includes the genes for heat shock proteins and tumour 
necrosis factors a  and p (TNF).
2:2 The structure of MHC molecules
MHC class I molecules are made up of a heavy (or a) chain and a light (or P) 
chain (P2 microglobulin) [see figure 2:1]. The a  chain is approximately 44 
kilodalton (KD) in humans, 47 KD in mice and 45 KD in rat and comprises 
approximately 350 amino acids. The non MHC encoded light chain is invariable, 
12 KD in size and known as p2-microglobulin. The heavy chain consists of 
three extracellular domains a l ,  a2, a3, a transmembrane region and a 
cytoplasmic tail at the carboxyl terminus. p2 microglobulin is non-covalently 
attached to the heavy chain. The a l  and a2 domains form a platform 
comprising an eight stranded p-pleated sheet supporting two parallel strands of 
a-helix thus forming a peptide accommodating groove approximately 1 x 2.5 
nm in size (figures 2:1) [Bjorkman et al, 1987]. The peptide accommodated in 
the binding groove appears to be an integral part of the protein complex since 
“ empty” class I molecules are generally unstable and not expressed on the cell- 
surface (Ljunggren et al, 1990 and Schumacher et al ,1990). Class I bound 
peptides are typically 8 to 11 amino acids long and are tightly mounted in the 
groove in an extended configuration. Comparison of the amino acid sequence of 
a large number of human and murine class I heavy chains have indicated that
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most of the polymorphic residues are located either in the a-helical sides of the 
peptide binding cleft or on the p-strands that form the floor of the cleft and are 
oriented such that the amino acid side chains point in to the cleft or toward the 
top of the helices. Thus polymorphism among class I MHC alleles serves to 
create variation in the chemical surface of the peptide binding cleft. In contrast, 
the a3 domain of the heavy chain and P2-microglobulin both have highly 
conserved amino acid sequences.
Class II MHC molecules comprise two non-covalently associated polypeptide 
chains (see figure 2:2). These chains (designated a  and p) are similar to each 
other in overall structure although the a  chain (32-34 KD) is slightly larger than 
the p chain (29-32 KD) as a result of more extensive glycosylation (Brown et al, 
1993). The peptide-binding groove of the class II molecule is formed by an 
interaction of both chains involving the a l  and pi domains (Brown et al, 
1988a). More specifically, a l  and pi fold to form an eight stranded p-pleated 
sheet platform supporting two a-helices; four strands of P-pleated sheet and 
one of the a-helices are formed by a l  and the other four strands of the P sheet 
and the other a  helix are formed by pi. As in the class I structure, the a  helices 
form the sides and the P strands form the floor of the peptide-binding cleft. 
Unlike class I, the ends of the class II binding cleft are open thus allowing 
bound peptide to extend out from the cleft. Peptides recovered from purified 
class II molecules range from 10 to 30 amino acids in length (mean of 14 amino 
acids) [Rammensee et al, 1993; Neefjes and Ploegh, 1992].
Figure 2:1 The polypeptide structure of the HLA-A2 class I molecule
(Bjorkman et al, 1987)
The three dimensional structure of the 
extracellular region was established from the 
X-ray crystallographic structure of the HLA-A2 molecule.
Figure 2:2 The polypeptide structure of HLA-DR1 class II molecule
(LJ Stern, 1994)
The three dimensional structure of the extracellular domains of 
the class II MHC molecule(HLA-DRl).
Like class I molecules, the polymorphic residues of class II molecules are 
concentrated in the a  1 and pi regions such that they lie in the a-helical sides or 
P-pleated sheet floor of the peptide-binding cleft with their side chains pointing 
in to the cleft or toward the top of the a  helices. For class II MHC molecules, 
like class I MHC, the amino acids polymorphism determines the specificity and 
affinity of peptide binding. A high level of polymorphism in the population 
ensures that some individuals are likely to bind antigenic peptides arising from 
any of the large number of pathogenic microbes in the environment and thereby 
providing an evolutionary explanation for the extensive seen in the MHC region 
(Lawlor et al, 1990).
2:3 Tissue distribution of MHC molecules
The distribution of class I and class II MHC antigens varies between organs and 
species. In general terms most nucleated cells express class I MHC whereas 
constitutive expression of class II MHC is much more restricted. Class I MHC 
is expressed on vascular endothelium cells. Renal tubule cells are weakly 
positive for class I antigens in both rats and humans (Hart and Fabre, 1981b ; 
Daar et al, 1984), but cardiac myocytes are generally class I negative. Interstitial 
dendritic cells are strongly class I MHC positive in both the rodents and human 
(Daar et al, 1984; Milton and Fabre, 1985).
Class II MHC is expressed constitutively on dendritic cells, B cells, monocytes, 
and macrophages, which all have the common property as antigen presenting 
cells for T lymphocytes. In addition, class II expression can be induced in 
vascular endothelium and thymic epithelium by certain cytokines (e.g. EFNy)
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(Klareskog et al, 1986; Collins et al, 1984). In rodents, resting endothelial cells 
are class II negative. In the rat, proximal renal tubules are class II positive (Hart 
and Fabre, 1981b) while in humans tubular expression of class II is variable 
(Fuggle et al, 1983) and in the mouse renal tubules are class II MHC negative 
(Benson et al, 1985).
Expression of both class I and class II MHC is dramatically upregulated by 
certain cytokines. Interferon y, for example, strongly induces expression of both 
class I and class II MHC whereas TNFa induces expression of class I MHC 
(reviewed by Arai et al, 1990 and Halloran et al, 1993a). Consequently during 
allograft rejection rat vascular endothelial cells express increased levels of class 
I MHC and become class II MHC positive.
2:4 Function of the MHC molecules
MHC molecules are expressed in abundance on the surface of antigen 
presenting cells and their biological function is to present peptides derived from 
foreign proteins to the T cell and thereby stimulate a T cell dependent immune 
response. MHC class I molecules present endogenously synthesised peptides to 
CD8 lymphocytes, which are usually cytotoxic T cells (CTL) (Yewdell et al,
1990). Expression of class I molecules depends on the expression of p2- 
microglobulin and mice lacking a functional P2-microglobulin gene do not 
express class I molecules on the surface. Such animals lack mature CD8 T cells 
(because they are not selected for maturation within the thymus) and have 
defective cell-mediated cytotoxicity (Zijlstra et al, 1990).
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MHC class EE molecules present exogenously derived antigens to CD4 T 
lymphocytes (Yewdell et al, 1990). MHC class II molecules expressed on 
thymic stromal cells plays a key role in the positive and negative selection of 
CD4 T cells during thymopoiesis and genetically engineered mice that do not 
express MHC class II antigens lack CD4+ T cells in the periphery (Cosgrove et 
al, 1991).
2:5 Minor histocompatibility antigens
The MHC is not the only genetic locus which influences tissue incompatibility 
and a large number of additional loci on different chromosomes may also play a 
role in graft rejection. These so called “minor” histocompatibility genes encode, 
minor histocompatibility antigens (mH). The ability of minor antigens to 
provoke graft rejection is usually, although not always, substantially less than 
that of MHC molecules. However, the fact that skin grafts between some MHC 
identical mouse strains may be rejected almost as rapidly as those between 
MHC incompatible strains demonstrates that minor antigens are not necessarily 
weak transplantation antigens (Loveland and Simpson, 1986). The precise 
nature of minor histocompatibilty antigens is enigmatic but over forty loci 
encoding allelic forms of mH antigens have been found throughout the mouse 
genome (Bailey, 1975). The best defined mH antigen is the H-Y antigen which 
is expressed by male but not female mice, and may provoke rejection of male 
skin grafts by syngeneic female mice (Loveland and Simpson, 1986). 
Incompatibility for the mH is cumulative and multiple minor histocompatibility 
antigen differences can result in a significant graft rejection response. The
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antigenic products of the mH loci are capable of activating either cytotoxic T- 
lymphocytes (CTL) or T-helper (Th) cells and those that lead to stimulation of 
CTL responses have been shown to be peptides derived from intracellular 
proteins (Wallny and Rammensee, 1990 and Griem et al, 1991).
2:6 Antigen processing and presentation
As already outlined, MHC molecules have the unique ability to bind short 
antigenic peptides and display them as peptide-MHC complexes in a form that 
can be recognised by T cells. The conversion of complex native proteins to 
MHC-associated peptide fragments by the antigen presenting cells is known as 
antigen processing.
2:6:1 Antigen processing and class I MHC transport
MHC class I molecules generally derive their bound peptide from intracellular 
proteins; these may be self proteins or foreign proteins (such as, those 
synthesised from viral RNA). Such proteins are broken down into peptides 
within the lysosome and class I antigen processing is inhibited by agents, such as 
brefeldin A, which block movement of membrane protein from the endoplasmic 
reticulum (ER) to the Golgi or the adenovirus E3/19K gene product, which 
specifically binds to class I molecules and retains them in the ER (Nuchtem et 
al, 1989 and Cox et al, 1990). The MHC class I associated peptides are 
translocated over the ER membrane by the TAPI and TAP2 (transporter 
associated with antigen presentation) proteins which are located in the ER 
membrane (Braciale et al, 1987). Assembly of MHC class I heavy chain, P2m 
and peptide to form a heterotrimer complex is essential for efficient release from
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ER (Ploegh et al, 1981). After release from the ER, MHC class I molecules are 
transported through the Golgi apparatus and the trans-Golgi reticulum network 
to the cell surface (Neefjes et al, 1988; Yewdel & Bennik, 1989).
As most nucleated cells express class I MHC and can therefore display peptide 
antigens in the class I binding groove, virally infected cells synthesising viral or 
mutant proteins can be marked for recognition and elimination by CD8 CTL. 
2:6:2 Antigen processing and class II MHC transport 
Antigens that enter an APC from the extracellular environment usually result in 
peptide fragments which associate with class II MHC molecules. Exogenous 
antigens include, for example, proteins synthesised by extracellular bacteria, 
fungi, and parasites as well as proteins administered during immunisation. 
Exogenous antigen usually enter the cell by phagocytosis or receptor mediated 
endocytosis. Internalised antigen localises in membrane-bound vesicles 
(endosomes) which facilitate degradation and intracellular transport. Class II 
molecules are assembled in the ER from an a-and (3- chain but, in contrast to 
class I MHC molecules they also associate with a third molecule, the invariant 
chain (I), which facilitates assembly and transport of the class El MHC molecule 
(Anderson et al, 1992) and circumvents premature endogenous peptide binding 
in the ER. Class II antigen processing is sensitive to inhibition both by 
lysosomotropic agents, such as chloroquine and ammonium chloride, which 
raise the pH of these compartments and to inhibitors of endosomal proteases 
(Takahashi et al, 1987). After MHC class II molecules enter the endocytic 
pathway, they are retained there for 1-3 hours before they appear at the cell
surface (Neeles et al, 1990). The invariant chain is degraded by proteases, 
thereby restoring the peptide binding capacity of class II molecules (Blum et al, 
1988 and Neeles et al, 1992).
2:7 T cell receptor structure and function
T cells recognise peptide antigens bound to MHC molecules through their T cell 
receptor (TCR). The TCR is a heterodimer consisting of two polypeptide 
chains, designated a  and p, covalently linked to each other by disulphide bonds. 
The a  chain is a 40 to 60 KD acidic glycoprotein and the P chain is a 40 to 50 
KD uncharged or basic glycoprotein. X-ray crystallography has confirmed the 
structural similarity between the a  and P chains of the TCR and 
immunoglobulin (Ig) polypeptides. Both a  and p chains have variable (V) and 
(C) regions. The junction between V and C regions is encoded by a joining (J) 
segment gene and, in the case of P chain only, a diversity (D) segment gene. 
TCRap receptors are present on most T cells (>95% of peripheral T cells and 
over 50% of thymocytes from adult mice). A small number (less than 10%) of T 
cells express instead the y5TCR. y6 T cells are found in higher abundance on 
lymphocytes located in epithelial surfaces.
The TCRaP associates at the T cell surface with a series of polypeptides which 
together comprise the CD3 complex. In man CD3 consists of four polypeptide 
chains designated; y , 8, e and C, chains (each of 20-28 KD). The y , 5 and 8 
chains are structurally related single domain members of the immunoglobulin 
supergene family whereas the C chain is unrelated and forms C,-Q dimers. In 
rodents, a fifth chain Cn) is also present. The stoichiometry of the most common
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TCRs is ap-ySs in man or aP-ySe Qr\ in rodents. The CD3 cytoplasmic 
domains each contain a motif called an Antigen Recognition Activation Motif 
(ARAM) or Tyrosine-based Activation Motif (TAM) (reviewed by Weiss,
1991).
2:7:1 CD4 and CD8 co-receptors
CD4 is a transmembrane glycoprotein which is expressed on approximately 
65% of mature T cells and is a member of Ig superfamily. CD4 was originally 
designated T4 in humans, L3T4 in mice, and W3/25 in rats. It is an important 
accessory molecule and facilitates the interaction of the T cell with APCs or 
CTL target cells. The function of CD4 (and CD8) is intricately associated with 
TCR function, and these molecules are sometimes designated T cell-co- 
receptors. CD4 is approximately 55 KD in size, and is expressed as a monomer 
on the surface of peripheral T cells and thymocytes. In humans and rats, 
although not in the mouse, CD4 is also present on monocytes, macrophages and 
langerhans cells (Wood et al, 1983; Barclay AN, 1981; Steininger et al, 1984). 
CD4 comprises four extracellular Ig-like domains [figure 2:3] (two membrane 
proximal (V4 and V3) and two membrane distal (V2 and VI) domains), a 
hydrophobic transmembrane region and a highly basic cytoplasmic tail 38 amino 
acids long. The gene encoding CD4 is located on human chromosome 12 (Isobe 
et al, 1986; reviewed by Bierer et al, 1989 and Keegan et al, 1992).
The crucial importance of CD4 in T cell function was initially demonstrated by 
the ability of anti-CD4 antibodies to block class II MHC-restricted antigen 
stimulation of CD4 T cells both in vitro and in vivo (Reinherz et al, 1979). CD4
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has two important functions in the activation of T cells. First, it serves as an 
adhesion molecule by virtue of its ability to bind via its two N-terminal Ig-like 
domains to the nonpolymorphic 02 domain of the class II MHC molecule 
(Eichmann et al, 1987; CA Janeway, 1989, Doyle and Strominger, 1987). 
Second; the CD4 molecule transduces signals and facilitates TCR complex- 
mediated signal transduction upon binding class II MHC , thereby promoting T- 
cell activation. Monoclonal antibodies directed against CD4 may have either 
stimulatory or inhibitory effects on MHC-independent T cell activation triggered 
by anti-TCR or anti-CD3 antibodies (Saizwa and Janeway, 1987). After 
stimulation of T cells by antigen plus MHC (or anti-TCR mAbs) there is rapid 
phosphorylation of serine residues in the cytoplasmic tail of the CD4 molecule. 
Furthermore, a lymphocyte-specific protein tyrosine kinase, called Lck (or 
P56lck), is physically associated with the cytoplasmic tail of the CD4 molecule 
and is essential for full T cell activation (Miceli et al, 1993).
The CD8 receptor is a glycoprotein present on class I restricted T cells and 
contributes to activation of these cells by binding to class I MHC on antigen 
bearing cells. The CD8 molecule was originally designated Ly2 antigen in the 
mouse, T8 in man and 0X8 in the rat. An important role for CD8 in T cell 
activation was first suggested by studies demonstrating that anti-CD8 mAbs 
could block target cell lysis by class I restricted cytotoxic T cells but not by the 
small subset of cytotoxic class D-restricted (CD4) cytotoxic cells (Braakman et 
al, 1987; reviewed by Bierer et al, 1989). CD8 comprises two chains (a  and 0), 
each with a single immunoglobulin-like external domain. The cytoplasmic region
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of the a  chain includes a binding site for the src-related tyrosine kinase P56lck, 
through which the co-signalling effects of CD8 engagement are presumably 
mediated. The a  chain can be expressed as a full length form or alternatively a 
spliced a  form which lacks the C-terminal cytoplasmic domain including the 
P56lck binding site. Most of the CD8 molecules are expressed as aP 
heterodimers but a  homodimers also exist (Bierer et al, 1989; Miceli and 
Pames, 1993).
2:7:2 T cell activation
T cell activation requires two transmembrane signals. The first signal is 
delivered through the engagement of TCR with MHC/peptide complex (figure 
2:4) and the second signal is provided through interaction of additional T cell- 
APC ligand-receptor pairs on T-cell and APC, including ICAM1-LFA1, CD2- 
LFA3 and CD28-B7 (figure 2:3).
TCR-mediated activation results in the phosphorylation of a number of 
intracellular proteins including the Src-family of protein kinases (e.g. P59fyn) and 
the CD3 ARAM motifs. Thereafter, the tyrosine-phosphorylated ARAMs 
recruit additional effector molecules by serving as interaction sites for ZAP-70 
kinase which contains a specialised binding domains (SH2) for phosphotyrosine 
residues. TCR engagement is not usually sufficient to trigger T activation and 
engagement of CD4 or CD8 co-receptors also necessary (reviewed by Fields 
and Roy, 1996).
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Figure 2:3 CD4 and CD8 T lymphocyte after engagement with T cell receptor 
(A &B). CD4 molecule extracellular domains (C).
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2:8 Allorecognition
It has long been recognised that the normal T cell repertoire contains a very 
high frequency (1-10%) of T cells capable of recognising and responding to 
alloantigens (Sherman and Chattopadhyay, 1993). Two principal hypothesis 
have been proposed to explain this high frequency of alloreactive T cells. 
Matzinger and Bevan (Matzinger et al, 1977) proposed that a single allo-MHC 
product can stimulate multiple T cell clones by formation of multiple “binary 
complexes” between MHC and different endogenous peptides. In the light of 
current understanding of TCR-MHC interactions, this hypothesis would imply 
that alloreactive T cells recognise allogeneic MHC molecules together with a 
wide range of different endogenous peptides displayed by the MHC molecules 
thereby stimulating multiple T cells clones each with specificity for different 
peptides presented by donor MHC.
Bevan (Bevan et al, 1984) subsequently proposed an alternative, but not 
mutually exclusive, possibility suggesting that the high frequency of responding 
T cells results from the very large number of MHC molecules displayed by APC 
(“high determinant density hypothesis”).
Further clarification of the molecular basis of allorecognition was provided by 
Lechler and his colleagues (Lombardi et al, 1989) in studies using T cell clones 
specific for HLA-DR. On the basis of their experimental findings they proposed 
that an allo-MHC molecule can be envisaged as having two important functional 
sites. The first site comprises amino acid residues on the upper face of the a  
helices which make direct contact with TCR. The second site is
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Figure 2:4 The tri-molecular complex of T-cell receptor, MHC molecule & 
peptide. (Robert Lechler, 1994)
formed by amino acids which form the antigen binding groove i.e. those 
residues on the inner surface of the a-helices and the exposed area of the (3 
strands forming the floor of peptide binding groove. These sites determine the 
nature of the bound peptide but do not contact the TCR directly. Lombardi et al 
showed that, depending on the nature of the MHC disparity, the TCR may 
recognise polymorphic residues on either the a  helices or the bound peptide 
itself (Lombardi et al, 1989).
Allogeneic MHC molecules are unique as antigens because they are able to 
directly stimulate T cells without the need for processing and presentation by 
recipient APC. This is known as direct allorecognition (reviewed by 
Auchincloss and Sultan, 1996). In addition, allogeneic MHC molecules may also 
be treated like nominal protein antigens and processed and presented as short 
antigenic peptides in the context of self-MHC by recipient APC, so called 
indirect allorecognition (reviewed by Auchincloss and Sultan, 1996).
2:8:1 The indirect allorecognition pathway
Although the direct pathway of T cell allorecognition is generally thought to be 
the principal pathway responsible for acute rejection, there is now increasing 
evidence that the indirect pathway may also plays a significant role (Shoskes 
and Wood, 1994). A role of the indirect pathway in allorecognition was first 
postulated by Butcher and Howard in 1982 (Butcher GW and Howard JC, 
1982) and by Lechler and Batchelor in the same year (Lechler et, 1982a). The 
latter authors argued that the indirect pathway accounted for the rejection of rat 
kidney allografts which lacked donor strain APC (Hart et al, 1980; Lechler and
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Batchelor, 1982a & 1982b). Later, Fangmann and colleagues (Fangmann et al, 
1992a) provided convincing evidence for the indirect pathway by demonstrating 
that Lewis rats primed with synthetic peptides corresponding to the Aa class I 
molecule displayed accelerated rejection of Aa disparate DA skin grafts. 
Similarly, Benichou and co-workers showed that spleen cells from BALB/c and 
SJL mice given AK strain skin allografts proliferated strongly when stimulated 
with AK class I MHC derived peptides in vitro (Benichou et al, 1992). 
Confirmatory data on the role of the indirect pathway was subsequently 
provided by several other groups (Shirwan et al, 1995, Gallon et al, 1995).
The potential contribution to graft rejection of T cells activated by indirect 
pathway is not limited to rejection of skin grafts. Benham et al, reported that 
semi-allogeneic (DA X Lewis) FI kidney allografts which had been depleted of 
donor interstitial dendritic cells (to minimise the possibility of direct T cell 
allorecognition) were rejected more rapidly by Lewis recipients which had been 
primed with DA class I peptides prior to transplantation (Benham et al, 1995). 
Despite such experimental data, information regarding the indirect pathway in 
clinical transplantation is still very limited.
The relative roles of the indirect and direct pathway in the rejection process is 
not clear, although it is generally held that the direct pathway is the major route 
responsible for acute graft rejection in non-sensitised recipients whereas the 
indirect pathway may play a contributory role in accelerated allograft rejection 
in previously sensitised recipients as well as in chronic graft rejection (Benham 
et al, 1995; Auchincloss and Sultan, 1996). The activation of recipient CD4 T
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cells by polymorphic donor peptides presented on various recipient APC might 
enhance various effector mechanisms of rejection. Fabre’s group, have proposed 
that T cells activated by the indirect pathway may provide help for conventional 
effector mechanisms, notably antibody production, cytotoxic T cell generation 
and intragraft DTH reactions (Fangmann et al, 1992b, Parker et al, 1992).
2:9 Mechanisms of graft rejection
Current understanding of the mechanisms responsible for graft rejection is 
largely based on the immunological response of laboratory animals to tissue or 
organ grafts from genetically dissimilar donors. The rejection process can, for 
the ease of description, be divided in to three different stages, namely the 
afferent stage, the central stage and the efferent stage.
2:9:1 Afferent phase of allograft rejection
During the afferent phase of allograft rejection, the immune system of the 
recipient recognises and becomes primed to graft alloantigens. Bone marrow 
derived dendritic cells within the transplant, the so called passenger leukocytes, 
play a key role in host sensitisation (reviewed by Roake et al, 1994). Dendritic 
leukocytes are found in the parenchyma of all commonly transplanted tissues 
(Hart et al, 1981a & Daar et al, 1984). These cells express high level of MHC 
class I and II antigens on their surface and are potent stimulators of the in vitro 
mixed lymphocyte reaction (Klinkert et al, 1980, Steinman et al, 1978, Mason et 
al, 1981). After organ transplantation, donor DC can be identified in the 
recipient spleen between days 1 and 4, where they form clusters with 
alloreactive lymphocytes and stimulate alloimmunity (Larsen et al, 1990, Austyn
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and Larsen, 1990). The importance of the DC in initiating rejection of allografts 
in vivo was first demonstrated by Lechler and Batchelor (Lechler et al, 1982a). 
They transplanted rat kidneys into intermediate hosts which had been pre­
treated with anti-donor alloantibody (enhancing antibody) to prevent rejection 
of the kidney (so-called passive enhancement). After several weeks, to allow 
donor bone marrow derived dendritic cells to disperse and be replaced by those 
of recipient origin, the kidneys were re-transplanted into a second unmodified 
hosts syngeneic with the intermediate host. In certain rat strain combinations, 
kidneys devoid of donor DC were not rejected by the second host. However, if 
the secondary recipient was injected with donor strain dendritic cells at the time 
of retransplantation, graft rejection was fully restored, thus demonstrating the 
importance of DC in initiating allograft rejection.
Certain other cell types, notably endothelial cells, are also capable of acting as 
antigen presenting cells, although they are generally much less efficient in this 
respect than DC and monocytes which are usually designated “ professional” 
APCs (Hirschberg et al, 1981). Purified vascular endothelial cells are able to 
stimulate proliferation of allogenic lymphocytes in vitro (Pober and Cotran, 
1991 and Hughes et al, 1990). As already noted, human endothelial cells as well 
as rodent endothelial cells do not constitutively express class II antigens, and in 
the resting state would not, therefore, be able to directly activate CD4 T cells. 
However, rat endothelial cells which have been cultured in vitro in the presence 
of IFNy to induce class II MHC are able, when injected intravenously, to 
sensitise recipients and accelerate allograft rejection thereby confirming the
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ability of rodent endothelial cells to initiate an alloimmune response (Ferry et al, 
1987).
2:9:2 Central phase of allograft rejection
The central phase of graft rejection encompasses the complex cellular 
interactions between APC and lymphocytes, and between lymphocyte subsets 
(e.g. T-B cell collaboration) and takes place mainly in the lymph nodes and 
spleen of the recipient. The T helper cell, usually a CD4 T cell, plays a central 
role in regulating and orchestrating the various cellular and humoral effector 
mechanisms responsible for graft rejection and does so by elaboration of a 
variety of cytokines (reviewed by Dallman, 1992 and Nadeau et al, 1996). 
Cytokines are soluble proteins which act through binding to specific receptors, 
in either an autocrine or a paracrine fashion and thus serve to mediate bi­
directional cell-cell communication. They are important not only for activation 
of the immune response but also for regulating of both the magnitude and 
nature of the resulting immune response. Fig 2:5 depicts the role of different 
cytokines in the generation of the alloimmune response. A detailed discussion of 
the role of individual cytokines in the development of the immune response is 
beyond the scope of this thesis but some important points are worthwhile 
highlighting (see later page 67).
2:9:3 T cell subsets and the efferent phase of allograft rejection
T lymphocytes are essential for allograft rejection (Dallman et al, 1982, Dallman 
and Mason, 1982, Bradley and Bolton, 1992). In T cell deficient rodents, 
reconstitution with CD4 T cells alone is usually sufficient to restore allograft
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rejection (Bolton et al, 1989; Grade et al, 1990; Bell et al, 1990). However, in 
certain experimental situations (some mutant class I MHC disparate mouse 
strain combination), adoptive transfer of CD8 T cells alone is sufficient to 
restore rejection of skin allografts (Rosenberg et al, 1992).
The T cell-dependent cellular and humoral effector mechanisms responsible for 
mediating allograft rejection are those which the immune system normally 
employs to deal with infectious agents i.e. there is no unique effector 
mechanisms responsible for the non-physiological phenomenon of allograft 
rejection. Specific cytotoxic T cells, activated macrophages and natural killer 
(NK) cells, and antibody dependent mechanisms may all, in principle, result in 
graft rejection. The relative role of each of these effector mechanisms in graft 
rejection has not been clearly defined and is probably dependant on factors such 
as the type of graft, the MHC disparity and whether the recipient has been 
previously sensitised (Bradley, 1996).
Overall, cell-mediated immune mechanisms are generally thought to be more 
important than antibody dependent responses in mediating acute allograft 
rejection in non-sensitised recipients and there has been much debate on 
whether specific cytotoxic T cells or DTH mechanisms are the most important 
(Bradley, 1996).
2:9:3:1 Cytokines and the generation of immune response
In 1986, Mosman and colleagues reported that most cloned lines of murine CD4 
T cells could be classified into two groups, designated Thl and Th2, based on
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Figure 2:5 The central role of the T helper cell and cytokines in the generation
of allo-immune response
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the type of cytokines they produced and their related functional activities as 
shown in figure 2:6 (Mosman et al, 1986). This work led to the development of 
the Thl\Th2 paradigm which encompasses the concept that CD4 T cells (ThO) 
differentiate into one of two T cells subsets, Thl and Th2, and these each 
produce a distinctive pattern of cytokines. Thl cells generally produce IL-2, 
IFNy, TNFa and are responsible for producing cell-mediated immune 
responses. Th2 cells generally produce the cytokines IL-4, IL-5, EL-6, EL-10 
and IL-13 and are important for humoral immune responses. Both T helper 
types produce EL-3, TNFa and granulocyte colony-stimulating factor (GM- 
CSF). Interestingly, the development of Thl and Th2 cells is itself closely 
regulated by cytokines. IL-12 and IFNy promote the development of Thl cells 
whereas IL-4 promotes the Th2 cells. There is also strong cross-regulation 
between the two T cell subsets (reviewed by Smith, 1989). IL-4, inhibits the 
development of Thl responses whereas EL-12 and IFNy, inhibit the 
development of Th2 cells. EL-12, in particular, has recently emerged as a key 
immunoregulatory cytokine controlling the balance of Thl and Th2 responses. 
It is a heterodimer consisting of two covalently linked glycosylated chains (P40 
and P35), and is produced mainly by monocytes, B cells and also dendritic and 
NK cells (Trinchieri,1993 and 1995).
4
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Figure 2:6 Cytokine production by Thl and Th2 T cell subsets.
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Th2 and Thl cells exert strong cross-regulation, EFNy from Thl cells inhibits Th2 cells whereas 
EL-4 from Th2 cells inhibits Thl cells. ThO cells may produce a mixed (Thl and TH2) cytokine 
pattern. 4
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2:9:3:2 The role of antibody in graft rejection
It has long been recognised that preformed cytotoxic alloantibodies may cause 
hyperacute rejection of kidney allografts in sensitised recipients. Such antibodies 
usually arise from a previous kidney transplant, pregnancy or blood transfusion 
(Kissmeyer-Nelsen et al, 1966; Williams et al, 1968; Patel and Tersaki, 1969). 
The binding of antibody to vascular endothelium leads to a sequence of events 
including complement fixation, platelet aggregation, fibrin deposition and graft 
destruction (Busch et al, 1971).
In the clinical setting preformed antibodies to class I MHC and to ABO blood 
group antigens are responsible for hyperacute rejection (Baldwin et al, 1991) 
but fortunately the clinical incidence of this problem has been greatly reduced by 
blood group matching, and screening recipient serum for the presence of 
cytotoxic alloantibodies against donor spleen cells and then avoiding 
transplantation in the presence of a positive cytotoxic crossmatch (Patel & 
Terasaki, 1969). Although IgM is the most efficient class of antibody for 
activating complement in vitro, IgG is more harmful to the transplanted organ 
(Baldwin et al, 1991). Alloantibody dependent effector mechanisms have not 
usually been thought to be responsible for acute rejection of organ allograft but 
Bradley and colleagues recently showed in the rat that alloantibody alone is 
able, in some circumstances, to effect acute allograft rejection (Morton et al, 
1993). Alloantibody may, in principle, mediate acute rejection by either 
antibody-dependent cellular cytotoxicity (ADCC) or by complement dependent 
lysis. In clinical practice evidence is also emerging which suggests that anti-class
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I alloantibodies may be associated with a vascular pattern of acute rejection 
during the first 6 months of transplantation (Halloran et al, 1993b).
2:10 Chronic graft rejection
Chronic rejection is responsible for the majority of late graft failures in clinical 
practice and is seen in all types of organ transplant i.e. kidney, heart and liver. 
Neither the aetiology nor the pathophysiology of the process is particularly well 
understood (Hayry et al, 1993, Paul and Benediktsson, 1993). However, several 
potential risk factors have been implicated in its aetiology. HLA matching is 
important and there is undoubtedly a lower rate of kidney allograft attrition in 
grafts from living related donors compared to kidneys from cadavers (Isoniemi 
et al, 1994). HLA-DR mismatching in particular increases the incidence of both 
acute rejection episodes and long term graft loss. Other important recipient 
factors contributing to chronic rejection are a high serum cholesterol and high 
LDL and triglyceride levels, as well as infection with cytomegalovirus (Almond 
et al, 1993).
The principle histopathological findings during chronic rejection, irrespective of 
the type of organ transplanted, are arteriosclerosis and interstitial fibrosis 
(reviewed by Hayry, 1995). Although both antigen-dependent and antigen- 
independent factors appear to contribute to the vascular endothelial injury which 
characterises chronic graft rejection, immunological factors are probably most 
important. Circulating anti-donor antibodies and antigen-antibody complexes 
may play an important role in triggering endothelial injury (Hayry, 1995). Much
4
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effort is currently being devoted to dissecting further the complex events 
underlying chronic allograft rejection.
4
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CHAPTER THREE 
Transplant tolerance: experimental strategies and possible mechanisms.
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3:1 Transplantation tolerance
The simple definition of transplantation tolerance as ‘specific absence of an 
immune response to an antigen’ does not adequately explain many of the more 
recent observations emerging from experimental studies of transplantation 
tolerance and there is wide agreement that the concept of ‘operational 
tolerance’ may be more useful. Operational tolerance is defined as the survival 
of a functional allograft in the absence of long-term exogenous 
immunosuppression even though the graft recipient may show apparent 
allorecognition of donor cells in vitro (Sachs, 1996). Operational tolerance can 
be achieved or induced by a variety of mechanisms.
3:2 Strategies for inducing experimental transplantation tolerance 
The strategies for inducing experimental transplantation tolerance can be 
broadly divided into those protocols in which some form of antigen pre- 
treatment is given (e.g. donor-specific blood transfusion, donor bone marrow or 
donor spleen cells) and experimental models in which non-specific 
immunosuppression is given around the time of transplant (either chemical 
immunosuppressant such as CsA or biological agents, notably monoclonal 
antibodies, against cell surface molecules or immunoregulatory cytokines).
3:2:1 Antigen pre-treatment
Its has been known for many years that donor specific blood transfusions 
(DSTs) may have a beneficial effect on the survival of subsequent renal 
transplant in rodents and humans (Marquet et al, 1971, Fabre and Morris, 1972, 
Opelz et al, 1973, Sollinger et al, 1986). In humans, pre-renal transplant DST
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was used at Washington University School of Medicine in 1971 (Newton et al, 
1973; Anderson et al, 1982). In the late 1970s and early 1980s pretransplant 
blood transfusion was widely accepted as having a significant beneficial effect 
on the survival of renal allografts from both living related and cadavers donors. 
Potential recipients were typically pre-treated with three aliquots (200-ml each) 
of whole blood DST at bi-weekly intervals under azathioprine coverage. Similar 
results have been obtained with a single transfusion performed immediately 
preoperatively (Davies et al, 1992; Alexander et al, 1992; Alexander et al, 
1993). It has been argued that blood transfusion only improves human kidney 
allograft survival when the recipient shares at least one HLA-DR antigen in 
common with blood donor (Lagaaij et al, 1989).
Recently, however, the improved results of transplantation together with the 
risk of viral disease transmission from transfusion led many centres to abandon 
deliberate blood transfusion as a method to improve kidney allograft survival. 
However, the Collaborative Transplant Study concluded that the potential 
benefit of blood transfusion was less than the risks of infection and 
presensitisation (Opelz, 1987) and interest continues in refining DST protocols. 
The potential of inducing transplantation tolerance by donor bone-marrow 
infusion has also been studied by several investigators. It is known that donor 
derived haemopoetic cells may be transferred to the recipient at the time of solid 
organ transplantation and detected as residents cells within recipient tissues 
many years afterwards (Larsen et al, 1990, Starzl et al, 1992). This observation, 
combined with evidence from experimental models that tolerance can be
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achieved if allogeneic haemopoetic cells are given to conditioned recipients, has 
led to the hypothesis that spontaneous haemopoetic microchimerism (the 
presence of cells of two genetically different tissue types in one individual) may 
be essential for the development and maintenance of immunological 
unresponsiveness to organ allografts (reviewed by Sykes, 1996). Barber and 
colleagues, in a protocol of DBM infusion for human cadaveric renal transplant 
recipients, used a 10-14 days induction course of Minnesota antilymphocyte 
globulin in 57 patients, beginning the day after transplantation and followed 7 
days later by transfusion of approximately 2-3 x 108 viable nucleated DBM 
cells/Kg body weight. All recipients were also treated with conventional triple 
therapy. Matched control patients did not receive DBM. While there was no 
difference in the number of rejection episodes, graft survival was significantly 
better in the DBM group than in the control group. Renal allograft survival in 
the DBM group at 12 and 18 months was 90% and 85%, respectively, versus 
71% and 67% , respectively, for the control group. In addition it had been 
possible in more than half of the patients in the DBM group to taper the amount 
of prednisone required (Barber et al, 1991).
The induction of a state of a mixed chimerism has been observed following 
human solid organ transplantation, and was noted to be present consistently in a 
group of successful long-term renal transplant recipients, in whom donor- 
specific reduction or diminution in mixed leukocyte reaction was observed 
(Starzl et al, 1993a). Although clinical strategies have been implemented to 
augment the chimeric state, no definitive relationship between the development
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of chimerism and immunological responsiveness has yet been identified (Schiltt, 
1997). It has been suggested that the capacity of allogeneic haemopoetic cells to 
induce tolerance results largely from their ability to induce intrathymic clonal 
deletion of thymocytes with TCRs that recognise antigens expressed by the 
haemopoetic cells (reviewed by Sykes, 1996). In essence, bone marrow 
transfusion attempts to harness nature’s clonal deletion mechanism. The 
potential mechanisms by which DST and DBM modulate the immune system 
are likely to be different in degree rather than in kind. These mechanisms include 
induction of T cell anergy, development of anti-idiotypic antibodies to HLA or 
TCRs, suppressor cell or veto cell activity, alteration of T cells subsets (Thl to 
Th2 shift), stimulation of regulatory CD4 T cells, clonal deletion by promotion 
of microchimerism or a combination of these various mechanisms.
Interestingly, the finding that freedom from immunosuppression was 
sporadically possible in long surviving recipients of liver allografts and the 
concurrent evidence that chimerism was uniformly demonstrable in such tolerant 
patients have led to prospective trials of complete weaning of 
immunosuppressive drugs in selective groups of transplant patients. The first 
report on weaning of immunosuppression was in 1993 by Thomas Starzl. He 
observed that 5 of 20 randomly selected long-surviving liver transplant 
recipients had stopped their medication for between 7 to 13 years (Starzl et al, 
1993b). In these 20 randomly selected patients along with additional 2 long­
term recipients, nine were female patients who had been given livers from male 
donors. In all nine the Y chromosome could be demonstrated in the skin or
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lymph nodes by in situ hybridisation and by PCR. Similarly, chimerism was also 
noted in the other 13 patients who were studied with HLA detection techniques 
to identify donor haplotypes (Starzl et al, 1993b).
In a small preliminary study, Starzl and colleagues weaned eight long-term 
recipients of renal allograft from immunosuppression therapy (Mazariegos et al, 
1995). These patients were recipients of living related kidneys of more than five 
years duration and had at least 2 years of stable graft function. Only one patient 
developed a rejection episode during weaning of immunosuppression and at the 
time of publication, the time off immunosuppressive drugs ranged from 3 
months to 29 years. Four of the patients were off immunosuppression for less 
than 2 years and are currently under follow up, whereas the other three patients 
were off immunosuppression for more than 14 years. This limited study of 8 
patients used only serum creatinine as an assessment of renal function. Ramos et 
al in a prospective randomised trial, evaluated seventy two long-surviving liver 
transplant recipients for weaning off of immunosuppressive drugs. Complete 
weaning was accomplished in 27.1%, with a 3-19 months drug-free follow-up 
period. Weaning is also progressing in 47.4% and has failed in 25.4% without 
graft losses. This prospective trial confirmed that many long-term survivors 
after liver transplantation can be successfully weaned off immunosuppression 
(Ramos et al, 1995). However the authors cautioned that this should only be 
contemplated 5-10 years posttransplantation and then only with careful case 
selection, and monitoring with a low threshold for reinstitution of 
immunosuppression. Recently, Starzl and colleagues reported the weaning of
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immunosuppressive therapy in 95 long-term recipients of liver transplants. 
Complete weaning was achieved in 18 of the 95 patients and 37 patients were, 
at the time of writing, in the uninterrupted process of drug weaning. In only 18 
patients was weaning interrupted because of a confirmed diagnosis of rejection. 
Twelve patients were withdrawn from the weaning protocol due to non- 
compliance (Mazariegos et al, 1997). One of the conclusions from this study 
was that neither the presence nor the quantity of microchimerism can be used as 
a guide to whether immunosuppression weaning should be considered in stable, 
long-surviving liver transplant recipients. In long-term liver allograft recipients, 
about 30% of recipients apparently can come off all immunosuppression 
without penalty of rejection. Stopping immunosuppression after other types of 
solid organ transplantation usually result in their rejection (Caine, 1997). 
Numerous reports have shown that injection of donor haemopoetic cells 
promotes allograft survival, for example, Salom et al achieved significant 
prolongation of rat cardiac allograft survival by perioperative intravenous 
injection of donor spleen cells and a single dose of CsA at day 2 after 
transplantation (Salom et al, 1993, Westra et al, 1991). Similarly, Wood et al 
have obtained indefinite survival of mouse cardiac allografts by pretreating 
recipients with DST and anti-CD4 mAb (Bushell et al, 1994). In a preclinical 
large animal model, injection of donor bone-marrow induced tolerance in 
bilaterally nephrectomised Rhesus monkeys who had received renal allografts. 
The animals received a 5-day treatment with rabbit anti-human thymocyte 
globulin (RATG) followed by donor BM infusion 7-8 days after the last dose of
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RATG treatment. No additional immunosuppression was given and, graft 
survival was more than 70 days in all animals. 30% of recipients lived for more 
than 100 days in comparison with control animals which received RATG only 
and rejected their grafts within 37 days. The addition of cyclosporin and 
prednisone in this experimental model led to graft survival of greater than 100 
days in 67% of animals (Thomas et al, 1989). Recently, Kawai et al induced 
mixed allogeneic chimerism and renal allograft tolerance in Cynomolgus 
monkeys by a regimen in which recipients were first conditioned by total body 
irradiation followed by donor BM and a short course of cyclosporin. This 
regimen led to graft survival of more than 100 days in all experimental animals, 
whereas control animals rejected their renal graft within 15 days. In addition, 
donor specific non-reactivity was confirmed by both MLR and skin 
transplantation. (Kawai et al, 1995). More recently, Thomas et al have induced 
tolerance to kidney allografts in Rhesus monkeys using perioperative anti-CD3 
mAb and donor BM without the need for continuous immunosuppression. The 
above protocol led to graft survival of more than 120 days in about 70% of 
experimental animals whereas the control animals rejected their renal graft 
within 10 days (Thomas et al, 1997).
3:2:2 Monoclonal antibodies in experimental organ transplantation
Monoclonal antibodies that deplete or block cells carrying their target antigen 
offer an exciting prospect for modifying graft rejection and have been studied 
extensively. With this in mind antibodies to a variety of T cell surface antigens 
[CD4, CD8, TCR, CD3, IL2-R, LFA1, CD28, CD40 and ICAM1] and
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cytokines [e.g. TNFa and IL-12] (Gorczynski et al, 1996) have been used (for 
summary see table 3:1). The mouse anti-rat TCRa(3 mAb (R73) has been shown 
to prolong cardiac allograft survival in both naive and sensitised recipients 
(Heideck et al, 1995 and 1996). Similarly, the soluble recombinant ligand, 
cytotoxic T lymphocyte A4 immunoglobulin (CTLA4-Ig), has been shown to 
block co-stimulatory signals delivered through the binding of members of the 
B7 family of molecules to their ligands (CD28 and CTLA4) on T cells. Therapy 
with CTLA4-Ig at the time of transplantation prolongs cardiac allograft survival 
in the mouse (Turka et al, 1992). In the rat, the blockade of CD28-B7 T-cell 
costimulatory pathway by administration of a single dose of CTLA4-Ig has been 
shown to result in tolerance to renal and cardiac allografts (Sayegh et al, 1995, 
Bolling et al, 1993).
In mice, a combination of anti-LFAl (leukocyte function antigen) and anti- 
ICAM-1 (intracellular adhesion molecule) mAbs have been shown to prolong 
survival of cardiac allograft indefinitely (Isobe et al, 1992). Recently, Larsen and 
colleagues used mAbs to block CD40 and CD28 simultaneously and achieved 
prolonged survival of cardiac allograft and, more impressively, skin allografts in 
the mouse (Larsen et al, 1996). In contrast, anti-CD8 mAbs when used alone, 
have been found to be ineffective in prolonging cardiac or pancreatic allograft 
survival in rodents (Roza et al et al, 1989a+b). However, Anti-CD8 used in 
combination with anti-CD4 may induce tolerance to allogeneic heart and skin 
allografts in the mouse (reviewed by Cobbold et al, 1996).
*
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Table 3:1 Prolongation of organ allografts survival by monoclonal antibodies in experimental
animals.
Target
molecule
Inducing mAb MAb
Type
Toleroge
n
GS Animal
model
Reference
CD3 FN18, Bll D Skin PS Mouse Stevens et al, 1990
CD3 145-2C11 D IL PS Mouse Mackieetal, 1990
CD4 OKT4A D Kidney PS Monkey Wee et al, 1992
CD4 OKT4A D Skin PS Monkey Jonkeretal, 1983
CD4 YTS-176.9.6 N Heart T Mouse Chenetal, 1992
CD4 YTS -191.1 D Heart T Mouse Pearson etal, 1993a+b
CD4 (0X38) D Heart T Rat Shizuru et al, 1990
CD4 (0X35) D Heart T Rat llano etal, 1991
CD4 (0X38) D Heart/Kid T Rat Yin & Fathman, 1995
CD4 (0X38) D IL T Rat Seydel et al, 1991
CD4 (0X35) D Heart T Rat Herbert & Roser, 1988
CD4, CD8 0X38+0X8 D+N Skin T Mouse Cobboldetal, 1990
CD4, B7 0X38, CTLA4Ig N SBT T Rat Yin etal, 1996
CD4 KT6,YTS199 N Heart T Mouse Darby et al, 1992 & 94
TCR ap TCR mAb D Heart T Rat Heidecke et al,1995, 96
CD28 CTLA4Ig * Kidney T Rat Sayeghetal, 1995
CD4,CD28 OX38+CTLA4 D+ * heart T Rat Yin & Fathman 1995
CD28,CD40 CTLA4-Ig,anti-gp3 9 ♦ Skin/heart T Mouse Larsen etal, 1996
ICAM1,LFA1 Anti-ICAM 1,LFA1 * Heart T Mouse Isobeetal, 1992
IL2-R NDS-61, 0X39 * Kidney T Rat Tellides et al, 1989
IL2-R ART-18, 0X39 * Kidney PS Rat Udeaetal, 1990
MHC-II HAK-75 * Kidney PS Dog Yamamoto et al, 1984
MHC-II HAK-75 * Heart PS Rat Sone et al, 1987
TNFa,p Anti-TNFa, p * Liver PS Rat Teramato et al, 1991
TNF-a Anti-TNFa * Heart PS rat Imagawa et al, 1990
D = Depleting mAb IL = Islets of Langerhans PS = Prolonged survival
T = tolerance SBT = Small Bowel Transplantation GS = Graft Survival
* = Blocking mAb N = Non-depleting mAb
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3:2:3 Targeting CD4 T cells
The CD4 molecule is an obvious target for mAb therapy because CD4 T cells 
play a central role in inducing and orchestrating the graft rejection responses 
(Mason and Morris, 1986; Hao et al, 1987; Hall, 1991 and Bradley and Bolton, 
1992). In rodents, depleting regimens of anti-CD4 mAbs have been shown to 
induce tolerance to cardiac (Shizuru et al, 1990) and pancreatic islets allografts 
(Alters et al, 1991). Non-depleting anti-CD4 mAb regimens have also been 
reported to prolong survival of pancreas (Burkhardt et al, 1989), skin (Qin et 
al, 1990) and cardiac allografts (Darby et al, 1994) in the mouse. Preclinical 
studies in Rhesus and Cynomolgus monkeys using the anti-CD4 mAb OKT4 
and OKT4a have demonstrated prolongation of both skin and renal allografts 
(Jonker et al, 1985 and Wee et al, 1992).
3:3 Mechanisms of transplantation tolerance
Since the pioneering studies of Medawar, a major goal in transplantation has 
been to develop clinically applicable strategies for tolerance induction in humans 
(Billingham and Medawar, 1953). A better understanding of the mechanisms 
responsible for inducing and maintaining tolerance is a necessary prerequisite to 
optimising clinically applicable protocols for inducing transplant tolerance.
The mechanisms underlying tolerance can be divided into two main categories: 
first thymic (or central) mechanisms and secondly extra-thymic (or peripheral) 
mechanisms. Although central mechanisms play the major role in maintaining 
tolerance to self antigens, it is likely that extra-thymic mechanisms are more 
important in maintaining transplant tolerance. This is undoubtedly an
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oversimplification, since continuous interaction between peripheral events and
those occurring in the thymus may occur to maintain a steady state of
immunological tolerance. There is, however, little evidence in adult models of
transplantation tolerance for clonal deletion, although this may be important in
neonatally induced tolerance to alloantigen (Streilein et al, 1993). Because it is
difficult in the tolerant animals to break tolerance by adoptive transfer of naive
or even alloantigen sensitised syngeneic lymphocytes the idea that tolerance is
maintained by an active form of suppression has gained popularity (Fabre &
Morris, 1972 and Shizuru et al, 1988). A considerable body of evidence has
now accumulated which suggests that tolerance is both induced and maintained
by regulatory or suppressor T cells. However, the failure to identify and clone a
separate population of suppressor cells in models of transplant tolerance has led
to a good deal of scepticism about the existence of a separate population of
suppressor cells whose only function is of immune suppression.
3:4 Central mechanisms of tolerance 
3:4:1 Self tolerance
T cell tolerance to self antigens is due predominantly to clonal deletion within 
the thymus as the result of contact between developing T cells and self antigen 
expressed on thymic epithelial cells. Burnet was the first to describe in his clonal 
selection theory that tolerance to self antigens is achieved by clonal deletion of 
autoreactive lymphocytes. Evidence supporting this theory was presented by 
Kappler and colleagues in 1987, who used antibodies recognising Vp 17+ TCR 
to trace the elimination of such T cell in I-E+ mice (Burnet, 1959; Kappler and 
Marrack, 1987). More recently, TCR transgenic mice were used and found to
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eliminate most of the cells expressing a self-reactive transgene (Sha et al, 1988; 
Von Behmer and Kisielow, 1989 and 1990). Once thymocytes express a surface 
TCR, they are subjected to two selective pressures in the thymus. First, is the 
positive selection which is imposed on cortical thymocytes and leads to the 
survival of only those thymocytes whose TCRs interact productively with 
thymically expressed (self) MHC molecules. Second, is the negative selection 
which occurs when the thymocytes have reached the thymic medulla and 
involves the elimination of thymocytes with autoreactive receptors. Thus, 
maturing thymocytes expressing high affinity TCR receptors for self-antigens 
are eliminated by apoptosis before they reach the periphery. Within the thymus, 
bone marrow derived dendritic cells (APC), thymic epithelial cells and 
thymocytes themselves all have been shown to contribute to self tolerance 
induction. The probable mechanism underlying these selective pressures is based 
on the different affinities for self MHC molecule/peptide complexes displayed by 
thymic epithelial and dendritic cells and this process can be summed up as the 
thymus ignores the useless, deletes the dangerous and selects the useful (Von 
Boehmer et al, 1989). Along with the concept of clonal deletion, clonal anergy 
(which is functional inactivation of a cell, without elimination) also emerged as a 
mechanism to explain how the immune system develops self-tolerance and 
avoids autoreactivity (Quill and Schwartz, 1987).
However, a small number of T cells may escape deletion within the thymus and 
must be rendered tolerant by peripheral mechanisms (Jenkinson et al, 1985; 
Kappler et al, 1988; reviewed by Matzinger, 1993 and 1994).
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3:5 Peripheral mechanisms of tolerance
The intrathymic events outlined above are clearly of great importance in the 
development and maintenance of self tolerance. The thymus is not able, 
however, to present the full range of either MHC class II or MHC class I 
associated autoantigens and it seems mandatory that additional systems of 
control for potentially autoreactive T cells must exist outside the thymus. Such 
mechanisms are likely to be of particular importance in the context of acquired 
transplantation tolerance. Four, non-mutually exclusive, hypotheses have been 
proposed to explain the induction of peripheral tolerance. These are, in broad 
terms, T cell ignorance, T cell anergy, immune deviation and suppression or 
active T cell regulation. Evidence that peripheral mechanisms of self tolerance 
exist, without clarifying how these mechanisms operate, comes from animal 
models which include those with spontaneous autoimmune disease and those 
expressing extrathymic transgene products (Bohme et al, 1990, reviewed by 
Kruisbeek and Amsen, 1996).
3:5:1 T cell ignorance
The concept of T-cell ignorance was originally proposed by Ohashi (Ohashi et 
al, 1991) following experiments in which expression of lymphocytic 
choriomeningitis virus glycoprotein as a transgene in pancreatic (3 cells was 
simply ignored by the immune system, evoking neither activation nor tolerance 
in T cells. Normally T cells are activated by the cross linking of their antigen 
receptor following the recognition of target antigen/MHC complexes presented 
on appropriate antigen presenting cells. There is evidence, mainly from studies
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in transgeneic mice, that peptides may be presented in the context of MHC class 
I on cells which are unable to trigger a response from T cells with appropriate 
TCRs (Gotz et al 1990; and Miller et al, 1990). T cells apparently ignore the 
presentation of antigen by these non-professional APCs and are not stimulated 
to undergo the metabolic or functional changes characteristic of either 
activation or inactivation. Similarly if an allograft is devoid of professional 
APCs (i.e. passenger leukocytes) then it may result in development of T cell 
ignorance within the recipient and thereby in graft acceptance (Lafferty et al, 
1986).
3:5:2 Anergy
The induction of anergy or functional inactivation of alloreactive T cells is one 
of the hypotheses currently receiving strong support as a mechanism of 
transplantation tolerance. T cells require two signals for full activation. The first 
signal is provided by engagement of the TCR with antigenic peptide plus MHC 
molecule on APCs (the tri-molecular complex figure 2:4). The second or 
“costimulatory” signal is provided by binding of specific receptors on T cells 
with their ligand or ligands on APC. It has been suggested that T cell anergy 
results from antigen receptor stimulation in the absence of costimulatory signals. 
MHC class II expression can be upregulated on various tissues including 
endothelial cells, kidney messengial cells and proximal tubule cells by certain 
cytokines, such as interferon y. This upregulation of class II may allow these 
cells to function as “non-professional” APCs which are lacking the 
costimulatory molecules for imparting the second signal. The best characterised
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costimulatory pathway is that provided by CD28 on T cells binding B7-1 and/ 
or B7-2 on APC (Linsley and Ledbetter, 1993 and Bluestone et al, 1995). B7 is 
an activation molecule found on B cells, monocytes and dendritic cells (Freeman 
et al, 1989; Larsen et al, 1992) whereas CD28 is found on all peripheral T cells 
in the mouse and up-regulated upon activation (Gross et al, 1992). Lamb and 
colleagues first described T cell anergy, when they showed that T-cell clones 
exposed to antigen on other T-cells in vitro responded in such a way that 
subsequent exposure to antigen presented by professional APC did not result in 
T cell proliferation (Lamb et al, 1983). Anergy has also been induced by 
stimulation of T cells with “non-professional” APCs such as islet cells 
(Markmann et al, 1988), keratinocytes (Gaspari et al, 1988). In these situations 
it seems likely that absence of costimulatory signals during stimulation is 
responsible for anergy induction. DeSilva et al showed that murine Thl clones 
stimulated with antigen presented by normal APC in the presence of anti-IL-2 
and anti-IL-2 receptor (IL-2R) antibodies also became anergic (DeSilva et al, 
1991). From their study, they suggested that the lack of accessory molecules for 
costimulation is not the only limiting step in induction of anergy. Instead, they 
argued that the lack of normal DL-2 production and cellular proliferation 
resulting from incomplete stimulatory activity was the critical event. In vivo 
data coincide with evidence that prevention of CD28-B7 interaction using 
cytotoxic leukocyte antigen (CTLA)-4 immunoglobulin fusion protein can 
induce tolerance to mismatched cardiac allografts in the mouse and rat model 
(Lin et al, 1993; Sayegh et al, 1995). Recently Cobbold et al have introduced a
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new term “infectious anergy”, which describes tolerance as being both inhibition 
and anergy working together (Cobbold et al, 1996). They have suggested that 
anergic T cells might compete with immunocompetent cells and, by depriving 
them of important costimulatory molecules and paracrine proliferative 
cytokines, cause them to default to an anergic state (Waldmann et al, 1990; 
Waldmann & Cobbold, 1993). Once tolerance has been established it could be 
maintained by infectiousness, where a cohort of tolerant T-cells are able to 
guide naive T cells specific for the same antigen to become tolerant themselves. 
Waldmann et al have proposed that prolonged blockade of important functional 
T cell surface molecules favours non-professional presentation to T cells and 
this is permissive for the emergence of regulatory T cells rather than those 
capable of destruction. This is because professional APCs have only limited time 
in which they are capable of sensitising T cells, or because the regulatory T cells 
are functionally less susceptible to blockade of their surface CD4 adhesion 
receptors. Either way the result would be dominance of the regulatory T cells 
and once these cells became established as dominant they would be able to 
guide other T cells in to the same role (reviewed by Waldmann et al, 1993; 
Cobbold et al, 1996).
3:5:3 Immune deviation
Recently, a number of authors observed that induction of transplantation 
tolerance correlated with an increase in IL-4 production within accepted heart 
allografts (Papp et al, 1992 and Hancock et al, 1993), and reduction or absence 
of IL-2 expression (Dallman et al, 1991; Mottram et al 1995 and Sayegh et al,
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1995). One interpretation of these experiments is the hypothesis that 
immunological tolerance is due to immune deviation from a Thl to Th2 
cytokine pattern. It has been postulated that a Th2 cytokine pattern is associated 
with transplant tolerance whereas a Thl pattern is associated with allograft 
rejection (reviewed by Strom et al, 1996). Several groups have shown 
preferential expression of IL-4 and/or IL-10 during the induction of tolerance to 
renal and cardiac allografts in rodents using tolerogenic strategies which include 
using low dose anti-CD4 antibody treatment (Takeeuchi et al, 1992; Nickerson 
et al, 1994). Similarly, some investigators have been able to prevent class II 
disparate skin graft rejection in mice by the transfer of thymocytes expressing 
Th2 cytokine repertoires (Maeda et al, 1994). However, there are some 
exceptions to the idea that transplantation correlates strictly, with a Thl to Th2 
cytokine shift (Bugeon et al, 1992; Dallman, 1995; Strom et al, 1996; Krieger et 
al, 1996; Sad and Mosmann, 1995). Interestingly, Thai et al found up regulation 
of both Thl (IL-2 & IFNy) and Th2 (IL-4 & IL-10) cytokine mRNAs in mouse 
liver allografts that were spontaneously accepted without immunosuppression 
(Thai et al, 1995). More recently, studies using IL-4 Knockout mice (Garside et 
al, 1995) or neutralising anti-DL-10 antibody (Aroeira et al, 1995), have shown 
that mice can be made tolerant to ovalbumin in apparent absence of any EL-4 
and/or any detectable Th2 cytokine response. From these studies, it is clear that 
although Thl to Th2 immune deviation is an attractive explanation for 
peripheral tolerance in some experimental models, it can not be uniformly 
applied to all transplantation models.
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3:5:4 Suppression
In many transplant models, evidence for T cell-mediated suppression has been 
derived from adoptive transfer systems in which T cells from an 
immunologically tolerant animals are able to mediate tolerance in naive recipient 
animals (Gershon, 1974; Kilshaw et al, 1975; Chen et al, 1993; Batchelor et al, 
1984 and Lombardi et al, 1994). The first report on suppressor cells and 
immunosuppression was by Gershon on a seminal paper published in 1974, 
where he described that T cells from tolerant animals could transfer tolerance 
that was antigen specifc. He outlined the case for these regulatory cells which 
he termed suppressor cells (Gershon, 1974). Various hypotheses have been 
proposed to explain the mechanism of this T cell mediated suppression. It has 
been suggested that suppression is due to the effects of T cell-derived cytokines, 
such as interleukin-4 (IL-4), IL-10, or transforming growth factor-P (TGF-P), 
which inhibit the activation of IL-2 producing T cells (Fiorentino et al, 1989; De 
Waal et al, 1993; Miller et al, 1992). This is analogous to Thl/Th2 paradigm 
proposed by Mossmann et al, as already described. This basic model (i.e. 
Thl/Th2 CD4 T cells subsets) has recently been extended by Bloom et al to 
explain the phenomenon of suppression and includes CD8 T cells. In this model 
CD8 T cells are divided into two populations, type 1 which suppress B cells and 
have CTL function and type 2 which provides B-cell help and suppress DTH. 
These CD8 T cells produce lymphokines as do CD4 T cells in order to carry out 
these function. Bloom et al used this model in attempt to explain the T cell 
mediated suppression phenomenon and place it within the context of current
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thinking of cytokine regulation (Bloom et al, 1992a & 1992b). A series of CD8 
T cell suppressor (Ts) clones were studied and shown to have no cytolytic or 
helper activity and to produce no DL-2 or IL-4. These Ts clones blocked the 
production of IL-2 by helper CD4 T cells (reviewed by Webb et al, 1994). 
Sehon et al have generated clones from mice tolerated by polyethylene glycol- 
conjugated antigens. These clones block production of immunoglobulin in a 
MHC class I-restricted and antigen specific fashion. All clones from this study 
were Thy-1.2+, CD4-, CD8+, CD3+, TCRaf3+, and were not cytolytic 
(Mokashi et al, 1989; Takata et al, 1991; Chen et al, 1992). Another hypothesis 
proposes that antigen-specific T cells that have been rendered non-responsive 
suppress other T cells that have the same specificity in a passive manner through 
competition for ligands and for cytokines such as IL-2 (Cobbold et al, 1992; 
Lombardi et al, 1994).
An in vivo veto phenomenon resulting in clonal deletion of CD4 T helper 
precursors that recognise class II MHC along with suppressor cell activity has 
been suggested to play a role in bone marrow acceptance (Nakamura and Gress, 
1990; Thomas et al, 1991) and in tolerance induced by donor-specific 
transfusions (Heeg and Wagner, 1990). Although it remains possible to 
demonstrate the phenomenon of T cell suppression, it has proved very difficult 
to isolate and characterise cells with suppressor activity and to explain the 
phenomenon of T cell mediated suppression by in vitro analysis.
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Aim of the thesis
A major goal in organ transplantation is to develop strategies for inducing 
transplantation tolerance or partial tolerance and thereby eliminate or reduce the 
problem of non-specific immunosuppression and the attendant risks of infection 
and malignancy associated with life-long treatment with the current 
immunosuppresive drugs. Because CD4 T cells are central to the mechanisms of 
allograft rejection, there has been much recent interest in the use of mAbs 
directed against the CD4 molecule with a view to the possibility that this may 
promote allograft survival and perhaps transplant tolerance. The principle aim of 
this thesis was to study aspects of anti-CD4 mAb therapy as a strategy for 
promoting transplant survival or tolerance in a rat cardiac allograft transplant 
model.
Initial studies aimed, using a mouse anti-rat anti-CD4 mAb (MRC 0X38), to 
characterise various aspects of the use of anti-CD4 mAb to prolong heart 
allograft survival and, in particular, determine to what extent rat strain 
dependant differences in the ability of the anti-CD4 mAbs to induce transplant 
tolerance exist. A second major aim of the work was to evaluate the ability of 
different anti-CD4 mAbs, particularly those mAbs directed against membrane 
proximal domains of the CD4 molecule, to prolong cardiac allograft survival. 
The third major aim of the thesis was to gain further insight into some of the 
possible mechanisms whereby anti-CD4 mAb are able to induce and maintain 
transplant tolerance in the rat. In this respect, particular emphasis was given to 
the question of whether anti-CD4 mAbs promote tolerance through immune
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deviation of functionally distinct CD4 T cells subsets and preferential 
suppression of Thl T cells (producing IL-2 and IFNy) and/or the dominance of 
Th2 T cells (producing IL-4, IL-5, IL-6 and IL-10). Notwithstanding the 
possible limitation of extrapolating the results from such studies to clinical 
human transplantation, it was anticipated that the experiments performed would 
allow better understanding of anti-CD4 mAb therapy which might eventually be 
of relevance to clinical transplantation.
i
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CHAPTER FOUR 
MATERIAL AND METHODS
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4:1 Animals
Inbred male rats were obtained from Harlan UK Ltd (Bicester) or were bred in 
the University of Glasgow Central Research Facility. They were housed in the 
Central Research Facility, maintained on standard rat diet and used when 8-16 
weeks old. The following strains were used: PVG ( RT1C), DA( RTla), Lewis 
(RT11) and Brown Norway (RTln).
4:2 Surgical procedures 
4:2:1 Donor heart retrieval
The donor rat was anaesthetised by continuous halothane inhalation, opened 
with a midline abdominal incision and heparinised with 250 units into the 
inferior vena cava (IVC). The aorta and IVC were transsected to exsanguinate 
the animal. The thorax was opened and cold saline was applied immediately to 
the heart to achieve cardioplegia. Using an operating microscope (Wild, 
Heerbrug, Switzerland) the IVC was dissected and ligated with a 6/0 braided tie 
close to the atrium. The thymus was then removed and the right superior vena 
cava (SVC) dissected away from the thymus and connective tissue and tied 
close to the atrium. These two vessels were left undivided to keep the heart 
anchored. The heart was displaced to the right to reveal the azygous vein and 
left SVC which were ligated just proximal to their union by a single tie passed 
through the fascial plane behind the vein. The veins were divided, exposing the 
pulmonary trunk, which was then carefully dissected from its connective tissue 
(figure 4:1 A). The ascending aorta was then dissected from its adherent 
connective tissue and transsected at two thirds of the distance from its origin to
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its arch for abdominal transplantation or distal to the innominate artery for 
cervical transplantation. The pulmonary trunk was dissected free of the aorta 
and transsected close to its bifurcation and the venae cavae were then divided. 
Lastly, the remaining vessels forming a pedicle at the back of the heart were 
included in a single ligature and the heart was dissected free. It was placed in 
cold saline on ice and gentle external pressure applied to flush the blood from 
the chambers.
4:2:2 Abdominal heart transplantation
Abdominal heart transplantation was performed according to the technique of 
Ono and Lindsey (Ono and Lindsey, 1969). The recipient rat was anaesthetised 
by continuous halothane inhalation, shaved, and secured to a heated board 
(switched off) with tape. The recipient was swabbed with alcohol then opened 
with a midline abdominal incision and the intestines were displaced and enclosed 
in a gauze swab moistened with sterile saline. Using an operating microscope at 
about lOx magnification, the aorta and IVC were exposed, the overlying 
peritoneum teased open, and the vessels cleaned between the renal vessels and 
the bifurcation (figure 4: IB). A suitable length of aorta and IVC was chosen (1- 
1.5 cm) and all the branches and tributaries of this section were ligated with 6/0 
braided ligature. Occlusion clamps were applied across the two vessels, either 
side of the intended anastomosis site, in such a way as to leave the vessels 
exposed side by side. Next an arteriotomy was made in the aorta equivalent in 
length to the diameter of the donor aorta. A venotomy was made similarly in the 
IVC and blood was aspirated from the lumina. End-to-side anastomosis of
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donor aorta to recipient aorta was performed using a continuous 9/0 
monofilament nylon suture (Ethicon Ltd, UK), under 16x magnification, 
followed by end-to-side anastomosis of the donor pulmonary artery to the 
recipient IVC (figure 4:2B). During anastomosis the heart was covered with a 
gauze swab and cold saline was continually applied. The inferior clamp was 
released briefly at first to allow haemostasis to begin, then the superior clamp 
was released. Once anastomosis was achieved the heated plate was switched on 
again. Ischaemic times of the heart during transplantation were around 30 
minutes. The intestines were replaced and the abdomen was closed in two layers 
with a continuous 3/0 absorbable suture (Ethicon Ltd).
4:2:3 Cervical heart transplantation
Cervical heart transplantation was performed using a modification of the 
method described by Heron (Ivor Heron, 1971). A right sided paramedian neck 
incision was made extending vertically from the upper border of the manubrium 
stemi to beneath the mandible. The external jugular vein was exposed and 
mobilised by blunt dissection. The sternocleidomastoid and strap muscles were 
separated by blunt dissection to expose the carotid sheet which was dissected in 
order to mobilise the internal carotid artery. Both vessels were individually 
clamped and ligated distally to leave stumps for anastomosis. End-to-end 
anastomosis of the donor innominate artery to the recipient internal carotid 
artery was performed using an interrupted 9/0 monofilament, followed by end- 
to-end anastomosis of the donor pulmonary artery to the recipient external
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Figure 4:1 Heterotopic cardiac transplantation in the rat.
A. Donor aorta and pulmonary artery were dissected free and ready to be 
divided.
B. Recipient abdominal aorta and inferior vena cava were prepared below renal 
vessels and clamped below and above the anastomotic site.
Figure 4:2 Heterotopic cardiac transplantation in the rat.
A. Donor heart lying across the anastomotic site ready for anastomosis.
B. End-to-side anastomosis was performed between donor aorta and recipient 
aorta, then donor pulmonary artery in similar fashion to the recipient IVC.
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jugular vein, again with an interrupted 9/0 suture. The arterial clamp was 
released followed by the venous clamp, and prior to closure both edges of the 
wound were subcutaneously dissected to prevent compression of the 
transplanted heart. The skin was closed in a single layer.
4:2:4 Assessment of graft survival
Graft survival was assessed by daily palpation of the graft in the abdomen or 
neck and rejection was defined as complete cessation of myocardial contraction. 
4:2:5 Thymectomy
Under halothane inhalation anaesthesia a 2 cm midline skin incision was made in 
the neck, followed by division of the manubrium stemi of about 7-10 mm in 
length. The strap muscles were separated and the thymus gland was mobilised 
by blunt and sharp dissection using an operating microscope (figure 4:3). The 
blood vessels entering the gland were divided and the thymus gland was then 
easily removed. The skin was closed quickly with a continuous suture and 
positive pressure ventilation was administered (by the operator blowing through 
the barrel of 2 ml syringe fitted over the nose of the rat) to prevent 
pneumothorax. The total duration of the procedure was 5 min (Barbul et al, 
1979 and Walker et al, 1994). Subsequent analysis of peripheral blood 
lymphocytes by flow cytometry confirmed the depletion of T lymphocytes 
positive for Thyl which is expressed on recent thymic emigrant. Post-mortem 
examination further confirmed complete thymectomy.
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Figure 4:3 Thymectomy
The thymus was exposed by midline neck incision followed by division of 
manubrium sterni (the needle is pointing to the thymus gland).
4:3 Antibodies
Monoclonal mouse anti-rat antibodies (mAbs) used for identifying rat leukocyte 
populations are described in Table 4:1. All antibodies were obtained from 
Serotec Ltd, Oxford, UK. Secondary polyclonal antisera were used to detect the 
presence of the primary mAbs by a range of techniques, for which the antiserum 
had been appropriately conjugated.
4:3:1 Preparation and purification of monoclonal antibodies
The anti-CD4 mAbs, 0X38, 0X70, 0X71 and 0X73 were produced as ascites 
from hybridomas (kindly provided by Dr Neil Barclay, Sir William Dunn School 
of Pathology, University of Oxford, Oxford) injected into B ALB/c mice primed 
intraperitoneally with 0.5 ml pristane (Sigma Chemical Company Ltd, Poole, 
UK) 7 days previously. Ascitic fluid harvested from the peritoneal cavity was 
centrifuged at 3000 rpm for 15 m at 4°C and separated from fat, fibrin clot and 
red cells, then filtered and stored at -20 °C until purification by protein-A 
affinity chromatography (Prosep-A, Bio-processing Ltd, England, UK). 
Antibodies were purified from ascites by adding an equal volume of diluting 
buffer (Glycine 75 g/1, NaCl 17.6 g/1, pH 8.6) for 12 h at 4 °C, then centrifuging 
at 3,000 rpm for 30 mins at 4 °C. A protein-A-sepharose column was prepared 
and equilibrated with binding buffer (Glycine 75 g/1, NaCl 8.8 g/1, pH 7.4), then 
loaded with diluted ascites.
The IgG was eluted with 0.1M sodium citrate, pH 3.0, at a flow rate of 2.7 
ml/min into 4 ml fractions, and the Ig-containing fractions (identified by
Table 4:1 Monoclonal mouse antibodies detecting rat leukocytes.
Antibody Specificity Reference
MRCOX8 CD8+ cytotoxic/suppressor 
T cells, majority of natural killer cells
Gilman et al, 1982
W3/25 CD4+ helper T lymphocytes, some 
macrophages
Brideau et al, 1980
R73 Constant determinant of the rat TCR- 
ap.
Hunig et al, 1989
MRC 0X12 Ig Kappa chain on B lymphocytes Hunt & Fowler, 1981
MRCOX22 Leukocyte common antigen (CD45R) 
(B lymphocytes, MRC 0X8+ and 67 % 
of W3/25 peripheral T cells, NK cells)
Spickett et al, 1983
MRC 0X21 Human C3b inactivator (used as 
negative control)
Hsiung et al, 1982
MRC 0X81 Rat EL-4 Ramirez et al, 1996
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screening their optical density [OD] at 280 nm) were pooled and immediately 
dialysed with several changes of PBS to neutralise the pH. Purified antibodies 
were quantified by OD280 and by radial immunodiffusion (RID) using rat 
isotype-specific RID plates and standards of known concentration (The Binding 
Site, Birmingham, UK).
4:3:2 In vivo treatment with monoclonal antibodies and cytokines
A panel of anti-CD4 (W3/25, 0X38, 0X70, 0X71 and 0X73) monoclonal 
antibodies (mAbs) were used to treat organ allograft recipients in vivo in an 
attempt to induce tolerance as described in Table 4:2. MRC 0X8 (anti-CD8) 
and 0X81 (anti-IL-4) mAbs (were used also as described in Table 4:2. Human 
recombinant interleukin 2 (rIL-2), a generous gift from Glaxo (Glaxo IMB, UK) 
was used at a dose of 400 or 20,000 U/day for five days (day 0, 1, 2, 3 and day 
4).
4:4 Preparation of cells
4:4:1 Peripheral blood lymphocytes (PBL).
Two to three mis of peripheral blood was collected in heparinised tubes (20 
U/ml) and diluted 1:1 with phosphate buffered saline (PBS). Peripheral blood 
lymphocytes (PBL) were separated by centrifugation of the heparinised blood at 
2000 rpm for 20 min over 75% iso-osmolar percoll (Sigma Ltd). Lymphocytes 
harvested from the interface were washed three times in PBS containing 0.2% 
bovine serum albumin (PBS-BSA).
i
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Table 4:2 The mouse monoclonal antibodies used in vivo(a).
Anti-CD4(b) Isotype Epitope/receptor
0X38 IgG2a Domain 1 & 2 of CD4
W3/25 IgGl Domain 1 & 2 of CD4
0X70 IgG2a Domain 3 and 4 of CD4
0X71 IgGl Domain 3 and 4 of CD4
0X73 IgGl Domain 3 and 4 of CD4
0X21 IgGl Human C3b inactivator
0X8 IgGl CD8
0X81 IgGl IL-4
(a) All these mAbs (except 0X8 and 0X81) were used at a dose of 10 mg/kg 
on day -3 and 2 mg/kg on day -2, -1 and day 0 (day of transplantation). 0X8 
was given at a dose of 5 mg/kg on day -1,0 (day of transplantation) and day 3 
after transplantation whereas 0X81 was given at a dose of 5 mg/kg on day 0, 1, 
3 and 5 post transplantation.
(b) These antibodies or hybridomas were a kind gift from Dr Neil Barclay (Sir 
William Dunn School of Pathology, University of Oxford, Oxford).
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4:4:2 Lymph node cells (LNC)
Cervical and mesenteric lymph nodes were removed from rats that had been 
sacrified by cervical dislocation. The excised lymph nodes were pooled, cut with 
a scalpel blade and then pushed through a fine stainless steel mesh with a 5 ml 
syringe plunger, in PBS-BSA. Lymph node cells were washed two or three 
times and aggregates of dead cells removed with a Pasteur pipette. Viability was 
consistently greater than 95% as determined by trypan blue exclusion.
4:4:3 Spleen cells
Spleens were removed from sacrificed rats, and teased apart with sterile 
disposable plastic forceps in PBS-BSA. Cells were washed once and aggregated 
dead cells were removed. The erythrocytes were removed by hypotonic lysis 
using 5 mis distilled water followed by 5 mis 1.8% saline. Splenocytes were 
washed three times before use.
4:4:4 Preparation of T lymphocytes
Spleen cells from 0X38 treated tolerant DA (RTla) rats were prepared as 
described in section 4:4:3. To isolate purified T-lymphocytes (i.e. both CD4 and 
CD8 T cells), a saturating amount of MRC 0X12 (Anti-Ig Kappa light chain, 
Serotec Ltd, Oxford, UK) was added to the cell suspension for 1 hour at 4 °C to 
coat B cells. The cells were washed three times with HBSS (Hanks Buffered 
Salt Solution)/2% FCS (Foetal Calf Serum) [Sigma Ltd], resuspended at lxlO8 
cells/ml and goat anti-mouse IgG-coupled magnetic beads (BioMag, 
Northampton, UK) were added at a ratio of 1 ml of beads per lxlO8 cells. This 
was incubated at 4 °C for 60 min with frequent agitation, and the beads were
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then removed using a magnetic particle concentrator (Dynal MPC-1, Norway). 
The cells were B cells depleted a second time with fresh Biomag beads, then 
washed three times in PBS and resuspended in PBS at 5xl08 or 5xl07 cells/ml 
before use in adoptive transfer experiments. Viability of cells was verified by 
trypan blue exclusion and were consistently > 95%. Purity of T cells was 
checked using flow cytometry with directly fluoresceinated R73 mAb 
(Phycoerythrin conjugated anti-rat oc/p TCR mAb, Serotec Ltd) and was always 
> 90 %.
4:4:5 Preparation of purified CD4 T ceils
Lymph node (LNC) or spleen cells from 0X38 and 0X70 treated tolerant DA 
(RTla) rats were prepared as described in sections 4:4:2 and 4:4:3. Saturating 
amounts of MRC 0X8 and MRC 0X12 monoclonal antibodies (Serotec Ltd) 
were added to the cell suspension of either the LNC or splenocytes for 1 hour at 
4 °C to coat CD8+ T cells and B cells respectively. The cells were washed three 
times with HBSS/2% FCS, resuspended at lx l08 cells/ml and goat anti-mouse 
IgG-coupled magnetic beads were added at a ratio of 1 ml of magnetic beads 
per lxlO8 cells, as described above. The purity of CD4 T cells was checked 
using flow cytometry with directly fluoresceinated W3/25 and 0X8 antibodies, 
and was always > 95 % as depicted in figure 4:4. Here LNCs were stained 
directly using anti-TCR-FITC (Y-axis) and either anti-CD8-PE (left panels, X- 
axis) or anti-CD4-PE (right panels, X-axis). Cells were stained both before 
(upper panels) and after (lower panels) negative selection of CD4 T cells.
4
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Figure 4:4 Flow cytometric analysis of LNCs before and after 
purification of CD4 T cells.
Before Beads
After Beads
Log 10 W3/25-PELog 10 OX8-PE
Double labeling flowcytometric analysis of LNCs showing (A) 0X8- 
PE versus R73-FITC before beads. (B) W3/25-PE Vs R73-FITC 
before beads. (C) 0X8-PE Vs R73-FITC after bead. (D) W3/25-PE Vs 
R73-FITC after beads.
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4:5 Flow cytometric analysis of lymphocyte subpopulation
The influence of anti-CD4 mAb treatment on lymphocyte subpopulation was 
determined by flow cytometric analysis of peripheral blood lymphocytes (PBL) 
and lymph node cells prepared from treated rats, lxl06 lymphocytes were 
incubated (in PBS-BSA on ice, for 45 min) either with fluoroscein-conjugated 
mAbs against rat leukocyte subpopulations, or with non-conjugated anti-rat 
CD4 mAbs followed, after 2 washes, by incubation with FITC-(fluorescein 
isothiocyanate) or PE-(phycoerythrin) conjugated rabbit F(ab')2 anti-mouse Ig 
(Dako Ltd, High Wycombe, UK) diluted to 1/20 in PBS containing 10% normal 
rat serum to block cross reaction with rat cell surface Ig. After 2 final washes, 
cells were resuspended in PBS and analysed using a Coulter EPICS- XL flow 
cytometer (Coulter Ltd, Luton, UK).
4:6 Mixed lymphocyte culture
Single cell suspensions of purified CD4 T cells at 2x105 cells/ml were prepared 
from mesenteric and cervical lymph nodes of 0X38 and 0X70 tolerant rats 
(responder cells) as described in section 4:4:5. Splenocytes from naive Lewis 
and PVG rats as donor specific and third party stimulator cells respectively were 
prepared by passing spleen cells through a fine steel mesh in tissue culture 
medium (RPMI/FCS; RPM3 1640 medium supplemented with 2 mM L- 
glutamine, 100 U/ml penicillin, 100 pg/ml streptomycin (all Life Technologies), 
50 pM 2-mercaptoethanol (Sigma Ltd) and 5% heat inactivated FCS. The 
stimulator cells were washed twice and irradiated (20Gy) prior to use. 
Proliferation assays were set up in triplicate in 96 U-well plates (Life
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Technologies) using 2x105 responders per well and 4xl05 stimulators per well; 
plates were incubated at 37°C in 5% CO2. After 3 and 4 days culture, cells 
were pulsed with 1 pCi/well of [3H]-thymidine (Amersham International PLC, 
little Chalfont, Bucks, UK) for 18 hours and harvested, to determine thymidine- 
incorporation by proliferating cells, using an automated cell harvester and liquid 
scintillation counter (1205 Betaplate, LKB Pharmacia, Milton Keynes, UK).
4:7 Capture ELISA for quantification of IFNy
100 pl/well of coating anti-interferon gamma (rabbit polyclonal anti-rat IFNy, 
kind gift of Dr. John Tite, Wellcome Research Laboratories, Beckenham, UK) 
antibody used at dilution of 1:2000 (i.e. 10 pi aliquot in to 20 ml of 0.1M 
NaHC03 buffer, PH 8.2) was added to 96 well microtiter plates (Dynatech 
Immulon 4). After overnight incubation at 4 °C, plates were washed three times 
in ELISA wash buffer (PBS containing 0.05% Tween 20) and blocked with 200 
pl/well of PBS containing 10% FCS for 1 hour at 37°C. Plates were washed 
three times with wash buffer, and 100 pl/well of each standard, control or 
sample (neat supernatant) was added in triplicate with 3 hours incubation at 
37°C. The plates were washed four times and incubated for 1 hour at room 
temperature with biotinylated anti-rat IFNy (DB1 , a kind gift of Dr. P.Vander 
Meide, Rijkswik, Netherland). After six washes, 100 pl/well of extravidin- 
peroxidase (Sigma Ltd) was added and incubated for 1 hour at 37 °C. After 
eight washes, 100 pl/well of TMB [tetramethyl benzidine] (Dynatech 
Laboratories, Billingshurst, UK) substrate was added for 30 minutes at room
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temperature and plates were read at 450 nm using an ELISA plate reader 
(Dynatech, MR 5000) and Biolinx software (Dynatech Laboratories).
4:8 Bioassay of IL-2 and EL-4 
4:8:1 EL-2 bioassay
The CTLL-2 lymphocyte line was maintained by 3x weekly treatment with 
human recombinant IL-2 (100 Unit/ml) and subculturing in RPMI 1640 
supplemented with 5% FCS, L-glutamine, penicillin/streptomycin and 2 
mercaptoethanol. Serial dilution of supernatants for day 3 mixed lymphocyte 
culture of purified CD4 T cells from 0X38 and 0X70 treated rats was mixed 
with 5x103 CTLL2 cells. Twenty four hour later, the cells were pulsed with 1 
pCi/well tritiated thymidine (Amersham International), incubated for 18 hours, 
harvested onto glass filter mats and counted in a liquid scintillation counter 
(1205 Betaplate, LKB Pharmacia, Milton Keynes, UK). Cytokine levels (in 
units per millilitre) were calculated from a standard curve with rIL-2.
4:8:2 EL-4 bioassay
Detection of IL-4 was achieved by bioassay to determine upregulation of 
expression of MHC class II molecules on B cells. Rat B cells were purified from 
lymph node cells by direct rosetting using W3/13 mAb-labelled sheep red blood 
cells (SAPU, Carluke, Scotland) to remove T cells, remaining erythrocytes were 
removed by hypotonic lysis. Purity of cell subset was checked using flow 
cytometry with directly fluoresceinated OX12 and was >85%. 100 pi of tissue 
culture supernatant was added to 100 pi /well of B cells (at 5x106 cells/ml) in 96 
well tissue culture plates. After incubating for 18 h at 37 °C, plates were
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washed twice with 0.02% PBS-BSA. Saturating amount of FITC-labelled 0X6 
mAb (Serotec Ltd) was added and plates incubated for 1 hour at 4 °C. After 
washing three times with 0.2% PBS-BSA, the increase in class II molecules 
expression was measured by the Coulter EPICS-XL flow cytometer (Coulter 
Ltd). Assay specificity was determined by means of neutralising mAb to rat EL-4 
(0X81) added at the beginning of the 18 hour culture period (at 50 pl/well of 
0X81 supernatant). Values are expressed as U/ml EL-4 derived from a standard 
curve constructed using serial dilutions of recombinant rat IL-4 obtained as 
tissue culture supernatant (104 U/ml) from a transfected CHO cell line. One unit 
was defined as that concentration of IL-4 that gave 50 percent of maximal 
induction of MHC class II on B cells as assessed by flow cytometry.
4:9 Statistical analyses
Except as specified below, survival data were analysed using Fisher's exact test, 
in which the proportion of animals surviving to 100 days was compared 
between two groups. The number of animals in each group was in general too 
small to permit the valid use of the chi-squared test, and hence in experiments 
containing more than two groups, they were compared on a pairwise basis using 
Fisher's exact test. Bonferroni's method was used to correct for the performance 
of multiple comparisons within a given experiment. For a given comparison to 
be considered statistically significant, a p-value of less than 0.05/n was required, 
where n is the number of simultaneous comparisons in that experiment. This 
procedure ensures that the probability of erroneously declaring any difference to 
be significant is less than 5% per experiment. Only comparisons of primary
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interest, in most cases those of treated groups with a control group, were 
included in n, and this number is specified in the results for each multi-group 
experiment.
In some experiments in which all animals, or all but one or two, failed to survive
for 100 days, the median survival times were compared with the Mann-Whitney 
♦
test. Bonferroni's method was used to correct for the performance of multiple 
comparisons, as described above.
Flow cytometric data were analysed by performing a one-way analysis of 
variance (ANOVA) to determine whether there were significant overall 
differences between the groups within a given experiment. If the results of the 
ANOVA showed there to be significant differences, a pairwise comparison was 
made between each anti-CD4 treated group and the naive control group using 
Dunnett's test (Dunnett, 1964). This test corrects for multiple comparisons by 
controlling the error rate for the family of simultaneous comparisons, in a 
similar manner to Bonferroni's method. Hence, the probability of erroneously 
declaring the difference between any treated group and the control group to be 
statistically significant is less than 5% per experiment. Dunnett's test was 
performed only at a 5% significance level, and hence all significant differences 
are quoted as p<0.05. When further comparisons were made between different 
anti-CD4 treated groups within an experiment, Tukey's test was used. This is 
similar to Dunnett's test, but is more conservative in that it controls the error 
rate for the family of all possible simultaneous pairwise comparisons, rather than 
only those between treated and control groups.
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To compare the effect of a given anti-CD4 antibody in depleting CD4 T cells in 
peripheral blood lymphocytes and lymph node cells, given that the percentage of 
CD4-positivity varied with cell type in naive animals, results were first 
expressed as a fraction of the mean CD4 percentage for cells of the same type in 
naive animals. Comparisons were then performed using Student's t test. A 
similar procedure was used to compare the depletion of OX22-high and 0X22- 
low CD4-positive T cells. In chapter eight part of the results were not 
statistically analysed because the experiments were performed on one occasion 
only.
Statistical analysis was performed using Minitab for Windows 9.2 (Minitab Inc.) 
and Statgraphics 2.6 (Statistical Graphics Corporation) software.
CHAPTER FIVE 
The ability of anti-CD4 (0X38) mAb to promote cardiac 
allograft survival in the rat.
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5:1 Introduction
As already outlined in chapter 2, CD4 T cells play a critical role in initiating and 
amplifying the immunological response to an allograft. The CD4 molecule has 
attracted, therefore, considerable interest as a target for mAb therapy to prevent 
graft rejection. In this thesis, I chose to examine the ability of anti-CD4 mAb’s 
to promote cardiac allograft survival in a rat heterotopic heart transplantation 
model. This experimental model is of more relevance to clinical organ 
transplantation than, for example, skin allograft models since it involves 
transplantation of a vascularised organ graft. Moreover, the model provides an 
easily detectable end-point (i.e. cessation of palpable cardiac contraction) with 
which to assess graft rejection and thereby allows an objective determination of 
the effect of anti-CD4 mAb treatment on heart graft survival.
By virtue of its greater size, relative to the mouse, the vascular anastomosis in 
the rat is more easily performed. Like the mouse the immune system of the rat 
has been well studied, although, the range of immunological reagents available 
for rat studies is not so extensive as that available for use in the mouse. 
Interestingly, in the rat, but not in the mouse, the CD4 molecule is found both 
on CD4 T cells and also on some activated macrophages (Wood et al, 1983; 
Barclay AN, 1981; Steininger et al, 1984). From an immunological perspective, 
it is also notable that rat CD4 molecule was one of the first lymphocyte cell 
surface molecules to be identified by monoclonal antibodies (Brideau et al, 
1980). In this particular chapter I examined the ability of the mouse anti-rat 
CD4 mAb, MRC 0X38 (0X38), to promote heart allograft survival. 0X38 has
1
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been shown in previous studies to be a partially depleting mouse anti-rat CD4 
mAb of the IgG2a isotype which labels a determinant on the distal domains of 
CD4 molecule and this mAb has been reported, in some rat strains 
combinations, to promote permanent heart allograft survival (Claesson et al, 
1987; Herbert and Roser, 1988; Shizuru et al, 1990; Seydel et al, 1991). After a 
series of preliminary experiments to establish, for myself, the rat cardiac 
transplant model I went on to use the model to examine the experimental 
circumstances and, in particular, the rat strain combinations in which treatment 
with 0X38 was able to prolong heart allograft survival in the rat.
5:2 Preliminary experiments to establish and validate the rat heterotopic 
cardiac transplantation model.
For initial transplant studies the fully allogeneic Lewis (RT11) to DA (RTla) rat 
strain combination was examined. The Lewis and DA rat strains differ from 
each other at both major and minor histocompatibility antigens and Lewis heart 
grafts are always rejected rapidly by unmodified DA recipients (Fabre et al, 
1972a and b and extensive unpublished studies from my supervisors laboratory). 
In an initial experiment, Lewis hearts allografts were transplanted to the 
heterotopic intrabdominal site of 12 DA recipients. All of the heart grafts 
underwent acute rejection with complete cessation of palpable cardiac 
contraction between days 8 and 10 after transplantation, with a median survival 
time (MST) of 9 days. To confirm that cessation of graft contractility in this 
fully allogeneic rat strain combination was attributable to immunological 
rejection rather than technical failure due to my relative inexperience at this
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early stage of the project with microsurgical techniques, 4 DA (RTla) to DA 
(RTla) syngeneic cardiac transplants were also performed. All 4 syngeneic heart 
grafts survived for greater than 100 days (when the experiment was terminated) 
with easily palpable cardiac contractility throughout the period of study, thereby 
excluding technical failure as a likely cause for graft destruction in the series of 
unmodified allogeneic heart transplants described above.
5:3 Ability of 0X38 mAb to prolong survival of Lewis heart grafts in DA 
recipients.
To determine the ability of 0X38 mAb to promote survival of Lewis heart 
allografts in DA recipients, DA animals were treated with affinity purified 0X38 
mAb at a dose of 10 mgs/kg on day -3 and 2 mg/kg on days -2, -1, and 0 (the 
day of transplantation). This antibody treatment regimen was chosen because it 
has been reported previously that a similar 0X38 antibody treatment protocol 
induces indefinite survival of Lewis cardiac allograft in ACI (RTla) recipients 
(Herbert and Roser, 1988; Roza et al, 1989; Shizuru et al, 1990; Seydel et al, 
1991; Yin and Fathman, 1995; Binder et al, 1996). Eight DA recipients were 
treated with 0X38 mAb using this regimen and then transplanted with a 
heterotopic Lewis heart graft. As shown in figure 5:1, 0X38 treatment 
significantly increased survival of Lewis heart grafts (MST>100 days, P= 
0.00072, Fisher’s exact test in comparison with the control untreated animals) 
and in 6 out of the 8 treated recipients permanent survival (>100 days) 
occurred. Two of the recipients rejected their heart grafts on days 11 and 18 
respectively. An additional control group of 3 DA recipients was treated with a 
control mAb, 0X21 (which labels human C3b inhibitor).
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Figure 5:1 The abi l i ty of 0X38 mAb to pro long  
surv i va l  of Lewis  h e a r t  g r a f t s  in DA r ec i p i en t s .
0X38 (n=8, MST> 100 days, P= 0.00072)* 
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DA (RTla) rats were treated with the mouse anti-rat CD4 mAb 0X38 (or 
control OX21 mAb) on day -3 (10 mg/kg) and on days -2, -1 and on day 0 
(2 mg/kg). On day 0, treated animals received a heterotopic Lewis (RT11) 
heart allograft. Graft rejection was defined as complete cessation of 
cardiac contractility.
* P value refers to comparisons with unmodified control (P= 0.00072, 
Fisher’s exact test).
As shown in figure 5:1, all 3 of these animals rapidly rejected their heart grafts 
in times comparable to those observed in unmodified recipients (MST 9 days in 
both groups).
In further studies, a limited analysis in a small number of animals was performed 
to determine whether a reduced dose of 0X38 mAb treatment was also able to 
prolong allograft survival. The results of this analysis are shown in figure 5:2. 
Treatment with 10 mg/kg 0X38 on day -1 and 2 mg/kg on day 0 led to long­
term graft survival in 2 of 3 treated recipients (P= 0.02857, Fisher’s exact test in 
comparison with the untreated control group).
Administration of a single dose of 0X38 mAb (10 mg/kg) on the day of 
transplantation led to long-term survival in only 1 of 5 treated recipients (MST 
11 days, P= 0.29412) demonstrating that this treatment schedule is insufficient 
to induce transplant tolerance. On the basis of these results, therefore, the 
majority of further studies using 0X38 were performed using the original 
regimen of anti-CD4 mAb treatment i.e. 10 mg/kg on day -3 and 2 mg/kg on 
days -2, -1 and 0 (the day of transplantation) which led to permanent allograft 
survival (MST> 100 days, P= 0.00072, by Fisher’s exact test).
5:4 0X38 treated DA rats bearing long-standing (> 100 days) Lewis heart 
grafts display donor-specific immunological tolerance.
Following transplantation of a vascularised organ graft it is well known that the 
donor strain dendritic cell population within the graft is destroyed in situ and/or 
migrates to the recipients spleen (Larsen et al, 1990, Austyn and Larsen, 1990).
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F i g u r e  5:2 T h e  a b i l i t y  of  d i f f e r e n t  d o s e s  of  
0 X 3 8  m A b  t o  p r o l o n g  s u r v i v a l  of  L e w i s  h e a r t  
g r a f t s  in DA r e c i p i e n t s .
Group 1 ----- 0 X 3 8  (n=8 ,  MST>100 d a y s )
Group 2 ---- 0 X 3 8  (n=3 ,  MST>100 d a y s )
Group 3 ---- 0 X 3 8  (n=5 ,  MST 11 d a y s )
 U n t r e a t e d  (n=12,  MST 9 d a y s )
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DA rats were treated with anti-CD4 mAb (0X38) using different treatment 
schedules and then given a heterotopic Lewis heart allograft. This data was 
depicted in fig 5:1 and is shown here for further comparison.
Group 1 received (10 mg/kg on day -3 and 2 mg/kg on days -2, -1 & day 0). 
Group 2 received (10 mg/kg on day -1 and 2 mg/kg on day 0 )
Group 3 received (10 mg/kg on day 0 i.e. the day of transplantation).
P value refers to comparisons with untreated control group (Fisher’s exact test). 
* A P value of less than 0.017 (0.05/3) was required for statistical significance 
(Bonferroni’s correction for 3 simultaneous comparisons).
Since dendritic cells are the most immunogeneic component of the graft, the 
prolonged survival of Lewis heart allografts in DA recipients following 0X38 
mAb treatment could, in principle, result from reduced immunogenecity of the 
Lewis heart with time and/or the development of specific immunological 
unresponsiveness in the recipient. To determine whether DA recipients with 
long-surviving Lewis heart allograft (i.e. >100 days) displayed donor-specific 
tolerance, they were transplanted with a second vascularised rat heart graft of 
either the original donor (i.e. Lewis- RT11), or third party (PVG-RT10) strain. 
The second heart graft was transplanted to the cervical site with end-to-end 
anastomosis of the donor common carotid artery and pulmonary vein to the 
recipient internal carotid artery and the external jugular vein respectively. Graft 
recipients received no additional anti-CD4 mAb immunosuppressive therapy at 
the time of retransplantation. As shown in table 5:1, all 8 DA recipients bearing 
a long-standing Lewis primary heart graft accepted a second Lewis heart 
allograft (MST> 100 days, P= 0.00004), whereas 9 comparable animals given a 
third party PVG heart graft all rejected their second heart graft rapidly (MST 8 
days). This result demonstrates, therefore, that recipients of long-term heart 
grafts after 0X38 treatment display evidence of donor-specific transplant 
tolerance (MST> 100 days, P= 0.00004, Fisher’s exact test in comparison with 
recipients of third party heart graft).
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Table 5:1 0X38 treated DA recipients with long-term Lewis heart allografts 
display donor-specific transplant tolerance.
Group Recipient Donorb nc Graft 
survival (days)d
MST
(days)
\ e DA Lewis 8 all >100 days >100
2 DA PVG 9 7, 7, 7, 8, 8, 8, 8, 
11, 12
8
(a) DA recipients had long-standing (> 100 days) heterotopic Lewis heart grafts 
(abdominal site) following perioperative treatment with 0X38 mAb. No 
additional immunosuppression was given at the time of transplantation of the 
second heart allograft.
(b) Haplotype of second (cervical) heart graft.
(c) Number of recipients per group.
(d) Survival of second (cervical) heterotopic heart allograft.
(e) Group 1 versus group 2 (P= 0.00004, Fisher’s exact test).
5:5 Ability of 0X38 mAb to prolong allograft survival in additional rat
strain combinations.
Although the Lewis to DA rat strain combination is fully allogeneic i.e. 
mismatched at major and minor histocompatibility loci, it is sometimes 
designated a relatively weak rat strain combination in the context of 
transplantation (McConnel and Hall, 1989; llano et al, 1989 & 1991). The 
ability of 0X38 to prolong survival of heart allografts was also examined, 
therefore, in a number of other fully allogeneic rat strain combinations, namely: 
Lewis (RT11) to DA (RTT), DA (RT1*) to PVG (RT1C) (unpublished data 
Dr.BC.Jaques), DA to Lewis and BN [Brown Norway] (RTln) to Lewis, as 
shown in table 5:2. For these studies 0X38 mAb was used at an identical dose 
to that used for the earlier studies in the Lewis to DA strain combination (i.e. 
10 mg/Kg on day -3 and 2 mg/Kg on days -2, -1 & day 0). As shown in table 
5:2, 0X38 led to a significant prolongation of cardiac allograft survival in DA 
to PVG (MST=12, P= 0.0097 using Mann-Whitney test) and DA to Lewis 
(MST= 18, P= 0.0369) strain combinations studied but only one animal from 
this series of experiments (i.e. the DA to Lewis strain combination) accepted its 
heart allograft permanently. These studies demonstrate that the ability of 0X38 
mAb (when given as a brief preoperative course) is highly dependent on the rat 
strain combination used. 0X38 mAb led only to a significant effective long-term 
cardiac allograft survival in the Lewis to DA rat strain combinations and not in 
any of the other three additional rat strain combinations tested (MST> 100 days, 
P= 0.0007 using Mann-whitney test and unmodified animals as a control group).
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Table 5:2 Ability of 0X38 mAb treatment to prolong cardiac allograft survival in
different rat strain combinations.
Heart
donor
Recipient n Graft Survival 
(days)
MST
(days)
* P
value
Treatment
DA PVG 4 7, 7, 8, 9 8 - Control 
(no treatment)
"DA PVG 7 11,11,11, 12, 
12, 17, 24
12 0.0097 0X38
(10 mg/kg on day -3 and 
2 mg/kg on day -2,-1, 0)
Lewis DA 12 8,8,9,9,9,9,10,
10,10,10
9 - Control 
(no treatment)
Lewis DA 8 11, 18, x6>100 100 0.0007 0X38,
(10 mg/kg on day -3 and 
2 mg/kg on day -2,-1, 0)
DA Lewis 3 7, 8, 10 8 - Control (OX21)
(10 mg/Kg on day -3 and 
2 mg/Kg on day -2,-1, 0)
DA Lewis 5 13, 17, 18,31 
& 1>100 days
18 0.037
0X38
(10 mg/kg on day -3 and 
2 mg/kg on day -2,-1, 0)
BN Lewis 3 7, 8,11 8 - Control 
(no treatment)
BN Lewis 4 15, 19,21,28 20 0.052 0X38
(10 mg/kg on day -3 and 
2 mg/kg on day -2,-1, 0)
Recipients animals were treated with 0X38 mAb as specified in the table. The survival of 
the heterotopic heart allografts in the 0X38 treated recipients was compared with 
control animals which received either no mAb or control 0X21 mAb which labels human 
C3 inhibitor.
*P-value refers to comparison with control animals in each group (Mann-whitney test). 
P- value of <0.05 was required for statistical significance
** Data kindly provided by Dr. BC.Jaques, Dept of Surgery, Western Infirmary, 
Glasgow (Unpublished data).
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5:8 Discussion
The CD4 molecule is an attractive target for modulating the graft rejection 
response and the results in this chapter show that the mouse anti-rat CD4 mAb 
0X38 is able, when given as a brief perioperative treatment, to cause indefinite 
survival of Lewis heart allograft in DA recipients. From the different dose 
regimens used, only the four days treatment was significantly effective in 
inducing long-term graft survival. Moreover, such animals are rendered 
permanently and specifically tolerant to their grafts as shown by their ability to 
accept a second donor (but not third party) heart graft without further 
exogenous immunosuppression. These findings are consistent with those 
reported by other groups in the Lewis to ACI rat strain combination (Shizuru et 
al, 1990, Yin and Fathman, 1995). Interestingly, the efficacy of perioperative 
0X38 treatment to produce transplantation tolerance did not extend to any of 
the other fully allogeneic three rat strain combinations tested, although in all 
cases except BN to Lewis there was evidence of a significant increase in 
allograft survival. There is little previously published data on the efficacy of 
0X38 in other rat strain combination although Yin and Fathman also found this 
schedule of 0X38 mAb treatment did not cause tolerance to cardiac allografts 
in the DA to Lewis rat strain combination (Yin and Fathman, 1995).
It is well known that there is very wide variability between different rodent 
strains combinations in their susceptibility to different immunosuppressive 
regimens (McConnel and Hall, 1989; Hano et al, 1989 and 1991) and the Lewis 
to DA combinations is generally regarded as more susceptible to experimental
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protocols designed to induce transplant tolerance. Nevertheless, unmodified DA 
rats reject Lewis heart allografts vigorously with complete destruction of the 
graft within 10 days and the ability of anti-CD4 mAbs to induce transplant 
tolerance in this strain combination may reflect a particular susceptibility to 
immunemodulation rather than a weak graft rejection response. It is worth 
emphasising that continued treatment with 0X38 mAb was not used in any of 
the rat strain combination tested here. It may be that either a higher dose of 
0X38 or prolonged mAb therapy may have improved allograft survival further. 
However, the efficacy of long-term mAb use is likely to be limited by the fact 
that the xenogeneic mouse mAb provokes an anti-mouse Ig-response which 
likely neutralises mAb in the long-term. This problem could potentially be 
overcome by constructing chimeric mAb, using molecular biological techniques, 
in which the constant region of the Ig molecule has been substituted by rat 
amino acid residues.
5:9 Summary
5:1 Administration of a brief preoperative course of anti-CD4 mAb (MRC 
0X38) significantly prolonged survival of Lewis cardiac allografts in DA 
recipients (P= 0.00072) and in most animals promotes permanent graft survival 
(>100 days).
5:2 The four days anti-CD4 treatment regimen (10 mg/kg on day -3 and 2 
mg/kg on days -2, -1 & day 0) was the most effective for inducing tolerance.
5:3 Following anti-CD4 treatment, recipients of a long-standing cardiac 
allograft showed specific immunological tolerance when challenged with a 
second heart allograft.
5:4 The ability of 0X38 mAb to induce long-term cardiac allograft survival in 
the rat was highly dependent on the rat strain combination used. Of the fully 
allogeneic strains tested, the Lewis to DA strain was the only one readily 
susceptible to tolerance induction.
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CHAPTER SIX
The ability of different anti-CD4 monoclonal antibodies 
to prolong survival of rat cardiac allograft.
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6:1 Introduction
In the preceding chapter, it was shown that the mouse anti-CD4 mAb 0X38 is 
able to induce indefinite heart allograft survival in the Lewis to DA rat strain 
combination. The efficacy of a particular CD4 mAb to induce prolonged 
survival of an allograft is likely to be critically dependent on the isotype of the 
mAb in question and its precise antigen specificity for the CD4 molecule. The 
extracellular part of the CD4 molecule comprises 4 Ig-like domains, as already 
described in chapter two (figure 2:3C). The membrane distal or N terminus Ig- 
like domains (VI and V2) of the CD4 molecule on the T cell bind to the (32 
domain of MHC class Et molecules on APC or target cells. The MHC contact 
sites of the CD4 molecule are in the CDRl-like and CDR3-like loops of the first 
domain (VI) and in the ‘strand F-loop 6- strand-G’ region of the second 
domains (V2). The contact point on class II MHC for the CD4 molecule is the 
loop three region of the (32 domain (Ryu et al, 1990; Parham, 1992; Fleury et al, 
1991 and Halloran et al, 1990). As already noted, 0X38 mAb is directed against 
an epitope on the distal 2 domains of the rat CD4 molecule and is of the IgG2a 
isotype.
There is little published information on the importance of epitope specificity of 
anti-CD4 mAb and its relationship to efficacy to prevent allograft rejection. In 
this chapter, studies were performed to assess the efficacy of anti-CD4 mAbs 
with different epitope specificity (and of different isotypes) for prolonging 
cardiac allograft survival in the rat. In addition to the IgG2a mAb 0X38, four 
other mouse anti-rat CD4 mAbs were studied. One of these, the mAb W3/25,
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also labels a determinant located on the distal two domains of rat CD4 and 
competes for binding with 0X38. However, unlike 0X38, it is of the IgGl 
subclass. The other three anti-CD4 mAbs used in the following studies were 
raised and kindly provided by Dr Neil Barclay (Sir William Dunn School of 
Pathology, University of Oxford, Oxford). These mAbs (0X70, 0X71 and 
0X73) were raised by immunising mice with a recombinant form of the soluble 
rat CD4 molecule and are all directed against epitopes located on the membrane 
proximal two domains (domains 3 and 4) of the rat CD4 molecule. The isotype 
and broad specificity of these anti-CD4 mAb is shown in table 6:1.
In additional studies in this chapter, the ability of anti-CD4 mAbs to induce 
indefinite allograft survival was examined in recipient rats which had been 
thymectomised (as adults) prior to heart transplantation. The latter studies were 
undertaken to determine whether the peripheral T cells pool could still be 
rendered unresponsive by anti-CD4 mAbs in the absence of new T cells 
emerging from the thymus. Finally, since the degree of CD4 T cells depletion 
following mAb treatment may make an important contribution to the efficacy of 
anti-CD4 mAbs, the ability of different CD4 mAbs to deplete T cells from the 
peripheral blood and lymph nodes of treated rats was examined.
6:2 Ability of different mouse anti-rat CD4 mAbs to prolong heart 
allograft survival.
Four additional anti-CD4 mAbs (W3/25, 0X70, 0X71 and 0X73) were tested 
for their ability to prolong survival of Lewis (RT11) cardiac allografts in DA 
(RTla) recipient animals. As in the preceding chapter, donor heart grafts were
131
Table 6:1 Isotype and broad epitope specificity of mouse anti-rat CD4 mAbs.
Antibody8’5 Isotype
CD4
Domain Membrane proximity
0X38 IgG2a 1 &2 Membrane distal domains
W3/25 IgGl 1 & 2 Membrane distal domains
0X70 IgG2a 3 & 4 Membrane proximal domains
0X71 IgGl 3 & 4 Membrane proximal domains
0X73 IgGl 3 & 4 Membrane proximal domains
(a) The anti-CD4 mAbs 0X70, 0X71 and 0X73 were a generous gift from Dr 
A.N Barclay (Sir William Dunn School of Pathology, University of Oxford, 
Oxford).
(b) Hybridoma cells secreting these monoclonal antibodies were grown as 
ascitis in BALB/C mice and the antibodies affinity purified prior to use.
transplanted heterotopically to the intrabdominal site and recipients were treated 
with anti-CD4 mAbs at a dose of 10 mg/Kg on day -3 and 2 mg/Kg on days -2, 
-1 and day 0 (i.e. the day of transplantation). All of the anti-CD4 mAbs were 
given by the intraperitoneally (I.P) route. Figure 6:1 summarises the results of 
the heart transplant studies using different mAbs to rat CD4. The survival data 
for 0X38 has already been described and depicted in fig 5:1 and 5:2. It can be 
seen from figure 6:1 that all of the anti-CD4 mAbs directed against membrane 
proximal regions (domains 3 and 4) of the CD4 molecule (mAbs 0X70 and 
0X73) significantly induced long-term heart allograft survival in the majority of 
treated recipients except 0X71 mAb which was marginally significant (P= 
0.014). Thus in DA recipients receiving the membrane proximal anti-CD4 mAb 
0X70, 7 of 9 treated animals retained their grafts indefinitely (MST> 100 days, 
P= 0.00031, using Fisher’s exact test in comparison with the unmodified control 
group) whereas 3 of 5 recipients treated with 0X71 (P= 0.0147) and 4 of 6 
recipients treated with 0X73 (P= 0.00049) retained their grafts indefinitely 
(MST >100 days in both groups). Interestingly, treatment with the mAb W3/25 
which is directed against the membrane distal domains of CD4 led to only a 
modest increase in heart allograft survival (MST 14 days, P>0.05) and none of 
the recipients treated with this particular retained their grafts for more than 17 
days.
6:3 Role of the thymus gland in anti-CD4 induced prolongation of heart 
allograft survival.
Experiments were next performed to determine whether the presence of an 
intact thymus gland plays a critical role in prolongation of heart graft survival
133
Figure 6:1 The ability of different anti-CD4 mAbs to 
prolong survival of Lewis cardiac al lografts in DA
recipients.
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0X71 (n=5, MST>100 days, P= 0.014) 
0X73 (n=6, MST>100 days, P=0.0049)* 
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DA recipients were treated with the different anti-CD4 mAbs at a dose of 
10 mg/kg on day -3 and 2 mg/kg on day -2, -1 and day 0 (the day of 
transplantation).
P value refer to comparisons with unmodified control animals (Fisher’s 
exact test).
* A P value of < 0.01 (0.05/5) was required for statistical significance 
(Bonferroni’s correction for 5 simultaneous comparisons).
following anti-CD4 mAb treatment in the Lewis to DA rat strain combination. 
Adult thymectomy was performed 10 weeks prior to anti-CD4 mAb therapy and 
heart transplantation. Thymectomised recipients were treated with anti-CD4 
mAb directed against either membrane distal (MRC 0X38) or membrane 
proximal (MRC 0X70) domains. MAbs were given at a dose of 10 mg/kg on 
day -3 and 2 mg/kg on days -2, -1 and day 0 (the day of transplantation). As 
noted earlier, this dose of anti-CD4 mAb (either 0X38 or 0X70) leads to 
indefinite allograft survival in the majority of euthymic treated DA recipients of 
Lewis heart allografts. The details of the surgical technique used for 
thymectomy are described in chapter 4 (material and methods). Fortuitously, 
recent thymic migrants in the rat express the cell-surface antigen Thy-1 for 
several days after emerging from the thymus and thereafter become Thy-1 
negative (Mason and Williams, 1980; Campbell et al, 1980). Thy-1, which can 
be labelled using the MRC 0X7, therefore provides a useful cell-surface marker 
with which to confirm that effective thymectomy has been accomplished. In the 
present experiments, flow cytometric analysis of PBLs from rats which had been 
thymectomised several weeks earlier confirmed in all animals tested the 
complete absence of Thyl positive lymphocytes, therefore demonstrating the 
completeness of thymectomy (results not shown).
Interestingly, both 0X38 and 0X70 anti-CD4 mAbs led to a modest increase in 
cardiac allograft survival in thymectomised DA recipients when compared to 
unmodified graft recipients (fig 6:2) but none of the recipients became 
permanently tolerant to their allograft (median survival times of 26 to 27 days
A
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Fig 6:2 Anti-CD4 mAbs  (0X38 & 0X70)  t r e a t m e n t  
of p r e - t h y m e c t o m i s e d  DA r e c i p i e n t s  of Lewis  
h ea r t  g r a f t s  (at  day 70).
Thymectomy + 0X70 (n=6, MST 27 days, P=0.0022)* 
Thymectomy + 0X38 (n=4, MST 26 days, P= 0.0079)* 
Sham thymectomy (0X70, n=5, MST> lOOdays)
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DA recipients were treated with anti-CD4 mAbs at a dose of 10 mg/kg on day -3 and 
2 mg/kg on days -2, -1 and day 0 (the day of transplantation). Recipients underwent 
thymectomy (or sham thymectomy) 10 weeks before transplantation.
P value refers to comparison with the sham thymectomised control group (Fisher’s 
exact test).
* A P value of < 0.025 (0.05/2) was required for statistical significance (Bonferonni’s 
correction for 2 simultaneous comparisons).
respectively). The difference between the thymectomised/anti-CD4 treated and 
the sham thymectomysed group as a control was statistically significant (P= 
0.00216 for 0X70 treated group and P= 0.00794 for the 0X38 treated group 
using Fisher’s exact test). As noted earlier 0X38 and 0X70 mAbs both 
produce, when given to euthymic DA rats, indefinite survival of Lewis heart 
allografts. In keeping with these observations, a group of sham thymectomised 
DA recipients treated with 0X70 mAb failed to reject Lewis heart allografts 
(MST>100 days). From these experiments, it can be concluded that the 
presence of an intact thymus gland is significantly important for the induction of 
tolerance by anti-CD4 mAbs (0X38 & 0X70) in this particular rat transplant 
model.
6:4 Depletion of CD4 T cells by anti-CD4 mAbs
In the following studies, the ability of different anti-CD4 mAbs (i.e. W3/25, 
0X70 and 0X73) to selectively deplete CD4 T cells from the peripheral blood 
(PBL) and lymph nodes (LNC) of DA rats was determined. Flow cytometric 
analysis was performed as described in details in chapter 4 (material and 
methods). The anti-CD4 mAbs were given at a dose of 10 mg/Kg on day -3 and 
2 mg/Kg on days -2, -1 and 0 (the day of transplantation) and flow cytometric 
analysis was performed on day 0 (the day of administration of the last dose of 
mAb) and on day 4. The flow cytometric analysis performed on day 4 was 
carried out on animals given anti-CD4 mAb and a heart allograft on day 0 and 
also on animals given anti-CD4 mAb but not a heart allograft.
The following mouse anti-rat monoclonal antibodies were used to identify 
residual lymphocyte populations in treated animals: W3/25 (anti-CD4), 0X8 
(anti-CD8), R73 (<xP TCR) and 0X22 (anti-CD45R). These mAbs were all 
FITC- or -PE conjugated. In addition, cells from anti-CD4 treated animals were 
labelled with rabbit anti-mouse-FITC directly so as to detect any residual anti- 
CD4 mAb on the lymphocyte cell surface or adding exogenous non-conjugated 
appropriate anti-CD4 mAb followed by rabbit anti-mouse-FITC to determine 
the total number of CD4 T cell population. In the rat, some activated 
monocytes/macrophages may also express the CD4 molecule (Brideau et al, 
1980) and some natural killer (NK) cells may express the CD8 molecule 
(Gilman et al, 1982). Two colour fluorescence labelling was therefore carried 
using PE-labelled anti-CD4/anti-CD8 antibodies and FITC-labelled anti-aP 
TCR (R73) so that the percentage of residual CD4 and CD8 T cells could be 
documented accurately. In the following figures, the FACS analysis data of 
individual experimental animals (of LNCs & PBLs) are depicted first followed 
by statistical analysis shown as bar chart on 4 animals in each anti-CD4 treated 
group. The percentage of CD4 and CD8 T cells in the LNC and PBL of anti- 
CD4 treated animals on day 0, i.e. after the completion of anti-CD4 treatment 
are shown in figures 6:3a, 6:3b and 6:4a, 6:4b. In normal unmodified DA rats, 
the percentage of CD4 T cells is 59.8% in LNC and 54.9% in PBL. There was 
an overall difference between the LNC groups and an overall difference between 
the PBL groups, as shown in figure 6:3c (P= 0.007, ANOVA) and, all the anti- 
CD4 treated groups (LNC & PBL) except the PBLAV3/25 treated animals were
significantly different from the control group (P<0.05, Dunnet’s test). W3/25 
mAb depleted CD4 T cells from 59.8 to 36.6 in LNC and from 54.9% to 41.7% 
in PBL as shown in figure 6:3a & 6:3b. The treatment with the anti-CD4 mAb 
W3/25 led to minimal CD4 T cell depletion which was only significant in the 
LNC treated group (P<0.05, Dunnett’s test) as shown in figure 6:3c. In 
contrast, both 0X70 and 0X73 mAbs treatment led to partial (but statistically 
significant) depletion of CD4 T cells and depletion was most marked in the PBL 
(P<0.05, Student t test). 0X70 and 0X73 mAbs reduced CD4 T cells in the 
LNC from 59.8% to 25% and 22.3% respectively whereas in PBL CD4 reduced 
from 54.9% to 20.3% by 0X70 and to 22.7% by 0X73 as shown in figures 
6:3a & 6:3b.
In normal untreated DA rats, the percentage of CD8 T cells is 13.7 in LNC and 
14.1% in PBL as shown in figure 6:4a & 6:4b. As shown in fig 6:4c, there was a 
small increase in CD8 T cells after 0X38, 0X70 and 0X73 mAb treatment. 
This increase was only significant after 0X70 and 0X38 mAbs in LNC group 
and significant only after 0X38 treatment in PBL group (P<0.05, Dunnett’s 
test). One exception was the lack of an increase in CD8 T cells in the PBL of 
0X73 treated animals. The effect of in vivo 0X38 treatment was not included 
in this particular experiment, since many previous experiments in this laboratory 
(B Jaques) had already been performed. These showed that 0X38 mAb, at the 
dose used here for anti-CD4 mAbs, depletes CD4 T cells to 27.6% in LNC and 
12.3% in PBL, i.e. comparable to those reported here for 0X70 and 0X73. The 
unpublished data shown for 0X38 mAb was kindly provided by Mr B. Jaques.
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Figure 6:3a Flow cytometric analysis of LNCs showing the depletion of CD4 T cells on
day 0 in animals treated by anti-CD4 mAbs.
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Single colour fluorescence analysis using FITC-conjugated rabbit anti­
mouse Y-axis (log10 FITCsignal). LNCs obtained on day 0 following (C) 
W3/25, (D) 0X38, (E) 0X70, (F) 0X73 mAb treatment. All LNCs were 
incubated with a saturating dose of appropriate anti-CD4 mAb [(A) Control 
cells had W3/25 added] followed by rabbit anti-mouse -FITC.
Figure 6:3b Flow cytometric analysis of PBLs showing the depletion of CD4 T cells on
day 0 in animals treated by anti-CD4 mAbs.
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Single colour fluorescence analysis using FITC-conjugated rabbit anti­
mouse Y-axis (log10 FITCsignal). PBLs obtained on day 0 following (C) 
W3/25, (D) 0X38, (E) 0X70, (F) 0X73 mAb treatment. All PBLs were 
incubated with a saturating dose of appropriate anti-CD4 mAb [(A) Control 
cells had W3/25 added] followed by rabbit anti-mouse -FITC.
Figure 6:3c Flow cytometric analysis of PBLs and LNCs showing the
depletion of CD4 T cells on day 0 (i.e. day of last dose of anti-CD4)
by different anti-CD4 mAbs.
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Peripheral blood lymphocytes (PBLs) and lymph node cells (LNCs) were 
harvested from unmodified (naive) DA rats and from DA rats treated with 
different anti-CD4 mAbs given at a dose of 10 mg/kg on day -3 & 2 mg/kg 
on day -2, -1 and 0 (the day of analysis). Results shown are mean and 
standard deviation of 4 treated animals in each group. The mAbs below 
each column are those with which the recipients were treated in vivo.
* There was significant overall difference between LNC groups (P= 0.007, ANOVA).
** There was also overall difference between PBL groups (P= 0.0007, ANOVA).
All the anti-CD4 treated groups (LNC & PBL) except the PBL/W3/25 treated animals 
were significantly different from the control group (P<0.05, Dunnett’s test).
0X70 & 0X73 treatment led to a greater depletion of CD4 T cells in PBL than LNCs 
(P<0.05, Student’s t test).
Figure 6:4a Flow cytometric analysis of LNCs (labelling CD8 T cells )
on day 0.
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Two colour fluorescence analysis using FITC-conjugated 
anti-TCRaP Y-axis (log10 FITCsignals) and PE-conjugated 
anti-CD8 X-axis (log10 PE signals). (A) Represents LNCs 
from a control naive untreated animal and (C), (D), (E) and 
(F) following treatment with different anti-CD4 mAbs.
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Figure 6:4b Flow cytometric analysis of PBLs (labelling CD8 T cells)
on day 0.
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Two colour fluorescence analysis using FITC-conjugated 
anti-TCRaP Y-axis (log10 FITC signals) and PE-conjugated 
anti-CD8 X-axis (log10 PE signals). (A) Represents PBLs from 
a control naive untreated animal and (C), (D), (E) and (F) 
following treatment with different anti-CD4 mAbs.
Figure 6:4c Flow cytometric analysis showing the percentage of
CD8 T cells on day 0 (i.e. day of last dose of anti-CD4 mAb).
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Peripheral blood lymphocytes (PBLs) and lymph node cells (LNCs) were 
harvested from unmodified (naive) DA rats and from DA rats treated with 
different anti-CD4 mAbs given at a dose of 10 mg/kg on day -3 & 2 mg/kg 
on day -2, -1 and 0 (the day of analysis).
* There was significant overall difference between LNC groups (P= 0.001, ANOVA).
* Only the 0X38 and 0X70 treated animals were significantly different from the 
control group (P< 0.05, Dunnett’s test).
** There was significant overall difference between PBL groups (P= 0.007, ANOVA). 
** 0X38 treated animals were significantly different from the control group (P< 0.05, 
Dunnett’s test).
Flow cytometric analysis of cells from animals 4 days after cessation of anti- 
CD4 mAb treatment showed that levels of CD4 T cell depletion were similar to 
those observed on day 0. As it can be seen from figure 6:5a & 6:5b, the data 
shown for day 4 is for W3/25 and 0X70 mAbs only. There was significant 
difference between all the groups (LNCs & PBL) except the transplanted 
PBLAV3/25 treated animals in comparison with the control (P<0.05, Dunnett’s 
test). In addition, there was no difference in the levels of CD4 T cell depletion 
between animals which had received a heart allograft and those which had 
received anti-CD4 mAb but had not been given a heart allograft except 
LNC/W3-25 treated animals (P<0.05, Tukey’s test).
To determine the amount of bound anti-CD4 mAb, immunofluorescence 
analysis was performed on LNCs & PBLs obtained on day 0 (the day of last 
dose of anti-CD4 mAb treatment) from control and treated animals using FITC- 
conjugated rabbit anti-mouse polyclonal antibody as shown in figure 6:7a & 
6:7b. The analysis showed that about 35% of PBL & LNC CD4 T cells are still 
coated by W3/25 mAb. In 0X38 treated animals, only 8.6% of PBLs and 31% 
of LNCs CD4 T cells are still coated whereas in 0X70 treated animals 18.2% 
and 20.2% of PBLs and LNCs respectively are still coated. In 0X73 treated 
animals, 19.5% and 8.7% of LNC and PBL respectively are still coated too. By 
day 4, no residual anti-CD4 was detectable on the surface of either PBL or 
LNC, as judged by labelling of cells with rabbit anti-mouse-FITC antibody as 
shown in figure 6:8a & 6:8b. However, in vitro labelling of PBL and LNC from 
anti-CD4 treated animals, using the anti-CD4 mAb W3/25 followed by rabbit
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anti-mouse FITC-labelled antibody, revealed that residual CD4 T cells showed 
comparable levels of fluorescence to cells obtained from normal animals i.e. 
there was no evidence of CD4 molecule modulation following prior in vivo 
treatment with anti-CD4 mAb.
In the rat CD4 T cells can be divided into two phenotypically distinct subsets 
according to their expression of the cell-surface molecule labelled by the mAb 
0X22. The 0X22 mAb labels the high molecular weight isoform of the 
leukocyte-common antigen. Using this mAb lymphocytes can be divided into 
either OX22low (CD45Rlw) or OX22“sh (CD45Rlueh) T cells (Spickett et al,1983; 
Sarwar et al, 1993). Recently, it has been reported that the cytokine production 
by CD45Rhigh and CD45Rlow CD4 T cells appears to have characteristic 
cytokine patterns correlating to Thl and Th2 cells respectively (Morrisely et al, 
1993; Bushel and Wood, 1995). In normal untreated rats, the percentage of 
LNC OX22high and OX22low CD4 T cells from the total labelled lymphocyte are 
30.7% and 21.1% respectively and in PBLs 36.2% are OX22high and 23% are 
OX22low CD4 T cells as shown in figures 6:6a & 6:6b. As shown in figure 6:6c, 
there was a significant overall difference between LNC OX22high groups 
(P=0.007, ANOVA) but no significant difference between LNC OX22low groups 
(P=0.09, ANOVA). A detailed analysis of 0X22 high and 0X22 low T cells in 
normal and anti-CD4 treated (W3/25 and 0X70) animals revealed that both 
W3/25 & 0X70 led to a significant preferential depletion of only OX22high cells 
from the LNC and only 0X70 mAb depleted OX22high CD4 T cell in 
comparison with control cells (P<0.05, Dunnett’s test). In addition, the
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depletion of OX22hi8h CD4 T cells was significantly higher by 0X70 than by 
W3/25 mAb in either LNCs or PBLs (P<0.05, Tukey’s test). As already noted, 
treatment with W3/25 had no significant effect on PBL CD4 T cells depletion 
on day 0.
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Figure 6:5a Flowcytometric analysis showing the depletion of LNC CD4 T
cells on day 4 in anti-CD4 treated and transplanted animals.
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Figure 6:5b Flowcytometric analysis showing the depletion of PBL CD4 T
cells on day 4 in anti-CD4 treated and transplanted animals.
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Figure 6:5c Flow cytometric analysis showing the depletion of CD4
T cells on day 4 (i.e. the fourth day after the last dose of anti-CD4).
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Peripheral blood lymphocytes (PBLs) and lymph node cells (LNCs) were 
harvested from DA rats 4 days after cessation of anti-CD4 mAb treatment. 
Animals were treated with anti-CD4 mAb alone or received a Lewis heart 
allograft on day 0 (last day of anti-CD4 mAb treatment). Naive animals 
were normal DA rats.
* There was significant overall difference between LNC groups (i.e. W3/25 & 0X70 
anti-CD4 treated) (P= 0.007, ANOVA).
** There was also overall difference between PBL groups except W3/25 treated group 
(P= 0.0007, ANOVA).
All the groups (LNCs & PBLs) except the transplanted PBL/W3/25 treated animals 
were significantly different firom the control group (P<0.05, Dunnett’s test).
There was no significant difference between transplanted and non-transplanted except 
LNC/W3/25 treated animals (P< 0.05, Tukey’s test).
6:6a Flowcytometric analysis of LNCs showing day 0 depletion of of OX22high
and low CD4 T cells by anti-CD4 mAbs.
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6:6b Flowcytometric analysis of PBLs showing day 0 depletion of of OX22high
and low CD4 T cells by anti-CD4 mAbs.
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Two colour fluorescence analysis using FITC-conjugated anti-CD45R Y-axis 
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Figure 6:6c Flow cytometric analysis showing day 0 (i.e. day of last dose of
anti-CD4) depletion of 0X22 low and high CD4 T cells by
the anti-CD4 mAbs.
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Peripheral blood lymphocytes (PBLs) and lymph node cells (LNCs) were 
harvested from unmodified (naive) DA rats and from DA rats treated with 
different anti-CD4 mAbs given at a dose of 10 mg/kg on day -3 & 2 mg/kg 
on day -2, -1 and 0 (the day of analysis). Results shown are mean and 
standard deviation of 4 treated animals in each group.
* There was a significant overall difference between LNC OX22lugh groups (P= 
0.007, ANOVA) but no significant difference between LNC OX22low groups 
(p= 0.09, ANOVA).
* Both W3/25 and 0X70 LNC OX22hlgh groups were significantly different 
from the control group (P< 0.05, Dunnett’s test).
** There was a significant overall difference between both PBL OX22hlgh & 
PBL OX22low groups (P<0.001 and P= 0.001 respectively, ANOVA).
** Only the 0X70 treated animals were significantly different from control in 
both PBL OX22high & PBL OX22low CD4 T cells (P<0.05, Dunnett’s).
The depletion of OX22h,sh CD4 T cells was significant for 0X70 mAb than for 
W3/25 mAb treatment, in either LNC or PBL (P<0.05, Tukey’s test).
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Figure 6:7a Day 0 labelling of LNC CD4 molecules following treatment
with different anti-CD4 mAbs.
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Single colour fluorescent analysis of LNCs using FITC conjugated rabbit 
anti-mouse (Y-axis). Rabbit anti-mouse-FITC was incubated with LNCs 
from (A) Control naive untreated animals (B) W3/25 (C) 0X38 (D) 
0X70 and (E) 0X73 treated animals.
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Figure 6:7b Day 0 labelling of of PBL CD4 molecules following
treatment with different anti-CD4 mAbs.
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Single colour fluorescent analysis of PBL using FITC conjugated rabbit 
anti-mouse (Y-axis). Rabbit anti-mouse-FITC was incubated with PBLs 
from (A) Control naive untreated animals (B) W3/25 (C) 0X38 (D) 
0X70 and (E) 0X73 treated animals.A
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Figure 6:7c Day 0 in-vivo labelling of bound anti-CD4 mAbs 
(LNCs and PBLs obtained from treated animals after the last dose of anti-
CD4 mAb)
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Results are expressed as the mean and standard deviation (from 3 treated 
animals in each group) of the fluorescence intensity of PBLs and LNCs 
following staining with rabbit anti-mouse-FITC of LNCs or PBLs from 
anti-CD4 treated animals (for residual in vivo anti-CD4 mAb labelling) or 
control which represent the untreated naive animals.
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Figure 6:8a Day 4 labelling of LNC CD4 molecules following treatment
with different anti-CD4 mabs.
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Day 4 single colour fluorescent analysis of LNCs using FITC conjugated 
rabbit anti-mouse (Y-axis). Rabbit anti-mouse-FITC was incubated with 
LNCs from (A) Control naive untreated animals (B) W3/25 (C) 0X70 
and (D) 0X73 treated and transplanted animals.
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Figure 6:8b Day 4 labelling of PBL CD4 molecules following treatment
with different anti-CD4 mabs.
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Day 4 single colour fluorescent analysis of PBLs using FITC conjugated 
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PBLs from (A) Control naive untreated animals (B) W3/25 (C) 0X70 and
(D) 0X73 treated and transplanted animals.
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6:6 Discussion
The results from the experiments described in this chapter demonstrated that all 
of the anti-CD4 mAbs used had the ability to induce significant indefinite 
allograft survival (>100 days) in the fully allogeneic Lewis to DA strain 
combination with the notable exception of the anti-CD4 mAb W3/25. This is of 
interest since 0X38 and W3/25 mAbs both label distal domains of the rat CD4 
molecule and indeed they compete for the same epitope. However, whereas 
0X38 is a mouse IgG2a subclass antibody, W3/25 is a IgGl subclass antibody. 
In vitro treatment with 0X38 causes marked, but not permanent, CD4 T cell 
depletion (Jaques, unpublished data, Yin and Fathman et al, 1995) whereas in 
vivo treatment with W3/25 was found to produce very little T cell depletion in 
the present study, suggesting that CD4 T cells depletion may, at least in part, be 
an important factor in contributing to the efficacy of 0X38 anti-CD4 mAb in 
inducing transplantation tolerance. There are no previous reports in the 
literature documenting the ability of mAb’s known to be directed against 
membrane proximal domains of the rat CD4 to induce transplant tolerance. In 
the present study mAb’s directed against the membrane proximal domains of 
CD4 (0X70, 0X71 and 0X73) all showed efficacy in promoting prolongation 
of cardiac allograft survival and this prolongation of graft survival was highly 
significant except 0X71 mAb which its effect was just marginally significant. 
This is of interest since they label components of the CD4 molecule which do 
not interact directly with the class II MHC molecule. However, all three of 
these anti-CD4 mAbs also caused significant CD4 T cell depletion, supporting
A
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the suggestion that, in this experimental model, depletion of CD4 T cells 
contributes to tolerance induction. However, it is important to note that because 
adult thymectomy prior to anti-CD4 treatment prevented effective induction of 
transplantation tolerance, CD4 T cell depletion can not be invoked the sole 
explanation to explain anti-CD4 induced tolerance. Cells newly emerging from 
the adult thymus gland appear to facilitate the emergence of the tolerant state. 
The reason for this phenomenon are not clear although it is reasonable to 
speculate that recently educated T cells may behave differently upon 
encountering graft alloantigen, perhaps, for example, showing preferential 
release of Th2 type cytokines (Onodera et al, 1997). If so, they may exert a 
regulatory effect on residual mature CD4 T cells which escape T cell depletion, 
and which in the absence of this regulatory effect are able to mediate allograft 
rejection. It was notable that anti-CD4 mAb therapy promoted preferential 
depletion OX22high rather than OX22low CD4 T cells. Again this might be 
broadly consistent with the idea that anti-CD4 mAb preferentially depletes Thl 
CD4 T cells since OX22high T cells are reported to produce IL-2, IFNy and 
TNFp and OX22low T cells produce IL-4, IL-6 and EL-10. Recently reported in 
vitro studies by Mason’s laboratory (Stumbles and Mason, 1995) have 
suggested that anti-CD4 mAb may preferentially promote Th2 T cells responses 
to alloantigens. Clearly, therefore, further examination of the role of Thl and 
Th2 cytokine response is warranted.
6:6 Summary
6:1 Analysis of a panel of mouse mAbs (0X38, 0X70 and 0X73) directed 
against either membrane proximal or distal domains of the rat CD4 molecule 
revealed that all of these mAbs were able to induce significant prolongation of 
Lewis heart graft survival in DA rats.
6:2 In contrast, the anti-CD4 mAb W3/25 did not induce transplant tolerance 
even though it labels an epitope on the membrane distal domains overlapping 
with that labelled by 0X38 mAb which, as shown in the preceding chapter, 
induced transplant tolerance.
6:2 The presence of thymus gland was essential for the induction of significant 
allograft survival by 0X38 and 0X70 mAbs in the Lewis to DA rat strain 
combination.
6:3 Flowcytometric analysis of anti-CD4 treated animals, showed that W3/25, 
in contrast to the other anti-CD4 mAbs studied, did not cause significant 
depletion of CD4 T cells from the peripheral blood of the treated animal.
6:4 On day 0 all of the used anti-CD4 mAbs are still bound to CD4 T cells but 
non was detectable on the surface of CD4 T cells by day 4.
6:4 More detailed flow cytometric analysis revealed that 0X70 (but not W3/25) 
significantly depleted the OX22high subset of CD4 T cells in PBLs and LNCs. In 
addition, the depletion of OX22high CD4 T cells was significantly higher by 
0X70 mAb than by W3/25 mAb treatment in either LNCs or PBLs. This finding 
raises the possibility that anti-CD4 mAb may promote the dominance of CD4 T 
cells which preferentially produce Th2 cytokine patem.
CHAPTER SEVEN 
Mechanisms underlying induction of transplant 
tolerance by anti-CD4.
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7:1 Introduction
The immunological mechanisms responsible for inducing and maintaining 
transplant tolerance are undoubtedly very complex and are likely to depend on a 
variety of factors such as the strategy used for inducing tolerance, the type of 
tissue transplanted and the time following transplantation. In this chapter I 
chose to address further some of the immunological mechanisms which may 
operate to establish tolerance to rat cardiac allograft during the early or 
induction period after anti-CD4 mAb treatment. A number of studies have 
suggested that defective IL-2 production by T cells may be an important factor 
in some experimental models of transplant tolerance (Malkovsky et al, 1984; 
Nossal, 1989 and Dallman et al, 1991). Moreover, several authors have argued 
strongly that induction of transplant tolerance correlates with, and may be 
attributable to, a switch from a Thl cytokine response (IL-2 and IFNy) to a Th2 
cytokine response (IL-4, 5 and 10) (Bugeon et al, 1992; Burdick and Clow, 
1990; Papp et al, 1992 and Kupiec-Weglinski et al, 1993).
These issues were addressed here by determining first of all whether the 
administration of exogenous recombinant IL-2 to anti-CD4 treated rats bearing 
cardiac allografts was able to abrogate anti-CD4 induced tolerance during the 
early post-transplant period and, secondly, whether the administration of a 
neutralising mAb to rat IL-4 was able to prevent induction of transplant 
tolerance. Finally, in this chapter, I examined whether the presence of CD8 cells 
was important during the induction of transplantation tolerance by anti-CD4 
mAb in the rat, since Fathman and colleagues recently suggested that CD8 T
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cells may play a role in induction of anti-CD4 induced transplantation tolerance 
(Seydel et al, 1991; Alters et al, 1993 & Yin and Fathman, 1995).
7:2 EL-2 treatment of 0X38 and 0X73 treated DA recipient of Lewis heart 
graft.
In this experiment, naive DA (RTla) recipients were transplanted with Lewis 
heart grafts and animals were then treated with either 0X38 or 0X73 anti-CD4 
mAbs. The dose of mAbs used was that which had been shown previously to 
induce transplantation tolerance in this strain combination i.e. 10 mg/Kg on day 
-3 and 2 mg/Kg on days -2, -1 and day 0 (day of transplantation). During the 
induction of tolerance, the recipient rats received either 20.000 Units or 400 
Units of human rIL-2 daily by the I.P route for five consecutive days. The rIL-2 
treatment was started on day 0 (the day of transplantation). Control animals 
received I.P injections of an equivalent volume of PBS instead of IL-2.
The results of this experiment are shown in table 7:1. It can be seen that 
administration of rIL-2, irrespective of the dose given, did not abrogate 
prolongation of cardiac allograft survival by anti-CD4 mAb, regardless of 
whether 0X38 or 0X73 anti-CD4 mAbs was used. An additional observation 
was that none of the rats treated with either dose of rIL-2 showed any signs of 
toxicity attributable to the cytokine administration.
In the animals receiving 0X38 mAb and treated with 400 U/day of rIL-2, one of 
the five animals studied rejected its heart allograft 15 days after transplantation 
whereas the other four animals retained their heart grafts indefinitely (MST > 
100 days, P= 1.00 using Fisher’s exact test in comparison with PBS treated
*
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Table 7:1 Effect of giving exogenous IL-2 on the ability of anti-CD4 mAb’s 
(0X38 or 0X73) to prolong cardiac allograft survival.
Group Anti-CD4a
mAb
rIL-2b
(U/day)
Number 
of animals
Graft Survival 
(days)
MST
(days)
1 0X38 4xl02 5 15, > 100 days (x4)* >100 days
2 0X38 2x104 5 9, > 100 days (x4)* >100 days
3 0X38 None 8 11, 18, > 100 days (x6) >100 days
4 0X73 2xl04 4 All > 100 days (x4)* >100 days
(a) DA rats were treated with anti-CD4 mAb (0X38 or 0X73) prior to 
receiving a Lewis cardiac allografts.
(b) Animals were treated with rIL-2 (or PBS as control) daily for 5 days starting 
on the day of heart transplantation.
* P value was non-significant (P=1.00, using Fisher’s exact test in comparison 
with PBS treated control group).
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control group). The same result was obtained with the group of DA recipients 
given 20.000 U/day of rIL-2; one recipient rejected its heart graft on day 9 and 
4 retained their heart for more than 100 days. Administration of 20.000 U/day 
of rIL-2 in 0X73 treated DA recipients also failed to abrogate tolerance 
induction and all four experimental animals retained their heart grafts for more 
than 100 days (MST> 100 days, P=1.00, using Fisher’s exact test). Therefore, 
the administration of rIL2 during the induction of tolerance by either 0X38 or 
0X73 mAbs failed to induce rejection in this rat model.
7:3 Anti-IL-4 (OX81) mAb treatment of 0X38 treated DA recipient of 
Lewis heart graft.
In this experiment, DA (RTla) rats were treated with anti-CD4 (0X38) mAb at 
a dose of 10 mg/Kg on day -3 and 2 mg/Kg on days -2, -1 and day 0 (the day of 
transplantation). In addition, however, they were also given an anti-IL-4 mAb 
(MRC 0X81) to neutralise endogenous IL-4. 0X81 is of the IgGl isotype 
which has been shown in previous studies to neutralise the activity of rat IL-4 
(Stumbles and Mason, 1995). It was given at a dose of 5 mg/Kg daily for four 
days (day 0, the day of transplantation and days 1, 3 and day 5 post 
transplantation).
The results of this study are shown in figure 7:1. It can be seen that four of the 
six DA recipients of Lewis heart grafts that were treated with 0X81, during the 
induction of tolerance with 0X38 mAb, rejected their heart graft (MST 21 days, 
P= 0.27 using Fisher’s exact test in comparison with control group) and only 2 
animals accepted their heart graft indefinitely. Control animals treated with 
0X38 received an equivalent volume of PBS instead of 0X81 mAb and six of
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Figure 7:1 The ability of anti-!L4 (MRC OX81)mAb 
to a b r o g a t e  early induced t o l e r a nc e  by 0X38 
mAb in Lewis to DA s t r a in  combinat ion.
 0X38+ PBS (n=8, MST> 100 days).
  0X81+0X38 (n=6, MST 21 days, P= 0.27)*
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DA recipients were treated with both OX81 (anti-IL4) mAb at a dose of 5 mg/kg 
on day 0, 1, 3 and 5 and 0X38 mAb at a dose of 10 mg/kg on day -3 and 2 
mg/kg on day -2, -1 and day 0 (the day of transplantation).
* P = 0.27 (using Fisher’s exact test in comparison with control group).
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these animals retained their heart grafts indefinitely (MST> 100 days). This 
latter finding is in keeping with this thesis previous experiments, in 
demonstrating the efficacy of 0X38 in inducing tolerance to Lewis heart graft in 
DA recipients.
7:4 Anti-CD8 mAb treatment of DA recipients of Lewis heart graft during 
the induction of tolerance by 0X38 mAb.
To determine whether CD8 cells are critical during the induction of tolerance by 
anti-CD4 mAb in the rat, five DA (RTT) recipients were treated with a 
depletive regimen of MRC 0X8 (anti-CD8) mAb at a dose of 5 mg/Kg on the 
day preceding transplantation (-1), the day of transplantation (0) and day 3 after 
transplantation. MRC 0X8 has been shown in several studies, including studies 
from this laboratory, to be highly effective at depleting CD8 cells from blood 
and lymphoid organs of treated rats (Sedgwick et al, 1988; Grade et al, 1990 
and Bell et al, 1989). Anti-CD4 (MRC 0X38) mAb treatment was given as 
before i.e. 10 mg/Kg on day -3 and 2 mg/Kg on days -2, -1 and day 0. Control 
animals received PBS during the induction of tolerance by 0X38 mAb.
The results are shown in figure 7:2. Five of anti-CD4 treated DA (RTla) 
recipient rats, which were given anti-CD8 (0X8) mAb, four rejected their heart 
grafts and only one experimental animal retained its graft indefinitely (MST 16 
days, P=0.102 using Fisher’s exact test). Although the statistical analysis was 
not significant due to the small number of animals used in this experiment, the 
result still suggests that CD8 cells play a role in tolerance induction following 
0X38 mAb treatment.
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Figure 7:2 The ability of Anti-CD8 (0X8) mAb to 
abroga te  early induced to lerance  by 0X38 mAb in 
Lewis to DA st rain combinat ion
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DA recipients were treated with both 0X38 mAb at a dose of 10 mg/kg on day - 
3 and 2 mg/kg on day -2, -1 and day 0 (the day of transplantation) and OX8 
mAb at a dose of 5 mg/kg on day -1, 0 (the day of transplantation) and day 3 
after transplantation.
* P = 0.102 using Fisher’s exact test in comparison with control animals.
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7:5 Discussion
In several experimental models of transplantation tolerance induction, there is 
evidence of a defect in the IL-2 pathway (Dallman et al, 1991, Malkovsky et al, 
1984; Nossal, 1989). The in vivo effect of exogenous rIL-2 treatment on 
tolerance induction in different mice and rat models of transplant tolerance 
described by other research groups is summarised in table 7:2. Administration of 
exogenous IL-2 (104 units/day for 4 days) has been shown to prevent 
prolongation of graft survival in blood transfused rats (Dallman et al, 1989) and 
of mice given anti-CD4 plus anti-CD8 mAbs and treated with rIL-2 (1600 
Units/day for 6 days) (Chen et al, 1996).
It was therefore of particular interest to determine whether administration of 
exogenous IL-2 was able to prevent prolongation of heart allograft survival by 
0X38 mAb in the rat. Such studies are potentially problematical since the half- 
life of administered cytokine is usually very short. Nevertheless, the results 
obtained were unequivocal in that giving rIL-2 daily for 5 days after heart 
transplantation did not abrogate allograft survival. The amount of rEL-2 given 
was comparable to that used by other groups and probably close to the toxic 
dose in the rat. The findings with exogenous IL-2 suggest that deficiency in 
endogenous IL-2 is not the critical event in the induction of transplant tolerance 
following 0X38 mAb treatment and in this respect, therefore, the model 
appears to differ from tolerance induced by donor-specific blood transfusion 
(Dallman et al, 1989).
*
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Table 7:2 Reported effects of exogenous IL-2 on induction of transplant
tolerance by different groups.
Immunosuppressive
regimen
Animal
model
Dose of IL-2 
U/day
Effect of IL-2 Reference
1. Donor blood 
transfusion
Rat 104 (for 4 days) Graft rejection Dallman et 
al, 1989.
2. Adoptive transfer 
of splenocytes 5xl07 
from tolerant mice
Mouse 1600 (for 6 days) No effect on 
graft survival
Chen et al, 
1996.
3. Anti-CD4 + anti- 
CD 8 mAbs
Mouse 1600 (for 6 days) Graft rejection Chen et al, 
1996.
4. Anti-CD4 mAb Mouse 1 Ox 103 Units on 
the day of Txn & 
then 30x103 U/day 
(for 5 days)
No effect on 
graft survival.
Pearson et 
al, 1993b.
5. Anti-CD28 
(CTLA4Ig)
Rat 1000 (for 5 days). Partial reversal. Sayegh et al, 
1995.
The studies performed in this chapter using the mAh 0X81 to neutralise 
endogenous IL-4 in vivo are interesting but not conclusive. Overall, neutralising 
IL-4 by 0X81 appeared to diminish the efficacy of tolerance induction by 0X38 
mAb but statistically was not significant. However, the 0X81 hybridoma was 
found to be particularly poor at yielding significant amounts of immunoglobulin 
and this in turn limited the amount of material available for the study. Hence the 
amount of 0X81 antibody which could be given per animal and the number of 
animals treated was suboptimal. In fiiture studies it would be interesting to 
administer larger amounts of 0X81 mAb, perhaps for a longer period to ensure 
complete blockade of IL-4. Another important point to consider in interpreting 
the present results is that IL-4 is also produced by other cell types in addition to 
Th2 T cells (Mosmann et al, 1986; Mosmann and Cofifinan, 1989). Eosinophiles 
and mast cells (Brown et al, 1988b; Rennick et al, 1987 and Zlotnik et al, 1987), 
for example may produce relatively large amounts of IL-4. It can not be 
assumed, therefore, that the experimental results obtained here necessarily 
suggest a role of Th2 T cells in transplant tolerance induction and further study 
of the this point is clearly worthwhile.
The observation that treatment with 0X8 mAb abrogated tolerance induction 
after anti-CD4 mAb treatment is intriguing. This finding is consistent with that 
reported by other groups who carried out similar work in mouse (Seydel et al, 
1991 and Alters et al, 1993) and rat models of transplantation tolerance (Yin 
and Fathman, 1995). Taken together, the results from these studies, indicate 
that the CD8 cell plays an important role in rendering or inducing potential
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allograft specific unresponsiveness in DA recipients of Lewis heart graft at the 
early stages of tolerance induction by anti-CD4 mAb. It should be emphasised 
that in the rat the CD8 molecule is expressed not only on CD8 T cells but also 
by some NK cells. The effect of anti-CD8 mAb can not necessarily be attributed 
exclusively to CD8 T cells. Nevertheless, the above results raise the question as 
to how the presence of CD8 T cells promotes anti-CD4 mAb induced transplant 
tolerance. One possibility is that CD8 T cells may be acting directly as 
suppressor or regulatory T-cells during the early stages of the in vivo 
alloimmune responses. Second, the possibility arises that during the induction of 
tolerance with anti-CD4 mAb alloreactive CD8 cells may compete with the 
alloreactive CD4 T cells for the essential co-stimulatory molecules on allogeneic 
APC and this competition may lead to the failure of the second signal being 
delivered to residual CD4 T cells and therefore to the induction of specific CD4 
T cell unresponsiveness. According to this hypothesis, on depleting the CD8 T 
cell population, competition for the co-stimulatory molecules on APC is 
reduced and this may, lead to the activation of residual CD4 T cells and hence 
rejection of the allograft. A third, possibility is that 0X8 mAb may penetrate the 
blood-thymus barrier and eliminate double positive CD8CD4 T-cells which may 
if not eliminated, provide an immuno-regulatory signal for positive CD4 T cell 
subpopulation. Clearly, it will be important in future studies to address these 
possibilities.
7:6 Summary
7:1 Induction of tolerance to a Lewis heart allograft in DA rats following anti- 
CD4 mAb is not attributable to a lack of IL-2 alone, since provision of 
exogenous rIL-2 failed to prevent the development of tolerance.
7:2 Endogenous IL-4 may facilitate induction of tolerance by anti-CD4 mAb 
since administration of a neutralising antibody to IL-4 partially abrogated 
tolerance although the results were not conclusive.
7: Although 0X8 mAb treatment appeared statistically not significant due to the 
small number of animals, CD8 cells might still play a critical role during the 
induction phase of anti-CD4 mAb induced tolerance.
CHAPTER EIGHT
Mechanisms underlying maintenance of transplant 
tolerance by anti-CD4 mAb.
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8:1 Introduction
In this chapter some aspects of the immunological mechanisms responsible for 
maintaining transplant tolerance in anti-CD4 treated recipients with long­
standing heart grafts were examined. As already discussed, the mechanisms 
which operate to maintain transplant tolerance are likely to be both complex and 
different from those responsible for initiation of the tolerant state. There is an 
increasing body of experimental evidence which suggests that regulatory or T 
suppressor cells may play a critical role in maintaining transplant tolerance 
(Matriano et al, 1982; Scully et al, 1994; Lombardi et al, 1994; Bushel et al, 
1995, Chen et al, 1996, Onodera et al, 1996 & 1997). Since, in the preceding 
chapter, evidence was obtained suggesting that CD8 cells may be important for 
the induction of anti-CD4 tolerance to a heart allograft after anti-CD4, the 
question arose as to whether CD8 cells may also participate in the maintenance 
of the tolerant state. Several recent studies in mice made tolerant to allografts 
by a combination of anti-CD4 and anti-CD8 mAbs have demonstrated the 
presence of regulatory T lymphocytes which, on adoptive transfer to a second 
syngeneic recipient, are able to prevent allograft rejection (Chen et al, 1996; 
Chen and Waldmann, 1993). Such studies point to a role for a regulatory 
lymphocyte population in maintaining transplant tolerance. One of the aims of 
the work described in this chapter was, therefore, to determine whether 
evidence existed for such regulatory lymphocytes in anti-CD4 treated rats 
bearing a long-standing heart allograft.
Finally, in view of the large amount of recent interest in the concept that 
transplant tolerance may be associated with, and indeed partially attributable to, 
a deviation in the T helper cytokine repertoire from a Thl to Th2 type cytokine 
profile (Mossman et al, 1989; Mottram et al, 1995 and Strom et al, 1996), the 
possibility that this phenomenon may offer an explanation for maintaining 
transplant tolerance after 0X38 mAb therapy was examined. Analysis of the T 
cell response in long-term tolerant rats also enabled examination of the 
possibility that transplant tolerance in the present studies was attributable to 
clonal deletion of potentially alloreactive T lymphocytes. This last possibility 
was, however, not considered likely. Although clonal deletion is well known to 
be the principle mechanism governing the export of potentially autoreactive 
lymphocytes from the thymus gland, this mechanism is not generally thought to 
be instrumental in anti-CD4 induced transplant tolerance (Shizuru et al, 1987). 
8:2 The role of CD8 cells in maintaining tolerance.
To determine whether CD8 cells were important in the maintenance of 
transplant tolerance induced by anti-CD4 (MRC 0X38) mAb, four 0X38 
treated DA rats bearing long-term (MST>100 days) Lewis abdominal cardiac 
allografts were treated with a short course of the depleting anti-CD8 mAb 
(0X8) and then immediately engrafted with a second Lewis heart graft to the 
cervical site.
In this study, 0X8 mAb was given at a dose of 5 mg/Kg for a total of three days 
(on the day preceding transplantation [day -1], the day of transplantation [day 
0] and day 3 after transplantation). As mentioned earlier (chapter 7), this
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regimen of 0X8 mAb treatment has been shown previously to be highly 
effective at depleting rat CD8 cells in vivo. Retransplantation of tolerant animals 
with a second Lewis heart graft was performed in this experiment, so as to 
exclude the possible contribution of reduced immunogenicity of the original 
Lewis heart graft to the experimental findings.
The results of this study are shown in table 8:1. All four long-term tolerant 
recipients treated with 0X8 mAb during the engraftment of a donor-specific 
cervical allograft retained their second heart grafts indefinitely (> 100 days). 
The original abdominal heart allograft was also noted to continue beating 
throughout this period of time. Five long-term tolerant control 0X38 treated 
recipients receiving a donor specific Lewis heart graft to the cervical site were 
given PBS instead of 0X8 mAb. These animals, as expected, retained their 
cervical heart graft indefinitely (MST> 100 days) and their original abdominal 
heart graft continued to beat for the duration of the study. The results of this 
experiment indicate that CD8 cells do not, therefore, appear to play an essential 
role in the maintenance of transplant tolerance following anti-CD4 mAb 
treatment in the rat as non of the grafted animals rejected its heart graft.
8:3 Ability of spleen cells from tolerant animals to mediate suppression.
The adoptive transfer technique is a potent method for analysing lymphocyte 
cell function in the field of experimental immunology and has been used with 
great effect in many studies to assess the ability of lymphocytes and lymphocyte 
subpopulations to effect or regulate allograft rejection. In the following
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Table 8:1 CD8 cells are not essential for maintenance of transplant tolerance in 
anti-CD4 treated DA rats bearing a long-standing Lewis heart allograft.
Group Recipient* mAbb Number of 
animals
Graft survivalc 
(Days)
MST
(Days)
1 DA OX8 4 all> 100 days >100d
2 DA PBS 5 all >100 days >100
(a) DA recipients had long-standing (> 100 days) heterotopic Lewis heart grafts 
(abdominal site) following perioperative treatment with anti-CD4 mAb (0X38). 
All recipients received a second Lewis heart allograft to the cervical site.
(b) 0X8 mAb was given at a dose of 5 mg/kg on day -1,0 (the day of cervical 
heart transplantation) and day 3 after the second heart transplantation. Control 
animals were treated with an equivalent volume of PBS.
(c) Survival of second (cervical) heart allograft. All of the primary abdominal 
heart allografts continued to beat for the period of the study.
(d) Group 1 versus group 2 (P = 1.0, using Fisher’s exact test).
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experiment, spleen cells harvested from 0X38 treated DA rats bearing long­
standing Lewis heart allografts were tested for their ability to suppress allograft 
rejection when adoptively transferred to a second naive syngeneic recipient 
which was then challenged with a Lewis heart allograft. The secondary 
recipients in this study received spleen cells from tolerant rats the day before 
challenge with a heart allograft and were not given any supplementary 
immunosuppression following transplantation. The results of this study are 
shown in table 8:2. It can be seen that adoptive transfer of 2x108 spleen cells 
from tolerant rats led, in 2 of the 4 secondary recipients tested, to the permanent 
acceptance (>100 days) of a Lewis heart allograft although the overall increase 
in graft survival failed to reach statistical significance, most likely because of the 
small numbers in experimental groups. The suppression observed in this 
experimental system was donor (i.e. Lewis) specific since when 2x108 spleen 
cells from tolerant rats were transferred into naive DA recipients which were 
then given a third party PVG (RT1C) heart allograft the following day, no 
increase in allograft survival was seen. The number of adoptively transferred 
spleen cells necessary to suppress allograft rejection in this study was more than 
lxl08, since the transfer of lx l08 tolerant spleen cells failed to extend the 
survival of a donor-specific (Lewis) heart allograft in a secondary unmodified 
DA recipient (table 8:2). These experiments suggest that cells within the spleen 
of long-term recipients bearing a cardiac allograft may exert a suppressive or 
regulatory effect which may be important in maintaining the tolerant state within 
such animals although caution is required in the interpretation of these results
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Table 8:2 Spleen cells from tolerant animals may suppress rejection of a 
donor strain but not third party heart allograft.
Number 
of spleen cells0
Recipient
strain1*
Strain of 
heart graft
Number of 
animals
Graft 
survival (days)
Pc
value
MST
(days)
lxlO8 DA Lewis 3 9, 9, 10 0.76 9
2x10* DA Lewis 4 10, 15, 
>100 (x2)
0.11 58
2x10* DA PVG 5 7, 8,11,11,12 11
(a) Spleen cells from DA animals bearing long-standing Lewis heart grafts were 
adoptively transferred into secondary unmodified DA animals. Spleen cells from 
tolerant animals were injected IV at the dose stated.
(b) Recipients animals were given either a DA (donor-specific) or PVG (third 
party) heart allograft the following day.
(c) P value using mann-whitney test in comparison with the group receiving a 
third party (PVG) heart graft.
because of the small number of experimental animals involved.
8:4 In vitro studies with purified CD4 T cells obtained from long-term 
tolerant 0X38 and 0X70 mAbs treated DA rats.
In the following studies, CD4 T cells obtained from anti-CD4 mAb treated DA 
bearing long-standing Lewis heart graft (> 100 days) were studied in vitro to 
determine their ability to proliferate and produce cytokines when re-stimulated 
in vitro with allogeneic APC. CD4 T cells were purified from the LNC of 
tolerant heart allograft recipients (and from normal control) animals by 
immunomagnetic beads (yielding a cell population > 95% of CD4 T cells) and 
stimulated in vitro with irradiated donor (Lewis) or third party (PVG) spleen 
cells. The following proliferation and cytokine data were not statistically 
analysed as the experiments were performed on one occasion.
8:4:1 Proliferative response of CD4 T cells from 0X38 or 0X70 treated 
tolerant DA rats.
In this experiment, the proliferative response of purified CD4 T cells from both 
0X38 and 0X70 treated long-term tolerant (>100 days) DA rats bearing Lewis 
heart grafts was determined. The results are shown in figure 8:1 and 8:2. It can 
be seen that purified CD4 T cells obtained from 0X38 treated tolerant animals 
showed a good proliferative response (at both 72 and 96 hours of culture) to 
Lewis (heart donor strain) stimulator cells and the levels of proliferation 
observed against Lewis stimulators were only marginally lower than those seen 
in response to third party stimulator cells (fig 8:1). The ability of cells from 
tolerant animals to respond to donor specific stimulators indicates that major
4
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Figure 8:1 Proliferative response of CD4 T cells from long-term tolerant
(0X38) animals.
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CD4 T cells were purified from the LNC of 0X38 treated DA rats bearing long­
standing (>100 day) Lewis heart allograft and used as responders in a MLR. 
Irradiated spleen cells from Lewis (donor-specific) or PVG (3rd party) rats 
were used as stimulators. Cultures were pulsed with fHJ-thymidine 18 hours 
before harvesting. Cells were harvested after 72 hrs (top panel) and 96 hrs 
(bottom panel) of culture. Results are mean of triplicate determinations. LNC 
CD4 T cells were pooled from three 0X38 treated tolerant rats.
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Figure 8:2 Proliferative response of CD4 T cells from long-term tolerant
(0X70) animals.
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CD4 T cells were purified from the LNC of 0X 70 treated DA rats bearing long­
standing (>100 day) Lewis heart allograft and used as responders in a MLR. 
Irradiated spleen cells from Lewis (donor-specific) or PVG (3rd party) rats 
were used as stimulators. Cultures were pulsed with ['H]-thymidine 18 hours 
before harvesting. Cells were harvested after 72 hrs (top panel) and 96 hrs 
(bottom panel) of culture. Results are mean of triplicate determinations. LNC 
CD4 T cells were pooled from three 0X70 treated tolerant rats.
deletion of donor alloreactive CD4 T cells has not occurred in long-term 
recipients after 0X38 mAb treatment and that deletion of alloreactive 
lymphocytes is not, therefore, likely to be the explanation for transplant 
tolerance in this experimental model. Similarly, CD4 T cells from long-term 
tolerant recipients following 0X70 mAb treatment (figure 8:2) proliferated as 
well to donor as to third party PVG stimulator cells and the proliferative 
response of CD4 T cells from tolerant animals was, at 72 hours, comparable to 
that shown by purified CD4 T cells from normal animals. After 96 hours of 
culture, however, the proliferative response of CD4 T cells from 0X70 treated 
animals was less than that seen in cells obtained from normal animals, although 
the response to both donor and third party stimulators was diminished (i.e. not 
donor specific). The reduction in proliferation of CD4 T cells from tolerant 
animals at 96 hours reflects the fact that either the proliferation had already 
peaked at 72 hours or this generalised non-specific immunosuppression . 
Overall, therefore, there was no evidence for clonal deletion of donor-reactive 
CD4 T cells in long-term tolerant animals following 0X38 or 0X70 anti-CD4 
mAb treatment.
8:4:2 Cytokine production by CD4 T cells from 0X38 and 0X70 treated 
tolerant rats.
To determine whether differential cytokine expression is likely to play a role in 
the maintenance of transplant tolerance induced by anti-CD4 mAbs, purified 
CD4 cells (from 0X38 and 0X70 treated tolerant and from naive control 
animals) were stimulated with irradiated donor (Lewis) or third party (PVG)
i
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spleen cells, as already described. Culture supernatants (after 72 and 96 hours of 
culture) were examined for the presence of both Thl (IL-2 and IFNy) and Th2 
(IL-4) cytokines.
The results obtained are shown in figures (8:3 to 8:7) and these will be 
described in further detail, considering, the individual cytokines separately for 
convenience.
Interleukin-2 (IL-2) production by tolerant CD4 T cells.
IL-2 production was determined by bioassay using the IL-2 sensitive CTL2 cell 
line (see material and methods). Purified CD4 T cells from 0X38 treated 
animals released slightly less IL-2 in response to donor-specific (Lewis) than in 
response to third-party (PVG) stimulator cells at both 72 and 96 hours. 
However, although IL-2 production by tolerant CD4 cells was lower for Lewis 
than PVG stimulators, significant amounts of bioactive IL-2 were, however, 
detectable after both 72 and 96 hours in culture. Purified CD4 T cells from 
0X70 treated animals showed a marked reduction in EL-2 production at both 72 
and 96 hours compared to normal CD4 T cells as shown in figure 8:4. 
However, there was no evidence for a donor specific defect since the low level 
of IL-2 produced by tolerant CD4 T cells were similar following both donor- 
specific (Lewis) and third party stimulation.
Figure 8:3 Production of IL-2 by CD4 T cells from long-term tolerant (0X38)
animals.
72 hours.
Stimulators
Tolerant
(Responder)
LB/V FVG
Normal
(Responder)
96 hours.
100
90
80
70 1
60
E 50 |
c
Z D 40
30
20 |
10 |
0
'mm
Stimulators l e w
i- •*%
wm
FVG
Tolerant
(Responder)
LEW
I
■
FVG
Normal
(Responder)
CD4 T cells purified from the LNC of 0X38 treated DA rats bearing long­
standing (>100 days) Lewis heart grafts were stimulated with irradiated spleen 
stimulators and culture supernatants harvested at 72 and 96 hours to determine 
IL-2 content by bioassay using the IL-2 sensitive cell line CTLL2. Results are 
the mean and standard deviation of triplicate IL-2 determinations.
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Figure 8:4 Production of IL-2 by CD4 T cells from long-term tolerant (0X70)
animals.
72 hours.
160
140
120
100E
jg 80c3 60
40
20
0
Stimulators LEW FVG
Tolerant
(Responder)
JL
.
LEW FVG
Normal
(Responder)
96 hours.
100
90
80
70
3  40
30 
20 
10 
0
Stimulators LEW FVG
Tolerant
(Responder)
LEW FVG
Tolerant
(Responders)
CD4 T cells purified from the LNC of 0X70 treated DA rats bearing long­
standing (>100 days) Lewis heart grafts were stimulated with irradiated spleen 
stimulators and culture supernatants harvested at 72 and 96 hours to determine 
IL-2 content by bioassay using the IL-2 sensitive cell line CTLL2. Results are 
the mean and standard deviation of triplicate IL-2 determinations.
Interferon gamma (IFNy) production by tolerant CD4 T cells.
The levels of IFNy in MLR culture supernatants were quantified by ELISA. 
Purified CD4 T cells from 0X38 treated animals produced similar amounts of 
IFNy as normal CD4 T cells at both 72 and 96 hours of culture as shown in 
figure 8:5. After 96 hours of culture, IFNy levels in culture supernatants of 
tolerant CD4 T cells were broadly similar after stimulation with donor-specific 
(Lewis) and third party (PVG) stimulation. In 0X70 treated animals, levels of 
IFNy were reduced in the supernatant from tolerant CD4 T cells at both 72 and 
96 hours of culture as shown in figure 8:6. However, this reduction of IFNy 
level was not donor-specific as tolerant cells produced a lower level on 
stimulation by third party (PVG) and donor specific (Lewis) stimulator spleen 
cells.
Interleukin-4 (IL-4) production by tolerant CD4 T cells.
Attempts to establish an ELISA for rat IL-4 were not successful and, therefore, 
IL-4 in MLR culture supernatants was examined by a bioassay using the 
induction of class II MHC on B cells as an indictor of the presence of IL-4 
(Stumbles and Mason, 1995). This assay is difficult and time consuming because 
of the need to prepare purified rat B cells. IL-4 levels were, therefore, only 
estimated for CD4 T cells obtained from 0X38 mAb treated recipients. As 
shown in figure 8:7, the IL-4 levels were similar in CD4 T cells obtained from 
tolerant rats and CD4 T cells from normal animals. Levels of DL-4 production by 
tolerant cells stimulated by donor-specific (Lewis) and third party (PVG) 
stimulators were similar.
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Figure 8:5 Production of IFNy by CD4 T cells from long-term
tolerant (0X38) animals.
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CD4 T cells purified from the LNC of 0X38 treated DA rats bearing long­
standing (>100 days) Lewis heart grafts were stimulated with irradiated spleen 
stimulators and culture supernatants harvested at 72 and 96 hours to determine 
IFNy content by ELISA. Results are the mean and standard deviation of 
triplicate determinations.
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Figure 8:6 Production of IFNy by CD4 T cells from long-term
tolerant (0X70) animals.
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CD4 T cells purified from the LNC of 0X 70 treated DA rats bearing long­
standing (>100 days) Lewis heart grafts were stimulated with irradiated spleen 
stimulators and culture supernatants harvested at 72 and 96 hours to determine 
IFNy content by ELISA. Results are the mean and standard deviation of 
triplicate determinations.
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Figure 8:7 Production of IL-4 by CD4 T cells from long-term
tolerant (0X38) animals.
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IL-4 was determined by bioassay to determine upregulation of expression of 
MHC class II molecules on B cells. Rat purified B cells were mixed with 
supernatants from CD4 T cells from long-term 0X38 treated animals which had 
been cultured in vitro for 72 hours with irradiated Lewis stimulator cells. Values 
for IL-4 were derived from a standard curve constructed using serial dilutions of 
recombinant rat IL-4 obtained as tissue culture supernatant (104 U/ml) from an 
IL-4 transfected CHO cell line.
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8:5 Discussion
The results from the studies described in this chapter provide further insight into 
the immunological mechanisms which contribute to maintenance of transplant 
tolerance after anti-CD4 mAb treatment. In marked contrast to the induction 
phase of anti-CD4 induced transplant tolerance (chapter 7), the experiments in 
which 0X8 mAb treatment was used to deplete CD8 T cells from long-term 
tolerant recipients suggest that the CD8 T cell subpopulation does not play a 
critical role in the maintenance phase of tolerance. Interestingly, however, the 
adoptive transfer studies using splenocytes from long-term (MST>100 days) 
anti-CD4 treated animals suggested that a regulatory or suppressor T cells may 
be instrumental in maintaining transplant tolerance in this model. Although the 
number of animals studied was small, spleen cells from tolerant rats appeared 
capable of prolonging, and sometimes completely preventing, allograft rejection, 
after transfer into secondary naive allograft recipients. The regulatory effect of 
the transferred spleen cells in these studies was donor-specific which suggests it 
was attributable to T lymphocytes. As already emphasised, however, caution is 
required in the interpretation of the adoptive transfer results because of the 
small number of experimental animals involved. Since CD8 T cells are not 
critical it is most likely that the cell responsible is a CD4 T cell. It would be of 
interest, in future studies, to define more precisely the nature of the spleen cell 
subpopulation responsible for transferring suppression in this experimental 
model. This could be approached by purifying the T cell subsets prior to 
adoptive transfer.
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The results of the adoptive transfer analysis obtained using cells from long-term 
tolerant rats are consistent with the studies of Waldman’s group in mice 
rendered tolerant by anti-CD4 and anti-CD8 mAb (Cobbold et al, 1992, Qin et 
al, 1993; Chen et al, 1993). Waldman and colleagues proposed that tolerance is 
maintained by “infectiousness”, and that a cohort of adoptively transferred 
tolerant T-cells are able to guide alloreactive naive T cells specific for the same 
antigen to become tolerant themselves (Cobbold et al, 1996). Waldmann has 
suggested that the prolonged blockade of important functional T cell surface 
molecules favours alloantigen presentation to T cells by non-professional APC 
and that this might be permissive for the emergence of regulatory T cells which, 
once established, become dominant and are able to induce tolerance in other T 
cells.
The demonstration that purified CD4 T cells from long-term tolerant rats after 
0X38 treatment are able to proliferate normally in the MLR argues strongly 
against a deletional mechanism for maintaining transplant tolerance in this 
model. Interestingly, cells from 0X70 treated animals showed a non-specific 
reduction in proliferation after 96 hours in culture which may indicate that 
0X70 has a generalised immunosuppresive effect rather than a donor specific 
effect. This is an unexpected observation and one which is worthy of more 
detailed investigation in future experiments both to validate the observation and 
to explore further why 0X70 should differ in this respect to 0X38. Although 
cells from 0X38 tolerant animals showed good proliferative response, such 
animals displayed donor specific tolerance by accepting second donor specific
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(Lewis) heart graft and rejecting a third party cervical heart graft. Over the last 
five years or so, a number of authors have provided evidence that transplant 
tolerance correlates with a decrease in the Thl cytokine response and, in some 
cases, an increase in the Th2 response. On the basis of these finding, some 
authors have suggested that a switch from a Thl to Th2 cytokine pattern is 
instrumental in maintaining the tolerant state (Bugeon et al, 1992; Kupiec- 
Weglinski et al, 1993; Strom et al, 1996, Dallman, 1995 and Onodera et al, 
1996 & 1997). However, the analysis of cytokine production by CD4 T cells 
obtained from tolerant anti-CD4 treated animals did not provide strong support 
for this idea. Overall, CD4 T cells from 0X38 tolerant animals were able to 
produce relatively normal amounts of IL-2 and IFNy after restimulation with 
donor stimulator cells in vitro. Moreover, CD4 T cells from 0X38 treated 
animals produced levels of bioactive IL-4 which were comparable to those 
produced by normal CD4 T cells i.e. there was no evidence of over production 
of this Th2 cytokine.
As with the proliferative data, the results of the cytokine analysis from animals 
made tolerant by 0X70 mAb were less straight forward. In contrast to 0X38 
treated recipients, animals made tolerant by 0X70 mAb showed a rather 
different cytokine response. They produced less IL-2 and IFNy proteins (i.e. 
Thl suppression). Measurement of IL-2 protein production in vitro is 
complicated by the fact that the proliferating cells may consume the secreted 
product. However, the possibility that there is a genuine failure of CD4 T cells 
from 0X70 treated animals to produce IL-2 protein and that there is Thl
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suppression can not be excluded. This reduction of both IFNy and IL2 proteins 
levels was non specific which may indicate that 0X70 mAb has a generalised 
immunosuppressive effect rather than donor specifc tolerogenic effect. As 
already discussed, it would be interesting to examine, in vivo, whether, long­
term 0X70 treated animals can accept or reject third party skin or heart grafts. 
Unfortunately, there was insufficient supernatant from the 0X70 CD4 T cell 
cultures to assess whether there is any increase of functional IL-4 protein. 
Similarly, no assay is yet available in the rat for measurement of IL-13 protein. 
Nevertheless, from the analysis of cytokine protein released from CD4 T cells in 
0X70 treated animals, immune deviation towards a Th2 response can not be 
excluded, and clearly further studies will be needed to clarify this. The 
differentiated cytokine response of CD4 T cells from 0X38 and 0X70 tolerant 
recipients raises the possibility that these two mAb’s may achieve transplant 
tolerance, at least in part, through different pathways.
*
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8:6 Summary
8:1 CD8 T cells did not play an essential role in the maintenance of transplant 
tolerance following anti-CD4 mAb treatment.
8:2 Spleen cells from long-term tolerant rats may be able, when adoptively 
transferred to naive animals receiving an allogeneic cardiac allograft, to induce 
transplant tolerance. This putative immunoregulatory effect was donor-specific 
and critically dependent on the total number of cells adoptively transferred.
8:3 CD4 T cells from 0X38 treated tolerant recipients showed a good 
proliferative response on in vitro stimulation in the MLR. There was no 
evidence, therefore, of clonal deletion of alloreactive T cells. In contrast, CD4 T 
cells from 0X70 treated recipients showed a generalised (i.e. not donor 
specific) reduction in proliferation.
8:4 There was a reduction in bioactive IL-2 in supernatants from both 0X38 
and 0X70 treated tolerant CD4 T cells. Although marginally reduced in 0X70 
treated tolerant animals, IFNy levels were reduced on stimulation with donor- 
specific and third party cells. CD4 T cells from normal and tolerant rats 
produced similar levels of IL-4.
8:5 0X38 mAb produces a donor specific tolerogenic effect whereas 0X70 
mAb appears at least on the basis of in vitro analysis to produce a non specific 
immunosuppresive effect. It must be emphasised, however, that further 
experiments are necessary to confirm these potential in vitro differences 
between CD4 T cells from 0X38 and 0X70 treated graft recipients.
CHAPTER NINE 
FINAL DISCUSSION
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Final Discussion
There is currently much interest, both experimental and clinical, in the use of 
anti-CD4 mAbs as a therapeutic tool for prolonging allograft survival and 
perhaps inducing transplantation tolerance. The experiments reported here were 
performed in the hope that they may provide further insight into the scope, 
limitations and possible mechanisms of anti-CD4 induced prolongation of 
allograft survival.
Several new finding emerged. In chapter 5, the anti-CD4 mAb 0X38 was 
shown to be effective at inducing tolerance of Lewis heart grafts in fully 
allogeneic DA recipients. However, this tolerising effect of 0X38 mAb was 
highly dependant on the rat strain combination used for transplantation. In none 
of the other rat strain combinations tested was 0X38 found to extend heart 
graft survival permanently. This important influence of the rat strain 
combination studied on the efficacy of anti-CD4 mAb is consistent with that 
observed for other strategies for inducing transplant tolerance in the rat. For 
example, pre-transplant donor-specific blood transfusion (DST) promotes 
allograft survival in the Lewis to DA rat strain combinations, but it is completely 
ineffective in the DA to Lewis strain combination. The observation here that the 
effect of anti-CD4 is highly strain dependent does not necessarily diminish its 
biological importance, but it does indicate the need to understand the 
determinants which are responsible for such strain dependent effects. For 
example, one could speculate that DA recipients are more easily rendered
tolerant than Lewis recipients because the regulatory mechanisms responsible 
for tolerance are more easily activated in the DA rat strain.
The studies using anti-CD4 mAb against epitopes on proximal domains of the 
rat CD4 molecule were of particular interest, since there is little published 
information on whether such antibodies are effective in prolonging transplant 
survival. As was shown in chapter 6, such antibodies were as effective as 0X38 
at inducing tolerance. Interestingly, however, the W3/25 antibody which labels a 
distal CD4 determinant did not induce tolerance, even though it is cross reactive 
with 0X38 mAb. W3/25 mAb was also notable by its failure, when given in 
vivo, to deplete CD4 T cells. All of the other anti-CD4 mAb used produced 
partial CD4 T cell depletion, suggesting that CD4 T cells depletion may be an 
important element of the ability of the anti-CD4 mAb tested to induce tolerance. 
It should be pointed out, however, that non-depleting anti-CD4 mAb’s have 
been shown in some studies to be highly effective at promoting transplant 
tolerance (Darby et al, 1992 and 1994). Although CD4 T cells depletion may 
have helped to prevent graft rejection following 0X38, 0X70, 0X71 and 0X73 
mAbs, the levels of depletion observed were not very profound and certainly not 
sufficient by themselves to ensure allograft survival. This was adequately 
demonstrated by the finding that removal of the thymus gland prior to 
transplantation or alternatively depletion of CD8 cells by anti-CD8 mAb at the 
time of transplantation were both able to abrogate tolerance induction in many 
of the treated animals. Clearly, therefore, sufficient alloreactive CD4 T cells 
remained to effect heart graft rejection in these situations.
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The observation in chapter 6 that anti-CD4 mAb treatment preferentially 
depleted the OX22high subset of T cells was of interest since CD4 T cells of this 
phenotype have been shown to produce cytokines of the Thl type (Powrie and 
Mason, 1990). Conversely, the OX22low subset, which were less effected by 
anti-CD4 mAb, have been shown to produce a Th2 cytokine pattern (Morrisey 
et al, 1993). This phenotypic difference in CD4 T cell subset depletion would be 
consistent with the view that anti-CD4 mAb promote a Thl to Th2 shift in the 
cytokine response. However, there is another interpretation of the findings. 
CD4 T cells newly emerged from the thymus are OX22Iow and it may be that 
immature CD4 T cells are less susceptible to depletion by anti-CD4 mAb. In this 
respect, the observation that intact thymus gland is needed for induction of 
transplant tolerance by anti-CD4 mAb (chapter 7) was particularly intriguing. A 
possible role of the thymus in anti-CD4 induced transplant tolerance in the rat 
was also reported by Fathman’s group (Yin and Fatman, 1995a+b)
These two explanations are not mutually exclusive, and it could be postulated 
that recent thymic emigrants may preferentially produce Th2 cytokines and 
thereby promote tolerance. Why CD8 cells should be helpful in the induction of 
tolerance by anti-CD4 mAb is less clear.
The experiments reported in chapter 7 and 8 were performed to address further 
the mechanisms contributing to the induction and maintenance phase of anti- 
CD4 transplant tolerance. In some models of tolerance induction, notably 
donor-specific blood transfusion in the rat, a defect in the IL-2 pathway has 
been demonstrated and this can be overcome by provision of exogenous IL-2.
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This did not appear to be the case in anti-CD4 induced tolerance since 
administration of relatively large amounts of IL-2 failed to prevent induction of 
tolerance after anti-CD4 mAb treatment. Interestingly, however, the treatment 
with a neutralising IL-4 during induction of tolerance did, in some animals, 
abrogate tolerance induction. These experiments were problematical and further 
studies are needed before firm conclusions can be made. However, the 
experiment did suggest that endogenous EL-4 may facilitate anti-CD4 induced 
tolerance. It must be remembered that IL-4 may be produced by several cell 
types e.g. easinophiles and mast cells (Brown et al, 1988b; Rennick et al, 1987 
and Zlotnik et al, 1987) in addition to Th2 T helper cells (Mosmann et al, 1986; 
Mosmann and Coffman, 1989). Perhaps the presence of EL-4 early during 
tolerance has a negative regulatory effect on Thl T cells during a critical phase 
of the immune response to the allograft.
Investigation of the mechanisms responsible for maintenance of anti-CD4 
tolerance (chapter 8) supported the view that a suppressor or regulatory T cells 
plays a critical role. Lymphocytes from long-term tolerant animals after 0X38 
mAb proliferated normally to donor alloantigen in MLR, excluding clonal 
deletion as a likely cause for transplant tolerance. There has been much recent 
interest in the idea that transplant tolerance may be attributable to a polarisation 
of the immune response from a potentially harmful Thl response to a potentially 
less harmful or “neutral” Th2 response. However, the detailed analysis of the 
cytokine repertoire of CD4 T cells from tolerant animals did not provide strong 
support for this hypothesis.
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In 0X38 treated animals there was no evidence for a Th2 cytokine bias. 
Analysis of in vitro response of CD4 T cells from 0X70 treated animals 
provided the unexpected finding that there was a generalised reduction in 
proliferation to both donor specific and third party alloantigen, suggesting that 
0X70 may have a different overall effect to 0X38 mAb. CD4 T cells from 
0X70 treated rats also showed generalised impairment in IL-2 production in 
keeping with the proliferation data. Why the results after 0X70 mAb should 
differ somewhat from those using 0X38 mAb is not clear and it would be 
unwise on the basis of the limited amount of data to draw firm conclusions from 
this finding without further studies.
Clearly, the mechanisms underlying anti-CD4 Induced tolerance are highly 
complex and much further work is required to clarify them. The ability to 
transfer tolerance by spleen cells provides the most compelling evidence that a 
powerful immuno-regulatory lymphocyte is present in tolerant rats and this area 
is undoubtedly the most important area to pursue. Detailed analysis of the 
phenotype and function of the cells responsible for transferring tolerance is 
required.
Although there are still many unanswered questions, knowledge of the complex 
cellular interactions which underlie anti-CD4 induced tolerance will be of value 
in designing protocols for mAb treatment in clinical transplantation. If the 
immuno-regulatory mechanisms which anti-CD4 mAb induces can be better 
understood, perhaps these immunosuppressive pathways can be harnessed for 
clinical application.
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